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Abstract
Currently there is no in vitro testing of glioblastoma biopsy material to assess tumour
sensitivity to radiation, which could form a basis for personalised treatment plans for
patients. In this work, a model to predict sensitivity to radiation, via the micronucleus
assay, is set out and a proof of concept is presented where numbers of micronuclei in a
glioblastoma cell line, LN18 is predicted.
One key requirement for the model is that any in vitro testing needs to yield results
within a few days, as the timeline for glioblastoma patients from diagnosis to treatment is
short. In order to achieve this, a flow cytometry technique is assessed against traditional
fluorescence microscopy for detection of micronuclei.
Flow cytometry was completed using an In Vitro Microflow R© kit from Litron Laborato-
ries. There was no previous experience using this kit in cancerous cell lines and limited
experience in cell lines that adhere to their flasks surface as the kit is used mostly in
peripheral blood lymphocytes.
The flow cytometry technique can be completed within the required time frame and is
much less labour intensive that fluorescence microscopy. However, there is a significant
amount of variance between samples which makes the microscopy results more useful
for fitting the modelling work to. It is expected with further experience and use of the
supplied template, as this was incompatible at the time of the experiments, will play a
role in reducing some of the variance.
The model, in its current state of development, is able to predict numbers of micronuclei
in a cohort of cells following doses of radiation between 1 and 3 Gy. The numerical
solution is based on a decision tree structure where each double strand break that would
be caused by radiation is run through the tree. The tree is traversed populated using
probabilities for each decision, such as the success of a repair pathway, and Monte Carlo
methods for predicting the cohort response to radiation. These probabilities are fitted
to experimental data.
The prediction of micronuclei is the first step for the MiNiMUS model. Future work
should prioritise incorporating cell death into the model and further assessing the suit-
ability of flow cytometry for rapid micronuclei detection.
ii
Acknowledgements
I am a man of few written words and I hope this thesis is a testament to that. However,
I would like to thank my long suffering family who have supported me throughout my
studies and illness. Thank you to my fiancee´, Beth, who has kept my blood to cookie
ratio firmly in the diabetic region and kept me fighting to finish this work.
I would also like to thank my supervisors, Prof’s Norman and Karen Kirkby, as well as
Dr Raj Jena for giving me the opportunity to work in such a diverse group. Dr Charlie
Jeynes and Dr Mike Merchant for their advice throughout the process. Dr Miriam Barry,
Dr Deborah Guest and Dr Lara Barazzuol for all their guidance, both in work and how to
keep yourself sane. Tom Mee and Natalie Mayhead, for giving me confidence in my own
abilities and as a sounding board for hypotheses over coffee. Finally, all the members
of the medical applications group for their support over the years and the Engineering
and Physical Sciences Research Council who supported this project.
iii
Contents
Abstract ii
Acknowledgements iii
List of Figures ix
List of Tables xi
Abbreviations xii
1 Introduction 1
1.1 General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Current Treatment of Glioblastoma . . . . . . . . . . . . . . . . . . . . . . 2
1.3 Current Research in Glioblastoma . . . . . . . . . . . . . . . . . . . . . . 3
1.4 Personalised Treatment Plans . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.5 Aims and Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.6 Thesis Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2 Theory and Literature Review 7
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.2 Ionising Radiation and Cellular Matter . . . . . . . . . . . . . . . . . . . . 7
2.2.1 Chromosomal Aberrations . . . . . . . . . . . . . . . . . . . . . . . 9
2.2.1.1 Dicentric Chromosomes . . . . . . . . . . . . . . . . . . . 10
2.2.1.2 Sister Chromatid Exchanges . . . . . . . . . . . . . . . . 10
2.3 Micronuclei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.3.1 Classifying Micronuclei . . . . . . . . . . . . . . . . . . . . . . . . 11
2.3.1.1 Types of Micronuclei . . . . . . . . . . . . . . . . . . . . 11
2.3.1.2 Centromeric Classification . . . . . . . . . . . . . . . . . 11
2.3.1.3 Fluorescent In Situ Hybridisation (FISH) . . . . . . . . . 11
2.3.1.4 Micronuclei in Epidemiological Studies . . . . . . . . . . 13
2.3.1.5 Use of the Micronuclei as a Biomarker and Biodosimeter 14
2.3.2 Microscopy Based Scoring of Micronuclei . . . . . . . . . . . . . . 15
2.3.2.1 CBMN Cytome Assay . . . . . . . . . . . . . . . . . . . . 15
2.3.2.2 MNVit Assay . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.3.2.3 Automated Scoring of Micronuclei . . . . . . . . . . . . . 16
iv
Contents v
2.4 Micronuclei Data in Literature . . . . . . . . . . . . . . . . . . . . . . . . 17
2.4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.4.2 Adherent Cell lines . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.4.3 Peripheral Blood Lymphocytes . . . . . . . . . . . . . . . . . . . . 18
2.4.4 Summary of MN Data in Literature . . . . . . . . . . . . . . . . . 20
2.5 DNA Repair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.5.1 General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.5.2 Homologous Recombination (HR) . . . . . . . . . . . . . . . . . . 21
2.5.3 Non Homologous End Joining (NHEJ) . . . . . . . . . . . . . . . . 22
2.5.4 Choice of Pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.6 Flow Cytometry Theory . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.6.2 General Concepts . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.6.3 DNA Staining and Fluorescence . . . . . . . . . . . . . . . . . . . 27
2.6.4 Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.6.5 Immunostaining . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.7 Micronuclei Detection by Flow Cytometry . . . . . . . . . . . . . . . . . . 28
2.7.1 General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.7.2 History of MN Detection by Flow Cytometry . . . . . . . . . . . . 29
2.8 Detection of DSBs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.8.1 General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.8.2 Pulsed Field Gel Electrophoresis (PFGE) . . . . . . . . . . . . . . 31
2.8.3 Immunofluorescent Staining and the γH2AX Assay . . . . . . . . . 31
2.8.4 PFGE Vs γH2AX Assay for DSB Quantification . . . . . . . . . . 33
2.9 Radiobiological Modelling . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.9.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.9.2 Model Types . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.9.3 Overview of Models . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.9.4 Chromosomal Aberration Models . . . . . . . . . . . . . . . . . . . 36
2.9.5 Phenomenological Models . . . . . . . . . . . . . . . . . . . . . . . 38
2.9.5.1 General . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.9.5.2 Target Models . . . . . . . . . . . . . . . . . . . . . . . . 38
2.9.5.3 The Linear Quadratic (LQ) Model . . . . . . . . . . . . . 39
2.9.6 Other Phenomenological Models . . . . . . . . . . . . . . . . . . . 39
2.9.7 Track Structure Models . . . . . . . . . . . . . . . . . . . . . . . . 40
2.9.7.1 PARTRAC . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.9.7.2 PARTRAC Track Structure Calculation . . . . . . . . . . 40
2.9.7.3 PARTRAC DNA Target Model . . . . . . . . . . . . . . . 41
2.9.7.4 The Local Effect Model (LEM) . . . . . . . . . . . . . . . 43
2.9.7.5 Microdosimetric Kinetic Model (MKM) . . . . . . . . . . 44
2.9.7.6 Wang Model . . . . . . . . . . . . . . . . . . . . . . . . . 45
2.10 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3 Methodology 48
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.2 Tissue Culture and Protocols . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.2.1 Cell Line Particulars . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Contents vi
3.2.1.1 LN18 and V79 Culture . . . . . . . . . . . . . . . . . . . 48
3.2.1.2 M059J and M059K Culture . . . . . . . . . . . . . . . . . 49
3.2.2 Passaging of Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.2.3 Cryopreservation of Cells . . . . . . . . . . . . . . . . . . . . . . . 50
3.2.4 Irradiation and Clonogenic Survival Assay . . . . . . . . . . . . . . 50
3.2.5 Cell Counting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.2.6 Growth Curve . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.2.6.1 Logistic Growth Curve . . . . . . . . . . . . . . . . . . . 52
3.2.7 Irradiation of Cells with X-Rays . . . . . . . . . . . . . . . . . . . 53
3.2.8 Induction of Micronuclei with Mitomycin-C . . . . . . . . . . . . . 54
3.2.9 Temozolomide treatment . . . . . . . . . . . . . . . . . . . . . . . 54
3.3 MN Detection Experiments . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3.3.1 General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3.3.2 Microscopy Experiments . . . . . . . . . . . . . . . . . . . . . . . . 55
3.3.3 In Vitro Microflow R© kit . . . . . . . . . . . . . . . . . . . . . . . . 55
3.3.4 General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.3.4.1 Staining Protocol . . . . . . . . . . . . . . . . . . . . . . 55
3.3.4.2 Cytometric Analysis . . . . . . . . . . . . . . . . . . . . . 56
3.4 Modelling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.4.2 The MiNiMUS Model . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.4.2.1 Modelling Assumptions . . . . . . . . . . . . . . . . . . . 58
3.4.2.2 Biological Assumptions . . . . . . . . . . . . . . . . . . . 59
3.4.2.3 DSB Induction Assumptions . . . . . . . . . . . . . . . . 59
3.4.2.4 Cellular probability . . . . . . . . . . . . . . . . . . . . . 59
3.4.3 Numerical Methods . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.4.4 Binary Decision Tree . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.4.5 Monte Carlo Methods . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.4.6 Calculation of the Beta Function . . . . . . . . . . . . . . . . . . . 62
3.4.7 Generation of Random Numbers . . . . . . . . . . . . . . . . . . . 63
3.4.8 Sensitivity Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.4.9 Automated Fitting of Node Probabilities . . . . . . . . . . . . . . 65
3.4.10 Coding Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.4.10.1 Computing Tools . . . . . . . . . . . . . . . . . . . . . . . 65
3.4.11 Coding The Decision Tree . . . . . . . . . . . . . . . . . . . . . . . 66
3.5 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
4 Results 67
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.2 Culture of M059J and M059K . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.3 LN18 Growth Curve . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.4 Clonogenic Survival of LN18 Cells . . . . . . . . . . . . . . . . . . . . . . 70
4.5 Brief Description of Experiments . . . . . . . . . . . . . . . . . . . . . . . 70
4.6 Cytometric Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.6.1 In Vitro Microflow R© MN Scoring Criteria . . . . . . . . . . . . . . 72
4.6.2 Changes to the Staining Procedure . . . . . . . . . . . . . . . . . . 72
4.6.3 Treatment of Cytometric Data . . . . . . . . . . . . . . . . . . . . 73
Contents vii
4.6.4 Relative Survival . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.7 Manual Scoring using Microscopy . . . . . . . . . . . . . . . . . . . . . . . 78
4.8 Dose Response of LN18 Cells . . . . . . . . . . . . . . . . . . . . . . . . . 84
4.8.1 Results of LN18 MN Frequencies using Flow Cytometry . . . . . . 84
4.9 Dose Response of V79 Cells . . . . . . . . . . . . . . . . . . . . . . . . . . 86
4.10 Correlation of EMA Positive results with MN Frequency . . . . . . . . . . 89
4.11 Modelling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
4.11.1 Validation of the Decision Tree Code . . . . . . . . . . . . . . . . . 91
4.11.2 Validation of Monte Carlo Sampling Routines . . . . . . . . . . . . 92
4.11.3 Modelling Adherent Cell Lines . . . . . . . . . . . . . . . . . . . . 93
4.11.3.1 Cell Phase Durations . . . . . . . . . . . . . . . . . . . . 94
4.11.3.2 Fitted Probabilities in Adherent Cell Lines . . . . . . . . 95
4.11.4 Modelling PBL Dose Response . . . . . . . . . . . . . . . . . . . . 96
4.11.5 Sensitivity Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 98
4.12 Key Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
5 Discussion 102
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
5.2 Project Outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
5.3 Assessment of Modelling Assumptions . . . . . . . . . . . . . . . . . . . . 104
5.3.1 Biological Assumptions . . . . . . . . . . . . . . . . . . . . . . . . 104
5.3.2 Cell Death Assumption . . . . . . . . . . . . . . . . . . . . . . . . 105
5.3.3 Background Micronuclei Levels . . . . . . . . . . . . . . . . . . . . 105
5.4 Use of the In Vitro Microflow R© Kit for Micronuclei Detection . . . . . . . 106
5.5 Modelling of the Micronucleus Frequency . . . . . . . . . . . . . . . . . . 107
5.5.1 Automated Vs Manual Probability Fitting . . . . . . . . . . . . . . 108
5.5.2 Modelling Lymphocytes with MiNiMUS . . . . . . . . . . . . . . . 109
5.5.3 Difference in Dose Response of PBLs and GBM . . . . . . . . . . . 110
5.5.4 Quantification of Foci using Flow Cytometry . . . . . . . . . . . . 110
5.6 The Role of Base Excision Repair in DSB Induction . . . . . . . . . . . . 113
5.7 The Future of MiNiMUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
5.8 Microscopy Based Techniques . . . . . . . . . . . . . . . . . . . . . . . . . 116
5.9 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
5.10 Subjectivity in Flow Cytometry . . . . . . . . . . . . . . . . . . . . . . . . 118
6 Conclusions and Further Work 120
6.1 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
6.1.1 Development of a Rapid Assessment Tool . . . . . . . . . . . . . . 120
6.1.2 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
6.1.2.1 General . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
6.1.2.2 Use of the In Vitro Microflow R© Kit . . . . . . . . . . . . 121
6.1.3 Modelling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
6.1.3.1 General . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
6.1.3.2 Modelling Assumptions . . . . . . . . . . . . . . . . . . . 122
6.1.3.3 Numerical Solution . . . . . . . . . . . . . . . . . . . . . 123
6.2 Recommendations for Future Work . . . . . . . . . . . . . . . . . . . . . . 123
6.2.1 Implementation of Cell Death within MiNiMUS . . . . . . . . . . . 123
Contents viii
6.2.2 Implementation of Ion Irradiation . . . . . . . . . . . . . . . . . . 124
6.2.3 Further Experiments to Aid Probability Fitting . . . . . . . . . . . 124
6.2.3.1 Repair Deficient Cell Lines . . . . . . . . . . . . . . . . . 124
6.2.4 Replacing MiNiMUS Probabilities with Mechanistic Models . . . . 125
6.2.5 Estimation of Dose Response . . . . . . . . . . . . . . . . . . . . . 125
A Contributions to Scientific Literature 127
A.1 Conferences Attended . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
A.2 Manuscripts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
B MiNiMUS Source Code 128
B.1 General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
B.2 Altering Model Probabilities . . . . . . . . . . . . . . . . . . . . . . . . . . 128
B.3 Running the Programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
Bibliography 130
List of Figures
2.1 Comparison of Dose Vs. Depth for Protons and X-Rays. . . . . . . . . . . 9
2.2 Examples of Micronuclei. . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.3 MN Frequency in Adherent Cell Lines. . . . . . . . . . . . . . . . . . . . . 18
2.4 Time Dependency of MN Frequency in Adherent Cell Lines. . . . . . . . . 19
2.5 MN Dose Response in PBLs. . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.6 The Homologous Recombination (HR) Repair Pathway. . . . . . . . . . . 22
2.7 The Non Homologous End Joining (NHEJ) Repair Pathway. . . . . . . . . 23
2.8 Repair Pathway Activity During the Cell Cycle. . . . . . . . . . . . . . . . 24
2.9 Diagram Showing Fluid Flow in a Flow Cytometer. . . . . . . . . . . . . . 26
2.10 Example of Stokes Shift. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.11 Double Fluorescent Stain Technique for MN Detection. . . . . . . . . . . . 30
2.12 Model Topology from the work of DiPierdomenico et al.. . . . . . . . . . . 37
2.13 PARTRAC Topology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.14 The Wang Model. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.1 Plot of Forward and Side Scattered Light for Gating in the In Vitro
Microflow R© method. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
3.2 The MiNiMUS Decision Tree v1.1. . . . . . . . . . . . . . . . . . . . . . . 61
4.1 Example of an M059J Glioblastoma Cell. . . . . . . . . . . . . . . . . . . 68
4.2 A Monolayer of LN18 Glioblastoma Cells. . . . . . . . . . . . . . . . . . . 68
4.3 Growth Curve of LN18 Cells. . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.4 Logistic Growth Curve Model Fitted to LN18 Experimental Data. . . . . 70
4.5 Clonogenic Survival of the LN18 Cell Line after Irradiation. . . . . . . . . 71
4.6 Example of a flow cytometry dot plot: FSC-A Vs. SSC-A. . . . . . . . . . 74
4.7 Example of a flow cytometry dot plot: FITC-H Vs. PerCP-Cy5.5-H. . . . 75
4.8 Example of a flow cytometry dot plot: FSC-H Vs. FITC-H. . . . . . . . . 76
4.9 Examples of Cell Scoring by Microscopy. . . . . . . . . . . . . . . . . . . . 83
4.10 Dose Response of V79 and LN18 with IR, Counted by Microscopy. . . . . 84
4.11 MN Frequencies of the LN18 Cell Line with IR by Flow Cytometry. . . . 85
4.12 MN Frequencies of the LN18 Cell Line with IR by Flow Cytometry and
Microscopy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
4.13 Irradiated V79s Dose Response. Counted using Flow Cytometry and
Microscopy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
4.14 Dose Response of V79s to Mitomycin C. . . . . . . . . . . . . . . . . . . . 88
4.15 Variation in Forward Scatter Signals by Population in LN18 Experiments. 89
4.16 Variation in EMA Fluorescence Intensities by Population in LN18 Exper-
iments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
ix
List of Figures x
4.17 MiNiMUS Decision Tree, Represented in TreeAge. . . . . . . . . . . . . . 91
4.18 Monte Carlo Sampling Verification Results. . . . . . . . . . . . . . . . . . 93
4.19 Increase in Sampling Efficiency Through Scaling. . . . . . . . . . . . . . . 94
4.20 Model Fit to Experimental Results for Attached Cell Lines. . . . . . . . . 96
4.21 Micronuclei Dose Response in PBL Samples from Literature. . . . . . . . 98
4.22 Model Fit to Literature PBL Dose Response. . . . . . . . . . . . . . . . . 99
4.23 MiNiMUS Tree Sensitivity Analysis. . . . . . . . . . . . . . . . . . . . . . 100
5.1 Clonogenic Survival and Micronucleus Frequency of V79s. . . . . . . . . . 103
5.2 Clonogenic Survival and Micronucleus Frequency of V79s. . . . . . . . . . 103
5.3 Cells Treated with 10µM Camptothecin Exhibiting Large Fluorescence
Intensities. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
5.4 Potential Model for DSB Quantification. . . . . . . . . . . . . . . . . . . . 113
5.5 Overview of Base Excision Repair and Single Strand Break Repair. . . . . 114
List of Tables
2.1 Table of MC codes used in biophysical modelling. . . . . . . . . . . . . . . 36
3.1 Seeding Numbers for Clonogenic Survival of the LN18 Cell Line. . . . . . 51
3.2 Constituents of Lysis Solutions. . . . . . . . . . . . . . . . . . . . . . . . . 57
4.1 Brief Description of Experiment Parameters. . . . . . . . . . . . . . . . . 71
4.2 % RS with IR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
4.3 % Relative Survival in MMC Experiments. . . . . . . . . . . . . . . . . . 80
4.4 Nuclei to Bead Ratio in IR Experiments. . . . . . . . . . . . . . . . . . . . 81
4.5 Nuclei to Bead Ratio in MMC Experiments. . . . . . . . . . . . . . . . . . 82
4.6 MN Counts in LN18 and V79 Cells after Irradiation. Counted by Mi-
croscopy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
4.7 Validation of Tree Code. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
4.8 LN18 Cell Cycle Phase Durations. . . . . . . . . . . . . . . . . . . . . . . 95
4.9 V79 Cell Cycle Phase Durations. . . . . . . . . . . . . . . . . . . . . . . . 95
4.10 Model First Fit Probabilities for Attachment Cell Lines. . . . . . . . . . . 96
4.11 Model First Fit Probabilities for PBLs. . . . . . . . . . . . . . . . . . . . 98
xi
Abbreviations
%RS % Relative Survival
ATM Ataxia Telangiectasia Mutated
ATP Adenosine Triphosphate
BER Base Excision Repair
C+MN Centromere Positive MN
C-NM Centromere Negative MN
CBMN Cytokinesis Block Micronucleus
CBMNcyt CBMN Cytome
CNS Central Nervous System
CP Control Pairs
CSTRs Continuously Stirred Tank Reactors
CT Computed Tomography
cyt-b Cytochalasin-B
DAPI 4’,6-diamidino-2-phenylindole
DMSO Dimethyl Sulfoxide
DNA-PKcs DNA-Dependent Protein Kinase Catalytic Subunits
DSB Double Strand Break
DZ Dizygotic
EMA Ethidium Monoazide
EMEM Eagle’s Minimal Essential Medium
ESMO European Society For Medical Oncology
FACS Fluorescence-Activated Cell Sorting
FBS Fetal Bovine Serum
FISH Fluorescent In Situ Hybridisation
FITC Fluorescein Isothiocyanate
xii
Abbreviations xiii
GBM Glioblastoma
Gy Gray
HR Homologous Recombination
IMFP Inverse Mean Free Path
IMRT Intensity Modulated Radiation Therapy
IR Ionising Radiation
LEM Local Effect Model
LET Linear Energy Transfer
LPL Lethal-Potentially Lethal
LQ Linear Quadratic
MC Monte Carlo
MGMT Methyl-Guanine Methyl Transferase
MiNiMUS Micronuclei Modelling At The University Of Surrey
MKM Microdosimetric Kinetic Model
MMC Mitomycin-C
MN Micronucleus or Micronuclei
MNBN Bi-Nucleated MN
MNMONO Mono-Nucleated MN
MNVit Mammalian Cell Micronucleus Test
MZ Monozygotic
NAD+ β-Nicotinamide Adenine Dinucleotide
NBR Nuclei To Bead Ratio
NEAA Non-Essential Amino Acids
NHEJ Non Homologous End Joining
PAHs Poly-Aromatic Hydrocarbons
PARP Poly(ADP-ribose) polymerase
PBLs Peripheral Blood Lymphocytes
PBS Phosphate Buffered Saline
PerCP Peridinin Chlorophyll
PE Phycoerythrin
PE Plating Effciency
PET Positron Emission Tomography
PFGE Pulsed Field Gel Electrophoresis
Abbreviations xiv
PI Propidium Iodide
PMT Photomultiplier Tube
PWBA Plane-Wave Born Approximation
Q-FISH Quantitative FISH
RBE Relative Biological Effectiveness
RCR Repairable Conditionally Repairable
RPA Replication Protein A
RSCH Royal Surrey County Hospital
SSB Single Strand Break
SSBR Single Strand Break Repair
TMZ Temozolomide
WHO World Health Organisation
Dedicated to my grandad, who sadly never saw me finish this work.
xv
Chapter 1
Introduction
1.1 General
Cancer cells and their progeny ‘proliferate in defiance of the normal constraints, invade
and colonise territories normally reserved for other cell types’ ([3], Ch. 20 pp 718). It is
this invasion of surrounding tissues that defines the tumour mass to be malignant rather
than benign. Another hallmark of cancer is the invasion of other tissues by spreading
through the blood or lymphatic system, known as metastatic spread ([4], Ch. 1).
More than 1 in 3 people in the UK will develop cancer in their lifetime [5]. Annual
incidence of cancer in the UK has nearly doubled since 1971 when 143,506 cases were
recorded, to 266,123 new cases in 2009 [6]. In more recent statistics, the number of
newly diagnosed cancers had risen to 286 950, of which 3 855 cases were tumours of the
brain or central nervous system (CNS). Data from the Malthus project [7] show that
29% of these would be either high grade gliomas or other high grade tumours of the
CNS, putting the figure of new incidences at approximately 1118 cases in 2011. Whilst
this number is relatively small compared to the overall number if new cases, the effect
of higher grade tumours makes this figure more significant.
Treatment for cancer comes in three basic forms, surgery, radiotherapy or chemotherapy.
Often a combination of these treatments will be used to treat any one patient ([4], Ch.
3). Treatment method of different tumour sites varies, with additional variation in
treatment options within a particular type of tumour, as described in Sec. 1.2.
It is estimated that approximately 50% of patients will receive radiotherapy at some
point in their treatment [8, 9]. With the rising incidence of cancer, pressure is being put
on radiotherapy departments. Conventional radiotherapy is given using photon based
radiation, such as x-rays. One way of easing this pressure would be to either find more
1
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effective treatments, such as proton or heavy ion therapy, or optimise the way patients
are given conventional radiotherapy.
Ion-based therapy is considered the next step from conventional x-ray therapy and the
UK government has invested in the technology by commissioning proton therapy centres
in the UK [10, 11]. Proton therapy has advantages over conventional x-rays because of
the way the energy is deposited in the tumour site. Conventional x-ray treatment gives
a dose to the tissue surrounding the tumour, whereas ion-based therapies can be tuned
such that there is much less dose to the surrounding tissues. This phenomenon, where
the energy is deposited in a small geographical area, is known as the ‘Bragg Peak’ ([12],
Section 6.6). However, the UK is currently lagging behind the rest of the world in ion-
based treatment with countries such as Germany, the USA and Japan having clinical
facilities already treating patients. Whilst this shortfall in technology is addressed it
should not be the sole focus of the radiobiology community.
There are still improvements that can be made that are independent of radiation source
such as better understanding of the biology of radiation interaction with cells and more
importantly the cell’s ability to repair this damage. This could yield enhancements in
conventional radiotherapy or tailored treatments for patients based on biopsy or blood
tests from the patient in question.
1.2 Current Treatment of Glioblastoma
Glioblastoma (GBM) is classified by the World Health Organisation (WHO) as a Grade
IV tumour [13]. Grade IV is the highest grade the WHO applies to tumours. Grade IV
tumours are defined as:
“. . . cytologically malignant, mitotically active, necrosis-prone neoplasms typically asso-
ciated with rapid pre- and postoperative disease evolution and a fatal outcome.”[13]
Median survival times with aggressive treatment is 9-12 months with that falling to 14
weeks with only palliative care [14]. GBM tumours account for more years of life lost
per patient than any other tumour [15]. A key characteristic of glioblastoma is their
cellular heterogeneity [16], which has implications for tumour treatment.
Treatment options vary depending on the severity of the disease and age of the patient.
Stupp et al. [17] and the later guidelines to the European Society for Medical Oncology
(ESMO) in 2010 [18] presented a new standard for the treatment of GBM. The report
states that in most cases surgery should be the primary treatment option to debulk
the tumour mass and then a course of radiotherapy with concomitant Temozolomide, a
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chemotheraputic drug, treatment and then adjuvant temozolomide following the course
of radiotherapy. Stupp et al. suggests that biopsy material should be used for discerning
the methyl-guanine methyl transferase (MGMT) gene status of the patient as this is an
indicator of how effective temozolomide may be.
The actual diagnosis of glioblastoma is made from biopsy material obtained from the
patient. If a sufficient amount is taken, this could be used for in vitro testing of the
tumourous tissue, such as the effect of ion based irradiation or drug sensitivity. It could
be argued that this is not in the patients best interest, but as only clinically approved
drugs could be tested, it could spare the use of some drugs which show no effect in the
tumour tissue. It could then then be possible to exploit potential inherent sensitivities
of the tumour tissue, which could lead to a more tailored radiotherapy treatment.
Prediction of normal tissue radiosensitivity has been the subject of a recent review by
Chua and Rothkamm [19] where they highlight alternative approaches to their own,
particularly an idea based on the work of Tucker et al.[20] who state: ‘individualising
radiotherapy doses based on the derived in vitro cellular radiosensitivity of each individ-
ual.’, so it is clear that this form of research is valuable to the radiobiology community.
1.3 Current Research in Glioblastoma
Specific research into GBM is widely being conducted across many disciplines, such as
medical physics, biochemistry and computational image analysis. A number of tech-
niques are in various stages of in vitro research or clinical trials and other more conven-
tional treatments are still subject to active research.
As Intensity Modulated Radiotherapy (IMRT) is an extension to traditional radiother-
apy, 4D adaptive radiotherapy (4DART) aims to take conventional treatments a stage
further [21]. In 4DART scans are taken at each treatment session, such that treatment
plans can be altered to cater for tumours that move or shrink between treatments and
other factors that could affect the optimal treatment plan between treatment sessions
This adaptive radiotherapy technique relies on software to recalculate the treatment
whilst the patient is awaiting treatment. In a more abstract method, mathematical
models are being used to treat glioblastoma. A team at the New York Genome centre
are using ‘Watson’, currently the world’s most powerful supercomputer, to aid physi-
cians in clinical decision making in the treatment of glioblastoma [22, 23]. Watson is
being used to perform the computational effort, demonstrating the large computational
requirements of mathematical models on the genetic pathway scale.
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As stated above, treatment of glioblastoma with radiation is not limited to just radia-
tion. Temozolomide is now routinely given to patients being treated for glioblastoma.
Other ‘targeted therapies’ for cancer in general are undergoing clinical trials, such as
PARP inhibitors [24], that aim to increase the amount of cells killed by restricting cells
ability to repair damage inflicted by radiation. Research on potential targeted therapies,
specific to glioblastoma, is also being carried out within the cancer research community.
For instance, Kitambi et al. [25] give details of patient derived glioblastoma cells that
were treated with a quinine derivatives, known as Vaquinols. In GBM animal models,
Vaquinol-1 showed significant slowing of disease progression by disrupting cell prolifer-
ation by a number of pathways, including disruption of the cell membrane. Whilst in
vivo animal models are a considerable step away from being available for patient use,
it shows that targeted therapies are becoming of increasing interest to the research and
wider community.
1.4 Personalised Treatment Plans
The focus of this work is to contribute towards a greater goal of personalising treatments
plans for patients with glioblastoma. The way in which this is achieved is by creating
a tool in which the assessment of the radiosensitivity of the patient’s own tissue can
be assessed in a rapid time frame. Glioblastoma cell lines can be very slow growing in
vitro. Whilst this may seem counter intuitive, it is not uncommon for some tumour cell
lines to take a number of weeks to form colonies a. The ‘standard’ method of assessing
radiation sensitivity is by using the clonogenic survival assay, which even with rapidly
proliferating cells can take 2 weeks before the results are ready to analyse. Given the
patient timeline from diagnosis of tumour to treatment desired [26], any tool created
needs to give results within a few days to be of use in the planning of any treatment.
The use of γH2AX immunostaining assays is a common method for detecting damage
inflicted to the DNA by either drugs or radiation, but the quantification of this damage is
often scored by eye, using fluorescence microscopy, which is time consuming. Automated
are being developed to score micronuclei in fluorescent stained samples, which are briefly
covered in Sec. 2.3.2.3. Micronuclei are either fragments of DNA or whole chromosomes
that are not included in either of the daughter cells after cell mitosis. They can be formed
because of ionising radiation or drug interaction in cells [27]. They can be formed by
a number of different pathways, but of most importance in the work presented here is
their formation after doses of ionising radiation. The frequency of micronuclei varies
with dose and so the micronucleus assay could be used as a direct measure of severe
aPersonal Correspondence with Group Members
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damage done to DNA [28, 29], that can be achieved within the desired time frame and
within a clinically relevant dose range. The use of flow cytometry to achieve this removes
the need for time consuming microscopy.
1.5 Aims and Objectives
The aims and objectives of this work can both broadly be categorised as either modelling
or experimental. The experimental aims are largely to support the modelling efforts.
The overall objective is to construct a model that predicts the number of micronuclei
arising from a specified dose of radiation. The model should be able to incorporate the
role of genetic defects that prevent certain cellular repair pathways, characteristics of
different cell types. The model will be called MiNiMUS which stands for MI croN ucleI
M odelling at the U niversity of Surrey. Its main purpose is to predict the number of
micronuclei arising from treatment with ionising radiation in order that dose response
curves can be constructed for micronuclei versus dose as a surrogate for survival curves
where survival curves are not practical to produce because of cell line characteristics or
the required short time frames.
To support the modelling work, empirical correlations of the numbers of MN arising
from doses of IR should be determined. The experiments should focus on using GBM
cell lines. Efforts should also be made to assess the effect of DNA repair pathways on the
MN frequency. There are already examples of MN dose response curves in the literature
with photons [30, 31, 32], but these tend to be in lymphocyte or blood cultures. There
are also some examples of MN frequency irradiated with ion species [33, 34], but these
are less well characterised in general.
Ideally, any model created will be based on a first principles approach rather than be
heavily reliant on empirical observations. To this end, it is hoped that an existing
radiobiological model can predict the amount of damage induced by IR in the form of
DSBs.
1.6 Thesis Structure
This thesis is split into 6 chapters. This introduction chapter covers the rationale the
work being undertaken and some of the wider background information from the field.
Chapter 2 is the main literature survey and theory chapter. This chapter introduces
more detailed information on micronuclei formation and factors affecting frequencies of
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micronuclei in both peripheral blood lymphocytes and tumours of the brain where pos-
sible. A review of the larger track structure models is present with a view to these being
candidates for driving the modelling work in terms of prediction of damage induction in
a cohort of cells. Theory is included in this chapter to the point that it can guide the
reader through the basics of the techniques used in the experimental program. Chapter
3 is the materials and methodology chapter, where the bulk of the experimental and
modelling work is described with additional information about the culture techniques
and experiments to validate the novel approaches proposed. Chapter 4 contains the
results of both the experimental work and relevant model output. Chapter 5 compares
the results of the experimental work to what was expected from literature and makes
further comment on some of the questions arising from the literature review. Finally
chapter 6 makes some concluding comments on the project measured against the aims
in Sec. 1.5 and conjecture about the next steps for the MiNiMUS model.
Chapter 2
Theory and Literature Review
2.1 Introduction
This chapter covers a few broad areas of research from different academic disciplines and
demonstrates how a multidisciplinary approach can often provide solutions to problems
that occur in other fields. It is also intended to give some basic theory in some areas of
the experimental plan where appropriate, for instance papers published in ‘Advances in
Space Research’ where these are of relevance to the study of human cell response to ion
therapy.
The topics cover a number of fields from experimental biology to mathematical modelling
of radiobiological systems. The experimental biology focusses on the underlying theory
of MN production, their detection methods and in particular their occurrence as a
result of Ionising Radiation (IR), which is a less well characterised field when compared
to that of drug interaction where the use of micronuclei (MN) as a biomarker for drug
effectiveness is commonplace.
2.2 Ionising Radiation and Cellular Matter
IR can come in a number of forms, but for the work presented here x-rays and light
ions will be used. Most of the theory presented in this section has either come from
“Basic Clinical Radiobiology” by Joiner and van der Kogel [12] or “Radiobiology for the
Radiobiologist” by Hall and Giaccia [35].
X-Ray irradiation is considered the conventional method of giving radiotherapy at the
moment with proton and other light ion irradiation becoming more prevalent for treat-
ment for certain types of cancer. In the UK there is currently only one facility offering
7
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clinical ion based therapy, at the Clatterbridge, but this is limited to certain ocular
cancers [36]. However, 2 new centres for more general treatment of cancer are expected
to be operational by the end of 2017 [37].
The history of radiation interaction with biological matter pre-dates Bohr’s model of
the atom. The discovery of X-rays was made in 1895 by Roentgen and the first reported
case of the effects of radiation on biological matter such as skin irritation was made a
year later. In 1903, the first cure for cancer was suggested by implanting radium.
The interaction of photons with matter to cause damage can occur in two ways, either
directly or indirectly. Indirect action is where a photon interacts with with an electron
of an atom. If this electron has sufficient kinetic energy from the interaction with the
radiation source such that it diffuses away from the parent atom. As the electron moves
away from the parent atom, it interacts with other molecules in the vicinity, such as water
molecules. These interactions can then cause free radical formation. It is then these
free radicals that cause DNA Damage as they are highly reactive because of unpaired
electrons in their outer shells. In addition to free radical creation, the ejected electrons
are also capable of subsequent ionisation events. The diffusion length of these electrons
is governed by the loss of kinetic energy due to interactions with other molecules and is
thought to be < 7 nm, [38].
Direct action is where the ejected electron interacts directly with a critical structure to
cause biological change, such as a break in the phosphate backbone. Typically direct
action is a hallmark of high Linear Energy Transfer (LET) radiation, such as ions.
Lesions in DNA structure occur along the path of the radiation track due to the limited
diffusion of the ejected electrons created by the radiation track itself.
LET describes how much energy is being deposited into the tissue along the energy
track. The definition of LET is given in Eqn. 2.1 where dE is the mean energy lost
by the ion due to, principally, interactions with other atomic nuclei along the distance
travelled by the ion, dl [39]. LET is most commonly given units of keV/µm. One of the
key advantages of ion therapies is that the energy deposited along its track rises along
its track a peak before dropping to zero beyond a certain depth, see Fig. 2.1. This
phenomenon is given the eponymous name, the Bragg peak. Photons do not exhibit
this same phenomena and so tissue will experience a significant dose all along the track
leading clinician’s to using multiple fields to minimise the dose to the healthy tissue
surrounding the tumour.
LET =
dE
dl
(2.1)
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Figure 2.1: Comparison of Dose Vs. Depth for Protons and X-Rays adapted from
[40].
Given the nature of the energy deposition in ion based irradiation, this leads to more
complex forms of DNA damage, where various distinct types of aberrations, such as base
excisions or strand breaks, occur in close spatial proximity [38, 41].
Regardless of how the DNA is damaged, it is widely known that the most significant
form of damage, from a cell kill point of view, is a double strand break (DSB)[35]. A
strand break is where a break occurs along the sugar phosphate backbone. A DSB is
where both strands of the DNA helix are broken. DSBs can be repaired by more than
one repair pathway, the most significant of which are Homologous Recombination (HR)
or Non Homologous End Joining (NHEJ). These are covered in detail in Sec. 2.5.2 and
2.5.3 respectively.
2.2.1 Chromosomal Aberrations
This section covers some of the chromosomal aberrations that occur after exposure to
ionising radiation. Although the micronucleus assay is the focus of this work, other aber-
rations should be considered including their possible impact on numbers of micronuclei.
A generalised drawback of chromosomal aberrations is that scoring by microscopy is
time consuming. Whilst this is also true of MN, the higher magnifications required to
see chromosomal aberrations rather than MN that can be seen at much lower resolution
increases the time taken to score each cell significantly.
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2.2.1.1 Dicentric Chromosomes
As the name suggests, dicentric chromosomes are aberrations which contain 2 cen-
tromeres. The occur almost exclusively after doses of ionising radiation and in PBLs
they exhibit a linear-quadratic type dose response [42]. In this respect they are very
similar to the dose response of MN to IR in PBLs, see Sec. 2.4.3. Dicentrics can be
formed from misrepaired DSBs [43, 44]. Vral et al. [29] describe the dicentric assay as
the ’gold standard’ for biological dosimetry, mainly due to the low variability of control
samples which makes the assay very sensitive to radiation dose.
2.2.1.2 Sister Chromatid Exchanges
Sister Chromatid Exchanges (SCEs) occur in naturally in cells as a result of DNA
replication or Holliday junction resolution, which can occur during DNA repair, see Sec.
2.5.2. SCEs occur when homologous portions of DNA between chromatids. Gomer et
al. [45] shows that the number of SCEs increases with dose between 2.5 and 10 Gy using
an x-ray source.
Kliegerman et al. [46] showed that SCEs are long lived, in the sense that the reduction
in numbers of SCEs in PBLs in patients having received radio and chemotherapy had
reduced by 25 % two months after treatment had finished.
2.3 Micronuclei
Micronuclei were originally observed at the end of the 19th and early 20th century
and first described by Howell and Jolly and became known eponymously as Howell-Jolly
bodies [27]. An image of cells containing micronuclei is shown in Fig. 2.2. MN are formed
during mitosis. Mitosis can be split into 5 distinct sub phases, prophase, prometaphase,
metaphase, anaphase and telophase. During prophase the mitotic spindle begins to
form and the chromosomes condense. Prometaphase is where the microtubules start to
connect to the centromeres of the condensed chromosomes before they align between
what will become the two daughter nuclei.
Micronuclei are formed during the anaphase of mitosis where either whole chromosomes
or fragments of DNA do not attach to the mitotic spindle and are subsequently not
pulled into either of the daughter nuclei [47]. They form their own nuclear envelope
during telophase as a separate entity to the 2 daughter nuclei [48]. It has also been
shown that micronuclei can be formed from the breakdown of nucleoplasmic bridges
during telophase [49]. However, as nucleoplasmic bridges are infrequent themselves,
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0 to 10 per 1000 bi-nucleated cells [43], it is not thought that this will influence the
micronuclei frequency a great deal.
2.3.1 Classifying Micronuclei
2.3.1.1 Types of Micronuclei
The ‘standard’ type of micronucleus investigated is a micronucleus arising in a bi-
nucleated cell (MNBN), if the cells have been blocked from dividing. The micronuclei
appear as separate entities to the two daughter nuclei.
However, micronuclei can also be present in cells that are mono-nucleated (MNMONO)
[27]. Mononucleated cells containing MN could arise for many reasons, for instance,
cells arrested in the G0 phase after undergoing mitosis where a MN was formed. Other
reasons for micronuclei existing as MNMONO are that they are insensitive to the drug
cytochalasin B (cyt-b) used in the Cytokinesis Block MicroNucleus (CBMN) assay, see
Sec. 2.3.2.1 for further details on the CBMN assay, resulting in two mononucleated cells
instead of a single bi-nucleated cell [27]. This may be an important point to note if
experiments are exhibiting less MNBN than expected.
As the project being undertaken is based on radiation exposure there should be little
need to be concerned with MNMONO and their causes as long as any cell lines used in
the experiments respond to treatment with cytokinesis blocking drugs.
2.3.1.2 Centromeric Classification
Micronuclei can be described as either being Centromere Negative MN (C-NM), B in
Fig. 2.2, or Centromere Positive MN (C+MN), A in Fig. 2.2. C-MN are acentric
fragments of chromosomes and as the name suggests, do not contain the centromere
of the chromosome they originated from. These are generally thought to be caused by
clastogens such as ionising radiation [30] though they can also be caused by genetic
heritability [50] or by epidemiological factors [49]. A clastogen [51] is a substance which
causes breaks in the DNA of a cell whereas an aneugen [52] is substance that disturbs
the mitotic spindle and causes aneuploidy.
2.3.1.3 Fluorescent In Situ Hybridisation (FISH)
Huber et al.[32] show clear evidence that Fluorescent In Situ Hybridisation (FISH)
using a pancentromeric probe gives good results in classifying micronuclei into either
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Figure 2.2: Examples of Micronuclei, Circled in White: A) C+MN B) C-MN. Repro-
duced from Norppa et al. [53].
centromere positive or negative. They also show that the clastogenic nature of ionising
radiation gives rise to mostly C-MN with no rise in level of C+MN over the dose range
0 to 3 Gy. Similarly the response to aneugenic insult, by vinblastine sulphate, was an
increase of C+MN and no change in the numbers of C-MN over the same dose range.
Although the standard method of detecting kinetochores and centromeres of micronu-
clei is to use FISH, Fenech [54] gives an alternative method. Fenech’s method classifies
MN by detecting the presence of the centromere using anti-kinetochore antibodies. A
kinetochore is a sub-unit of a centromere. The kinetochore is the part of a centromere
where the microtubules attach during anaphase ([55], Fig. 24-1), and so the classifi-
cation between centromere positive and negative MN can be made. The method uses
colchicine. Decordier et al.[56] state that colchicine is not a good method for assessing
metaphase cells as, after 4 hours of exposure, chromosomes may condense which makes
them unscorable.
Whilst FISH can label micronuclei based on the the presence of centromeric material
Chapter 2. Theory and Literature Review 13
and Q-FISH (Quantitative FISH, a technique most commonly associated with telomere
length analysis [57]) has given researchers the ability to quantify results, these techniques
are still based on microscopy. Coupled with a protocol that requires specialist equipment
and training, the FISH method is not suitable to be used as a rapid assessment tool. Even
with the development of Flow-FISH [58], where FISH is combined with flow cytometry,
this technique does not hold any benefit for estimation of MN induction by ionising
radiation over the EMA/SYTOX green double staining flow cytometric technique, see
(Sec. 2.7.2, para. 2), as there is no need to know the amount of C+MN if the assumption
that radiation produces exclusively C-MN is correct.
2.3.1.4 Micronuclei in Epidemiological Studies
Micronuclei can also occur naturally. Their number depend on factors such as occu-
pational exposure to ionising radiation [47]. They have also been shown to increase in
frequency in patients with diseases such as type 2 diabetes and cardiovascular disease
[59]. However it should be noted that it is still uncertain as to whether micronuclei are
a by-product of existing conditions or could be used as a marker of future illness.
Pavanello et al. [60] used micronuclei frequency as a variable in a study looking at
telomere length of coke oven workers who are occupationally exposed to poly-aromatic
hydrocarbons (PAHs). They found a correlation, such that an increase in micronuclei
frequency is associated with subjects who have shorter telomeres. Their overall hypoth-
esis was that people exposed to PAHs, which are known to be carcinogenic, will have
shorter telomeres.
In a separate study, Pavanello looked at telomere shortening in alcohol abusers [61]. In-
terestingly, in this study, which appears to have very similar goals to the study on people
occupationally exposed to PAHs, the team did not use micronuclei in their analysis [61].
They modelled the factors known to have an impact on telomere length such as age,
BMI, smoking and occupation. These factors have also been shown to have an impact
on the number of micronuclei a cohort of cells are expected to have [59]. There appears
to be no mention of why micronuclei frequency was dropped from their analysis. It was
suspected that the link between telomere length and factors also affecting micronuclei
frequency was such that the analysis was considered surplus to requirements.
In contrast to Pavanellos work that initially used the frequency of micronuclei in the
determination of telomeric length, other studies use micronuclei as an endpoint rather
than an intermediate stage to further analysis. Work by groups such as the group from
Ulm University Hospital [50] and Ghent University [29] are using micronuclei frequency
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as predictors for cancer risk and as bio-dosimeters respectively, see Sec. 2.3.1.5 for
details.
Surowy et al. [50] assessed heritability of micronuclei by taking groups of monozygotic
(MZ) and dizygotic (DZ) twins, (identical and non-identical twins, respectively) as well
as randomly matched control pairs (CP). The micronuclei frequencies from the subjects
samples were scored at baseline and radiation induced readings. It should be noted that
despite data suggesting that the heritability is quite strong (h2 =∼ 0.7 on a scale of 0
to 1 where 1 is perfect heritability), it should be taken with some scepticism as the data
suffered from high variability and few subjects in one of their subgroups.
It is because of these epidemiological and inheritability factors that the cell lines to
be used in the experimental portion of this project will need to be tested for baseline
micronuclei levels. It has been noted by several authors [43, 62, 63] that micronuclei
frequency is very small compared to the number of cells seeded. This could give problems
in terms of providing statistically relevant results. The generally accepted method of
overcoming this is by scoring many cells. This does, to some extent, negate the advantage
of the micronuclei assay of being a quick method for delivering results if the cells have
to be scored by eye.
2.3.1.5 Use of the Micronuclei as a Biomarker and Biodosimeter
Surralle´s et al. [64] suggested in 1995, the use of MN as a biomarker for base excision-
repairable damage. This was achieved by converting the damage into a micronuclei by
interrupting a step of the base excision repair pathway. More recently, Ainsbury et
al. [42] evaluated the MN assay as a biodosimeter for exposure to IR exposure. They
concluded that the MN assay, using the CBMN protocol, was a good measure of full body
exposure when restricted to C-MN, although this was not the case with partial body
exposure. This is obviously for lymphocyte culture where they are dispersed around
the body. For partial exposure, the use of tissue samples, rather than lymphocytes may
yield better results, as can be sure that the tissue tested received a dose. However this
is much less simple than taking a blood sample from patients at a scene of an accident.
These findings were echoed by Vral et al. [29]. Further to this, Vral et al. stress the need
for high speed automated analysis of MN, which is one of the goals of the MiNiMUS
project.
Bonassi et al. [65] provided ‘preliminary evidence’ of a link between MN frequencies in
PBLs and cancer incidence. However, it was noted in their study that despite a large
study group that the cancer incidence per disease site are low. They expect this to
improve as the age of the study participants increases. Surowy et al. [50] confirmed
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that genetic factors play a role in MN frequencies by investigating the heritability of
MN in twins. This has led to them suggesting that MN frequencies could be predictors
of cancer risk.
Pinto et al. [28] evaluated the micronucleus assay as measure of genotoxicity in a clinical
setting, similar to the envisaged use of MiNiMUS. The main disadvantages centred
around the variability of MN from donor to donor, which is often linked to lifestyle.
In this study, analysis of dicentrics could be argued to be better suited to biodosimetry
because of the specificity to IR, low background frequency of endpoint in control samples
and lower limit of detection. Advantages of the MN assay over dicentric analysis were
limited to it being an easy assay to perform. In this case the MN analysis would have
been completed using microscopy. This may not be the case if the MN assay was to
be carried out using flow cytometry. Although the protocol is easy to complete with
relatively little training, the maintenance of the machine itself warrants a particularly
skilled person.
2.3.2 Microscopy Based Scoring of Micronuclei
2.3.2.1 CBMN Cytome Assay
The Cytokinesis Block Micro Nuclei (CBMN) assay has been developed over the past
25 years, but the basic premise remains the same: block the cells from dividing in
metaphase and count the chromosomal aberrations. The block is required because the
assay’s scoring criteria is restricted to binucleated cells. The reason for this is to reduce
potential variability caused by cell lines that have altered cell division kinetics, which is
an issue with other MN assays that do not distinguish between cells that can and cannot
divide [43].
CBMN has been developed for looking primarily at peripheral blood lymphocytes, how-
ever Fenech notes that the protocol can be easily adapted for use in other cell lines
including primary tumour cell cultures and gives basic details that could form the basis
of a protocol [43]. The most recent version of the assay is called the CBMN cytome
(CBMNcyt) assay which also provides criteria for other chromosomal aberrations such
as nuclear budding and apoptosis.
Given the potential that, even with 1000 binucleated cells, there could be no micronuclei
formed, it is tempting to leave the cells blocked with cytochalasin-B for longer to block
more cells. However, Fenech [43] warns against this approach because cells will still at-
tempt nuclear division and hence cells will go from being bi-nucleated to multi-nucleated
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cells. As the scoring system for the CBMN assay is based on binucleated cells this would
make the cohort difficult to score using standard conventions.
2.3.2.2 MNVit Assay
The in vitro Mammalian Cell Micronucleus Test (MNVit) has been drafted as a guideline
for testing of cytotoxic chemicals by the OECD [66]. This method is specifically for
mammalian cells, although the emphasis is still on PBLs and specific common rodent
cell lines such as V79. The reasoning for this is because the focus of the assay is for the
testing of toxins and so the characterisation of cell response to control drugs should be
well known. This does not stop the methodology being used with other cell lines, but it
should be used with caution with appropriate concurrent control experiments. As the
guidelines have been written with the testing of drug compounds in mind the methods
and reporting are very proscribed in the way they are to be completed. Although this
may not be necessary in this work as any experiments using the MNVit protocol will
stand as a control experiment to check the effectiveness of the flow cytometric techniques.
The key difference between the CBMNCyt assay and the MNVit is the stance on cytoki-
nesis blocking drugs. Whilst the CBMNcyt assay insists on the use of cytochalasin-b
(cyt-b) and warns of potential false negative results [43]. The MNVit assay provides
methods for both using and not using cyt-b with established cell lines. However, due to
the cell cycle characteristics of lymphocyte cultures, particularly if they are pooled from
multiple donors, cyt-b must always be used when using PBLs.
It is stated that methods not using cyt-b should be able to demonstrate that the cells
have gone through mitosis at least once [66]. Given this caveat it is sensible to use cyt-b
as a matter of course. The length of time cells are left in cyt-b is crucial so that cells do
not become multi-nucleated instead of bi-nucleated. For this reason and for the sake of
consistency with other experiments any experiments using cyt-b will be blocked for 1.5
doubling times, unless otherwise indicated.
2.3.2.3 Automated Scoring of Micronuclei
Automated scoring of micronuclei has been a goal of the radiation biology community for
some time [30, 67, 68, 69], with systems from 2 manufacturers being used in more recent
years; MNScore by MetaSystems and the Pathfinder suite by IMSTAR. The systems
have evolved to the point that binucleated micronuclei are able to be scored, which
makes these systems of interest in terms of comparison to manually scored results using
the CBMN protocol, see Sec. 2.3.2.1. There are still some drawbacks to the automated
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systems, for instance Decordier et al. [30] state that false positives were enough of a
concern to have a manual verification step added. Similarly, Baeyens et al. [69] added
a manual step in their technique using FISH, to detect the presence of centromeres in
the stained sample. Rossnerova et al. [68] stated that the automated scoring found
binucleated cells difficult to detect, both with and without micronuclei.
Overall, automated scoring systems should definitely be considered for use in future as
the drawbacks in terms of use and results are small. The more considerable disadvantage
is the cost of the systems and software. This should be balanced against the cost of flow
cytometry systems where there is no specific software needed, despite the initial cost of
the hardware in both cases.
2.4 Micronuclei Data in Literature
2.4.1 Introduction
Most data for radiation interaction causing micronuclei comes from the early nineties.
Most current literature use the micronucleus assay as a measure of genotoxicity [70], for
instance, in consumer products or new drug formulation [71]. A lot of this data focusses
on peripheral blood lymphocytes (PBLs), particularly when looking at occupational
exposure to toxins [47, 60]. PBLs give a good dose response curve and, in general,
give dose response curves that all agree in terms of a characteristic shape, but vary in
magnitude. This is partly due to the baseline levels of MN varying between donors,
but also whether MN have been scored as centromere negative, positive or with no
classification at all. Collated data is shown in Fig. 2.5 and discussed further in Sec.
2.4.3. Information on adherent cell lines, also known as anchorage dependent cell lines,
is less common, but there are still some examples. The bigger gap in knowledge comes
in the characterisation in dose response between photons and ions.
2.4.2 Adherent Cell lines
The Medical Applications (of Ion Beams) Group works primarily with adherent cell
lines, particularly glioblastoma cell lines. In general, papers reporting micronuclei in
adherent cell lines are in the minority in literature when compared to PBLs. However
there is one notable example from Shibamoto et al. [72]. One of the cell lines in the
Shibamoto paper is ‘A6’ which is described as an ‘Astrocytoma grade III-IV’, however
the doubling time, an in vivo measure of cell growth is given as 5 days, which is much
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longer than the in vitro doubling time for LN18 which is used as the focus of most of
the experimental work in this thesis.
For all cell lines in Shibamoto et al. [72], the dose response is linear which is at odds
with PBL data. The data is also for doses in the range, 0-4 Gy. Medvedeva et al.
[73] also give data for an astrocytoma cell line, SF268, at different doses and time
points after radiation exposure, that show slight non-linearity when analysed as a dose
response at a set time after exposure. No data is given about the SF126 cell line beyond
it being an astrocytoma cell line. Work by Rutka et al. [74] confirms that SF126 is
not a glioblastoma cell line. The dose response in the BJ human foreskin fibroblast is
not similar to the dose response in SF126 cells. The response appears to peak at 1 Gy,
regardless of fixation time post exposure. The data has been reproduced in Fig. 2.3, but
as approximate frequencies of MN given that the authors state “at least 300 binucleated
cells per slide were scored for analysis” [73]. It can be seen that the frequencies are non
linear, but seem to follow a generally positive dose response. The time point at which
the analysis takes place is also critical. Data from Yoshikawa et al. [75] shows the effect
of time in adherent cell lines showing MN, which is reproduced in Fig. 2.4. It should be
noted the frequencies concur reasonably with each other although the origins of the cell
lines and genetic stabilities differ.
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Figure 2.3: MN Frequency in Adherent Cell Lines Created from Data in [73].
2.4.3 Peripheral Blood Lymphocytes
One of the key pieces of literature is from Huber et al. [32]. The method of cell culture
used by Huber et al. uses PHA, which is known to stimulate lymphocytes into DNA
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Figure 2.4: Time Dependency of MN Frequency in Adherent Cell Lines Reproduced
from [75].
replication and hence undergo cell division. This is important, as MN arising from MN
require the cell to divide to form.
May et al. [76] have shown, using γH2AX immunostaining, that PBLs have the capacity
to repair DSBs. Given the culture method, it is likely that the cells were in G0 phase
until shortly after irradiation and hence it is assumed that repair would be via the NHEJ
pathway. The fact that PBLs have the capacity to both cycle and repair damage via
both NHEJ and HR [77] means they are compatible, in theory, with the model presented
in Sec. 3.4.2.
Dose response curves for MN arising from PBLs treated with ionising radiation are
presented in Fig. 2.5. Wuttke et al. [78] did not give absolute numbers, but instead
gave parameters for a ‘linear-quadratic fit’ (y = c+ aD + bD2).
It can be seen from Fig. 2.5 that the dose response is not linear across the clinically
relevant dose range. Micronuclei formation above 5 Gy is rare as cells will die before
completing a nuclear division due to the extensive damage [29]. Radiation qualities uses
in the data presented in Fig. 2.5 vary slightly. Decordier et al., Vral et al., both the
1997 and 2011 papers, [29, 30, 31] used a Co60 source for γ -rays, Huber et al. [32] used
a Cs137 source. Wuttke et al. [78] used a 240 kVp x-ray source. This would suggest
that x-rays have a larger impact on MN production than γ-rays, but with only one
x-ray result, this is not conclusive evidence. Similar analysis methods were used in all
experiments, 1000 binucleated cells scored by microscopy. In the case of Huber et al.
and Wuttke et al. the cells were stained using FITC/PI and Giemsa respectively. These
differences in scoring procedure should not make a significant difference to the results.
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Figure 2.5: MN Dose Response in PBLs with Photon Based IR [29, 30, 31, 32, 78].
2.4.4 Summary of MN Data in Literature
Presented above, Fig. 2.5, are just a few of the many examples of MN frequencies in
literature. The main differences between PBL samples and adherent cell lines appears
to be the shape of the dose response. PBLs exhibit a classic ‘linear-quadratic’ type
non-linear curve, see Sec. 2.9.5.3 for more information, whereas there appears to be no
distinctive correlation in adherent cell lines. This could be because the classification of
‘adherent cell lines’ is far too broad and should be further classified by their species of
origin and any genetic defects. As adherent cell lines in general are less well characterised
in terms of their MN response to radiation, it is certainly worth exploring the possibility
of modelling the dose response from in vitro experiments. It is clear that the response
in PBLs is consistent in characteristic shape and as such should lend itself to being
modelled, which could be of clinical use to assess sensitivity to radiation.
2.5 DNA Repair
2.5.1 General
Several authors [12, 79, 80] state the importance of the Homologous Recombination (HR)
and Non-Homologous End Joining (NHEJ) repair pathways in the repair of double strand
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breaks. It should be noted that whilst these are the two important pathways for DSB
repair, they are not the only repair pathways available to the cell. The Base Excision
Repair (BER) pathway repairs damage where, instead of the phosphate backbone of the
DNA having been broken, the link between the backbone and the base, the nitrogen-
carbon bond, is broken. This is discussed briefly, in the context of this work, in Sec. 5.6.
Strand breaks can also occur where one of the phosphate backbones breaks, known as
a Single Strand Break (SSB). They are repaired by a pathway known as Single Strand
Break Repair (SSBR). These, in addition to base excisions, occur much more frequently
than DSBs ([12], Sec. 2.8), but are also repaired with significant ease compared to DSBs.
2.5.2 Homologous Recombination (HR)
Homologous Recombination relies upon there being an undamaged copy of the broken
strand to act as a template for repair. Having a template to repair means that the
damage can be repaired error free. However the obvious drawback is that in some phases
of the cell cycle there may not be a suitable template available. Joiner and Van der Kogel
([12], Sec. 2.7) describe the process diagrammatically as reproduced in Fig. 2.6. Pardo
et al. [81] suggest that HR can be broken down into 3 broad stages; resection of the
break site, strand invasion into a homologous section of DNA and then resolution of
recombination intermediates.
Haber [80] gives details of 3 forms of HR repair, single strand annealing, gene conversion
and break induced replication. It is stated that single strand annealing is the simplest
form of HR repair. In the following description, the step numbers refer to the numbers
superimposed to the left of Fig. 2.6.
Regardless of the HR mechanism, the start of the process is the same: either side of
the DSB, part of one of the strands is resected to produce a single stranded DNA ‘tail’
by either exonucleases or a helicase coupled to endonuclease, step 1. This is done by
the MRN complex, which is made from MRE11, Rad50 and Nbs1 in mammalian cells
[82]. A lack of the MRN complex does not necessarily halt the repair process, but does
slow the process [81]. The resected tail is then covered in replication protein A (RPA)
which is a single strand binding protein. This attracts RAD51 which then searches for
homologous regions of DNA for strand invasion, step 2.
Strand invasion is also known as the synapsis phase [83] and is the last phase that is
common to all forms of HR repair, step 3. Whilst HR is used for DSB repair from a
number of sources, Jeggo et al. [84] describe the process for IR induced DSBs: Strand
invasion occurs creating a ‘D loop’, also known as a Holliday junction. A number of
proteins are used in this step, including Rad52p, Rad54p and Tid1p.
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Figure 2.6: The Homologous Recombination (HR) Repair Pathway. Adapted from
([12], Fig. 2.7).
The resolution of the Holliday junction and subsequent ligation of the DNA ends is the
end of the repair process, steps 4 and 5. Depending on the method of repair the repair
may be known as a crossover or non crossover repair, depending on whether the DNA in
the repaired part of the strand break originated in a sister chromatid or not respectively.
There are many ways in which HR can be accomplished and so the simplest has been
detailed here. Both Li and Heyer [83] and Pardo et al. [81] give detailed descriptions of
the proteins involved at each step of the process.
2.5.3 Non Homologous End Joining (NHEJ)
NHEJ is a multi-stage process that has been described by Joiner and Van der Kogel
([12], Sec. 2.7). The process can also be represented diagrammatically as shown in
Fig. 2.7 with the numbers on the right hand side of the figure being used as a reference
points for the following description. On sensing the DSB, proteins Ku70 and Ku80
bind to the DNA ends, step 2. A complex of MRE11/Rad50/NBS1, known as MRN
performs a number of functions, both in NHEJ and HR. Specifically in NHEJ following
treatment with IR, MRE11 is responsible for exonuclease activity to remove 3’ ‘blocking
groups’ [82], step 2. The Ku70/Ku80 heterodimer recruits DNA-dependent protein
kinase catalytic subunits (DNA-PKcs). These form a bridge over the break to keep
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the ends in close proximity during repair, shown in step 4. The other main function
of DNA-PKcs is to phosphorylate both themselves and proteins involved in the repair
and cell cycle checkpoints. Autophosphorylation of DNA-PKcs is necessary for efficient
repair as it stimulates dissociation from the DNA allowing other repair factors to the
break site. The protein, ARTEMIS, is used to further process the DNA ends at the
break site, step 5, ready for ligation by ligase IV in step 6.
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Figure 2.7: The Non Homologoues End Joining (NHEJ) Repair Pathway. Adapted
from ([12], Fig. 2.8).
NHEJ is often referred to as ‘error-prone’ repair, but it can also be precise [85]. The fate
of NHEJ being either precise or error-prone depends on the type of double strand break
caused. If the break can be described as ‘clean’, meaning complimentary overhangs
of the 5’ phosphate and 3’ hydroxyl groups, then the break can be repaired precisely
[79]. Durant [79] estimates that 25-50% of nuclease breaks are repaired by precise NHEJ.
Breaks induced by nuclease are ‘clean’ which enables this error-free NHEJ. The question
must be asked about the type of break produced by radiation? The issues appears to
be not as simple as whether IR produces clean breaks as it also depends on the genetics
Chapter 2. Theory and Literature Review 24
of the cell line being treated. Jiang et al. [86] suggest that precise NHEJ repair is
more likely when BRCA1 is present to stabilise the Ku80 protein in G1 phase. With a
dependence on tissue genetics as well as DNA damaging agent it is likely that it would
not be suitable to try and define NHEJ repair to be error-prone or error-free in the
model at this point in time.
2.5.4 Choice of Pathway
Given that HR repair requires homologous lengths of DNA to repair, it is clear that in
the G1 phase it is not possible to perform HR. This has been noted by a number of
authors [80, 83, 87]. Further to this, Rothkamm et al. [87] states that HR cannot be
performed until late S phase. They have shown (diagrammatically, reproduced below
in Fig. 2.8) where HR and NHEJ are active in the cell cycle. At odds with this is a
statement by Joiner and Van der Kogel ([12], Sec. 2.7) whereby they state that HR
is possible in the G1 phase as within the nucleus there is a homologous chromosome,
but this will be too far away spatially to be considered by the repair pathway and so in
practical terms it is extremely unlikely that HR will be possible in the G1 phase.
Figure 2.8: Repair Pathway Activity During the Cell Cycle [87]. Darker areas indicate
pathway activity.
One of the cell lines in use in the Rothkamm et al. experimental program, irs1SF, has
a reduced capability for HR repair, rather than a lack of pathway activity all together.
For this reason Rothkamm et al. cannot quantify the contributions of HR and NHEJ in
the G1 phase.
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However, given that several authors have noted the lack of HR repair in G1 phase it
is acceptable to take this as a suitable assumption. Given that doubts exist in some
circumstances it would be prudent to check the specifics of cells lines that are said to be
deficient in one or other repair pathways.
Liang et al. [88] state that 30-50% of the breaks induced by a specific endonuclease are
repaired by HR and the rest by NHEJ. It should be noted that endonuclease induced
breaks will differ from damage induced by IR. Depending on radiation quality the com-
plexity of break will vary. Eccles et al. [89] state that with sparsely ionising radiation,
approximately 30 % of the ionising events are clustered. Their modelling studies show
that this figure increases when dealing with low LET radiation, 30-40 %, up to >90 %
with high LET radiation.
This means that the choice of pathway will not always be as straight forward as position
in the cell cycle. Lomax et al. [90] note that DNA-PKcs is preferentially recruited in
complex DSB repair, which would suggest that NHEJ plays a significant role, even when
homologous DNA is available for HR.
2.6 Flow Cytometry Theory
2.6.1 Introduction
The bulk of this theory section is based on a Ormerod’s “Flow Cytometry” (3rd Edition)
book [91] unless otherwise stated. This section is included because flow cytometry is
not commonly used in chemical engineering and so understanding of the basics of the
technique is key to the experimental plan.
2.6.2 General Concepts
The basic theory of flow cytometry is to pass a fluid containing biological matter through
a laser beam. In general, there are two methods for gathering data: the first is to measure
the amount of light that is scattered when a cell passes through the laser, and the second
is to use fluorescent antibodies or stains that are excited by the particular lasers used in
the cytometer to measure an intensity of fluorescence which would correlated to uptake
of the stain or number of antibody binding events.
When a sample is run through the machine, several parameters can be adjusted, such as
sample flow rate. Samples can be run either at a high flow rate which correlates to low
fidelity output, but rapid data acquisition or lower flow rates which increase the fidelity
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of the output, but also increases the data acquisition time. Analysis tends to not be
measured by set volumes of sample, but number of events detected. Depending on the
concentration of the sample being measured and the number of events to be recorded the
time for analysing a particular sample can be in the order of seconds, or up to a number
of minutes, still making analysis effectively rapid. The sample is drawn up the sample
tube and is hydrodynamically focussed using a sheath fluid as it passes through the
laser. At this point, the sample can be treated in two ways: it is either sent to a waste
container or retained for further analysis. The process is represented diagrammatically
in Fig. 2.9.
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Figure 2.9: Diagram Showing Fluid Flow in a Flow Cytometer.
Flow cytometry is sometimes known as FACS, Fluorescence-Activated Cell Sorting, al-
though this is a particular extension of standard flow cytometry whereby the cells are
sorted based on one or more of the measured parameters. Cell sorting can be achieved
by vibration of the sample such that it forms droplets, then charging of these droplets
such that they can be deflected into specific collections tubes for further analysis [92].
Whilst cell sorting would be an interesting method to look at the fate of micronucleated
cells it would not work with the staining procedures used in this work to detect them,
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because the cell membranes are lysed in order to get stain ‘healthy’ cells, so that they
can be accounted for in the analysis. If the cell has an intact cell membrane then it
would not stain. Cell sorting is generally achieved with antibodies that are bound to
the antigens on the cell membrane surface.
2.6.3 DNA Staining and Fluorescence
For fluorescing samples, the samples is scanned with a laser capable of exciting the
fluorochrome bound to the sample. As the fluorochrome comes back to its ground state,
it will have exhibited a Stokes shift and emit light with a maximum intensity at a higher
wavelength then was received. An example can be found in Fig. 2.10.
Figure 2.10: Example of Stokes Shift.
These emitted pulses are collected and then filtered to the appropriate wavelengths for a
gallery of photomultiplier detectors. It is at this point that the light is converted into an
electronic pulse. Photomultiplication is where a single electron generated from a photon
striking the cathode is multiplied using dynodes. In the case of photomultiplier tubes
(PMTs) this multiplication can be >10 million electrons per photon. The voltage of
a PMT can be adjusted to change the spread of the data and hence how it is further
analysed within the flow cytometer software [92].
2.6.4 Compensation
Compensation refers to making sure that the emission spectra of the fluorochromes don’t
overlap, which can give false positive signals if compensation is not set up correctly. For
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instance, if the peaks in Fig. 2.10 were emission spectra of FITC and PE respectively
compensation would need to be applied to avoid false positives in both detectors. This
process is generally completed once for a set of similar experiments. The easiest method
of checking whether emission spectra are overlapping into other detectors is to single
stain samples with each of the dyes being used and also have an unstained sample avail-
able to detect any background autofluorescence. When the samples are run individually
it is possible to see where their emission spectra are being detected and alter the compen-
sation variables in the cytometer software such that they only appear on the appropriate
detectors.
2.6.5 Immunostaining
There are several ways that cells can express fluorescence with the main two being an-
tibody staining or DNA staining. When defining populations of cells based on their
cellular properties, most analysis uses cell surface antigens to bind to specific antibod-
ies introduced to the sample. The antibodies are then conjugated with a fluorescent
fluorochrome such that it can be detected by its Stokes shift when excited by a laser.
DNA stains, such as ethidium monoazide (EMA) or propidium iodide (PI) bind to DNA
by intercalation although other methods of binding to DNA exist. This is where the
stain, in the case of EMA and PI, binds in-between and parallel to the bases. Some of
these stains need to be photoactivated to bind, particularly EMA [93], which opens up
possibilities to double stain cells as after the first dye is washed off the photoactivated
dye remains bound to the double helix.
2.7 Micronuclei Detection by Flow Cytometry
2.7.1 General
Radiobiology was once dominated by experiments aimed at bulk experimental programs
designed to support clinical radiotherapy. However with the invention of faster tech-
niques, such as flow cytometry, some of these bulk experimental outcomes can be anal-
ysed on a per cell basis [94]. Studies with flow cytometry become particularly powerful
when combined with immunostaining that would traditionally be analysed using mi-
croscopy. The trade off by using flow cytometry is that there is no visualisation of the
cells which makes validation a more labour intensive task in the first instance, for an
easier experimental program subsequently. The other obvious drawback is the initial
cost and training required to operate the equipment. The multiparametric nature of
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flow cytometry is possibly the strongest advantage of the technique. This type of anal-
ysis can often show connections that would previously not have been possible, with the
larger number of events when compared to events scored by microscopy giving a stronger
basis from which to draw statistical conclusions [94].
2.7.2 History of MN Detection by Flow Cytometry
The original work on subpopulations of cell nuclei was completed by Nu¨sse and Kramer
[95]. The method still bears resemblance to the current protocol. A two stage process
whereby dye is mixed with a detergent then, in a second step, dye is mixed with an
acid sucrose mixture. However a critical difference is that the same dye was used in
both steps of the Nu¨sse and Kramer method. In the current protocol separate dyes are
now used. This is probably due to technological development meaning that multiple
fluorochromes can be measured at once. However EMA is still used in this first step.
Various improvements to the method have been attempted over the years, reviewed by
Kirsch-Volders et al.[70], but the most significant development have come from Bryce et
al.[1, 62, 96, 97]. The method employed by Bryce et al. still uses the 2 stage lysis with
EMA, but the fundamental difference is the first dye (EMA) is photoactivated with the
cells before any lysis occurs. This binds the EMA to cells with membranes that have
already been disrupted, such as can be found in apoptotic and necrotic bodies. The
cells are then incubated with the second dye (SYTOX Green) such that all DNA in the
samples will stain with the second dye. This gives a double positive stain for apop-
totic/necrotic bodies allowing for easy discrimination from healthy and micronucleated
cells. A representation of this can be found in Fig. 2.11. The stains will only bind to the
DNA if the membrane has been disrupted, either by cellular processes such as apoptosis
or the use of chemicals to lyse the membranes. This is key to discriminating apoptotic
cells as the membranes of ‘healthy’ cells will be intact when the sample is stained with
EMA.
The method has been made into a commercially available kit (In Vitro Microflow R©
Micronucleus Assay Kit) by Litron Laboratories which contains protocols for both sus-
pension and attachment cell lines [93]. However, the method has not been tried in
human attachment cell lines, or in cancerous cell lines before. After confirming some
details with Litrona, it was decided that the protocol should still work as the LN18 cell
line is still actively cycling, aided by the p53 mutation in the LN18 cell line [98].
Given the proven success of the method in inter-laboratory testing [1] and when compar-
ing flow cytometry and microscopy results [96], no further investigation was necessary
aPersonal Correspondence with Stephen Bryce
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Figure 2.11: Double Fluorescent Stain Technique for MN Detection. Reproduced
from [93].
to find other flow cytometric methods for MN detection. It should be noted that experi-
ence with attached cell lines and the In Vitro Microflow R© kit is limited [99] and nothing
has been published using human or cancerous cell lines. The In Vitro Microflow R© kit
was chosen as the preferred method for micronuclei detection given that results from
experiments are obtainable within a couple of days from treatment, depending on cell
cycle duration, which satisfies one of the key aims for the experimental part of this work,
to be completed in under a week.
2.8 Detection of DSBs
2.8.1 General
Two main experimental techniques will be reviewed in this section, PFGE and the
γH2AX assay. Whilst there are other experimental techniques that can measure num-
bers of DSBs, PFGE and the γH2AX assay are the most common. PFGE is the more
mature technique, but recently the γH2AX has been extensively used, probably due to
the protocol’s relative ease compared to PFGE studies. There are other methods for
quantifying DSB breaks, such as sedimentation, where fragments of DNA move through
sucrose at a rate which can be used to determine fragment size [100]. Elution methods
can also determine DSB counts by fragments lysing cells on a microporous membrane
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and denaturing the DNA helix such that fragments elution time is based on their molec-
ular weight [101]. Both of these methods have become less favourable for quantification
of DSBs due to their lack of sensitivity to lower doses of IR and development of other
gel electrophoresis methods described below.
2.8.2 Pulsed Field Gel Electrophoresis (PFGE)
The basic principle of gel electrophoresis is to hold chromatin in an agarose gel and
apply a potential difference such that the chromatin separates based on the size of the
fragments. Standard gel electrophoresis has a resolution limit of 50 kilobases. In order to
differentiate between larger fragments of DNA, a modified approach is used. Pulsed Field
Gel Electrophoresis is an extension of gel electrophoresis where the current is alternated,
in order to separate larger agglomerations of chromatin, that would stick together in
standard gel electrophoresis protocols. This pulsing can differentiate fragments as large
as 10 megabases [102].
Whilst PFGE is widely used, Barnard et al. [103] state that caution should be used when
measuring damage done by IR. During the preparation of PFGE samples, labile sites
can induced by IR can be converted to DSBs curing cell lysis. Barnard et al. estimate
this could be contribute to approximately 30 % of all measured DSBs. A linear dose
response, in terms of number of DSB, when measured by PFGE up to doses of several
hundred Gray. The caveat to this is that the technique is not as sensitive at lower doses
[103].
Several authors [35, 103, 104, 105] have shown that the DSB dose response is linear with
dose. With most agreeing that the number of DSBs is approximately 40 DSBs per Gray
per mammalian cell.
Within the scope of this project, PFGE has some drawbacks. Principally among these
is that it is most effective at doses above those used in clinical radiotherapy. To address
this, immunofluorescence based assays could be used used, which are sensitive to lower
doses than PFGE.
2.8.3 Immunofluorescent Staining and the γH2AX Assay
DNA strands are packed into structural units called nucleosomes, which contain 8 sub
units called histones which are formed of 2 of each of the core histone families - H2,
H3, H2B and H2A. One of the minor variants of the H2A histone is known as H2AX
[106]. The H2AX histone is thought to represent between 2 and 25% of the cellular H2A,
with other estimates falling within this range [107, 108]. As a response to IR the H2AX
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homolog becomes rapidly phosphorylated, in the order of 1-3 minutes [109] and is given
the notation of γ before it [106]. This is further confirmed by Burma et al. [110] who
also show that the phosphorylation is dependent on the presence of ATM.
Most authors [106, 111, 112] agree that every γH2AX focus corresponds to a single
DSB. Sedelnikova et al. [113] raise concerns over the assumptions made in Rogakou et
al.’s work [112]. Sedelnikova et al. [113] suggests that in cases where the break ends
are separated by a significant distance, such as the case in micronuclei formation, that
two foci would form. This is dismissed on the basis that the frequency of these events
‘would not be expected to increase the ratio of γH2AX foci to DSB ratio significantly’
[113]. Similarly, Sedelnikova et al. [113] note that there could be DSBs that are not
counted if DSBs occur in close spatial proximity, the example given is the approximate
diffusion range of an OH radical being 6 nm, as a single focus covers megabase sections
of chromatin. This, in practice, would be difficult to quantify.
Paull et al. [109] also show evidence that γH2AX foci co-localise with other repair
factors such as Rad50 and the MRN complex, showing that γH2AX plays an important
role in both NHEJ and HR. It should be noted that the recruiting of Rad50 is on a
longer timescale than that required to recruit the MRN complex, which would probably
be due to the availability of the HR repair pathway being limited to certain phases of the
cell cycle. It is important to note that γH2AX foci can also be induced in S phase cells
by exposure to UVB, UVC or drugs such as MMS amongst other agents by inducing
replicative stress [108]. Whilst this is unlikely to make a difference in experiments with
IR, MMS is a common aneugenic alkylating drug used in the study of base excision
repair.
Takahashi and Ohnishi [108] state that IR induced γH2AX foci phosphorylation is
controlled by ATM and DNA-PK, which are key parts of the HR and NHEJ repair
pathways respectively. Normally ATM is present throughout the cytoplasm, but it
transfers into the nucleus to aid the phosphorylation of γH2AX .
Apoptosis, also known as programmed cell death, is one of many pathways by which
cells are destroyed. It is a well understood process ([12], Sec. 3.2), and given one
possible fate of MN being apoptosis [114], it is essential to understand any factors that
may affect the model output. Srivastava et al.[107] give a detailed review of γH2AX
phosphorylation and state that when cells begin to fragment during apoptosis, H2AX
becomes phosphorylated. If the γH2AX response is being measured this should be
taken into account to avoid systematic errors occurring.
The γH2AX assay has been used for many years to visualise the double strand breaks
that arise from either drug or IR treatment. However there is still some speculation
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about the accuracy to which these assays can predict numbers of DSBs. In the field
of radiobiology, there are a number of texts [35, 113, 115, 116, 117, 118] that claim 40
DSBs will be created per Gy per human diploid cell. However, this number of 40 DSBs
per Gy per cell is not universally recognised. For instance Paull et al. [109] show data
for cells irradiated with 12 Gy from a Cs137 source, which gave a maximum of 50 γH2AX
foci and Barazzuol et al. [119] reports 12 γH2AX foci for 2 Gy of photon irradiation 1
hour after exposure. The estimate of 40 DSBs per Gy per Cell given in ‘Basic Clinical
Radiobiology’ edited by Steel [115] has been revised to 20-40 in the 2009 edition edited
by Joiner and Van der Kogel [12]. It has been shown that there is a dependence on LET
for γH2AX foci formation ([12], Sec 4.7). Similarly, experimental results are given in
Sorokina et al. [120] who state 5 γH2AX foci per Gy per cell using Co60 source for
γ-rays.
2.8.4 PFGE Vs γH2AX Assay for DSB Quantification
Presented in the sections above have been a number of figures for yields of DSBs when
exposed to photon based irradiation. Estimates of DSB yield based on the γH2AX assay
range from between 12 to 50 DSBs per Gy per mammalian cell while most authors, based
on PFGE and γH2AX data agree that the yield is between 20 and 40, with most stating
40 DSBs per Gy per mammalian cell.
One of the key considerations when measuring numbers of DSBs is whether the measure-
ment being taken is a physical representation of the break itself or the cell’s response to
the damage induced. Both approaches have merit based on the nature of the analysis.
Whilst it is now widely accepted that 1 DSB equates to a single γH2AX foci, which
Rothkamm and Lo¨brich [105] also confirmed using parallel experiments using PFGE,
the counting of the foci can be problematic. As with all image analysis, subjectivity
is introduced by individuals scoring foci differently. In addition to this, higher doses
may make individual foci difficult to score, particularly with high LET radiation. An
example of this can be seen in Fig. 5.3.
There is some discrepancies in the literature about the time period in which the cell
begins to repair. Studies using the γH2AX assay agree that the maximum number
of strand breaks is seen between 30 minutes and 1 hour after exposure [42, 121, 122].
However, using PFGE methods, it has been shown that a significant proportion of the
initial numbers of DSBs have been repaired by this point [103, 123, 124]. Barnard et
al. [103] state that this discrepancy is possibly due to the detectability of foci formed
soon after treatment or the fluorescence being indistinguishable from background noise.
This could be down to experimental technique as Rothkamm and Lo¨brich [105] used a
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3 minute post treatment time point where PFGE and a γH2AX assays were almost
identical, 39 DSBs per Gy and 36 foci per Gy respectively. The only different between
the two experiments were that the PFGE experiments were conducted between 10 and
80 Gy, whilst the γH2AX experiments were conducted at 0.2 and 2 Gy.
As well as background noise, the levels of DSBs are known to vary greatly from cell line
to line and between cell phases due to errors in cellular functions, like replication fork
stalling during DNA synthesis [125]. Similarly to MN, background γH2AX foci can
also be influenced by epidemiological factors, such as smoking [126]. It is clear that the
γH2AX has a place in biodosimetry, given its relative ease compared to other methods
of DSB detection, but the data must be considered with some caution. Whilst PFGE
would appear to be the more accurate method for DSB detection, in terms of it being
less susceptible to error when compared to the γH2AX assay, at lower doses γH2AX
may be more sensitive for absolute numbers of DSB.
As the MiNiMUS model is, initially, designed to work with a fixed number of DSBs per
Gy, it is proposed that the general consensus between PFGE and γH2AX assay of 40
DSBs per cell per Gy is used as the basis of the model. Further details of the modelling
efforts are given in Sec. 3.4.
2.9 Radiobiological Modelling
2.9.1 Introduction
Despite great advances in the field of radiobiological modelling, there are no track struc-
ture models that currently predict the formation of micronuclei. It could be argued
that chromosomal aberrations are often overlooked as the goal of larger scale models
are to predict cellular proliferation or cell death. With DSBs widely being recognised
as a key contributor to this [100, 127, 128, 129], it is not surprising that other chro-
mosomal aberrations such as dicentrics, sister chromatid exchanges and micronuclei are
overlooked despite their potential role in cell death mechanisms.
The goal of MiNiMUS, in this proof of concept stage, is to predict the number of mi-
cronuclei. Whilst this could be achieved using solely a track structure model there are
better methods to achieve this. A track structure model attempts to model the path
of a radiation track as it interacts with biological matter, typically predicting strand
breaks. On a lengthwise scale the prediction of DSBs is on a much smaller scale than
MN. The plan is to use a decision tree to model the formation of micronuclei; however
it is possible that a track structure model could be used to drive the MiNiMUS model.
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So in this section literature about modelling DNA damage, specifically DSBs will be
reviewed.
Mechanisms of MN formation have been covered previously in this chapter, but it is
important to note that they can be formed from other chromosomal aberrations, such
as the breakdown of nucleoplasmic bridges [49]. The model by Countryman and Heddle
[130] does consider chromosomal aberrations such as rings, dicentrics and translocations,
but does not consider repair mechanisms. Whilst it could be worth considering other
models of chromosomal aberration and then adapting them to fit MN formation, an ab
initio approach is preferred.
A track structure model would be used to give the amount of initial damage, in the form
of DSBs, that should be considered for a specific radiation dose and quality. If a track
structure model were used with the MiNiMUS model, selection of the model would be
key as many models consider DSBs an intermediate and report cell survival as the main
output. Equally, some models would not be suitable as they only valid for certain cell
lines or radiation types.
2.9.2 Model Types
Models can broadly be defined as wholly phenomenological or based on fundamental
theory in the most part. The borders start to blur where some ‘fundamental’ models are
integrated with equations like the Linear Quadratic (LQ), which is phenomenological.
Cell growth models can be classified as segregated or unsegregated and structured or un-
structured. Unsegregated models consider the cells to be a homogeneous mass whereas
segregated models will give each cell individual characteristics [131]. Similarly, struc-
tured models include details of the varying composition of intracellular components,
often in the form of a mass or molar balance of components of interest [132]. There is
a trade-off because structured, segregated models are computationally more demanding
whereas unstructured, unsegregated models are less complex and will compute quicker.
Although these descriptions are based on cell growth models in continuously stirred
tank reactors (CSTRs), also known as ‘chemostats’, the principle can be applied to
other forms of biophysical modelling. The MiNiMUS model considers each cell to have
its own individual characteristics hence it is a segregated model. As the MiNiMUS model
contains no cellular growth, beyond the cell reaching the M phase but not completing it,
and each cell is being treated individually there is no intra-cellular components to model
in the case of radiation it would be an unstructured model. The CSTR assumption may
not hold true for all types of radiobiological experiments as CSTRs are a well mixed
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system. However, the assumption should be valid for in vitro cell culture as the media
covers the cell monolayer. There is no internal agitation in the flasks, but as they are
moved around on a day to day basis the assumption should still be valid.
2.9.3 Overview of Models
Nikjoo et al. [133] provide an overview of Monte Carlo (MC) track structure codes.
They give a great amount of depth into the mathematics of track structure models.
As the table reproduced below, Fig. 2.1, only gives MC codes there are some notable
models not included.
Code Particle Energy range Reference
CPA100 e− ≥10 eV100 eV e− Terrissol and Beaudre, 1990
DELTA e− ≥10 eV10 keVe− Zaider et al.. (1983)
ETRACK e− , p ≥eV10 keVe− Ito (1987)
KURBUC e− ≥10 eV10MeVe− Uehara et al.. (1993)
LEEPS e− , e+ 0.1100 keV Fernandez-Varea et al.. (1996)
LEPHIST p ≥1 keV1MeV Uehara et al.. (1993)
LEAHIST α ≥1keV/u2MeV/u Uehara and Nikjoo (2002a)
MC4 e− , ions ≥10 eV e−, ions ≥ 0.3MeV/u Emfietzoglou et al.. (2003)
NOTRE DAME e− , ions ≥10 eV e−, ions ≥ 0.3MeV/u Pimblott et al.. (1990)
OREC e− , ions ≥10 eV e−, ions ≥ 0.3MeV/u Turner et al.. (1983)
PARTRAC e− , ions ≥10 eV e−, ions ≥ 0.3MeV/u Friedland et al.. (2003)
PITS04 e− , ions ≥10 eV e−, ions ≥ 0.3MeV/u Wilson et al.. (2004)
PITS99 e− , ions ≥10 eV e−, ions ≥ 0.3MeV/u Wilson and Nikjoo (1999)
SHERBROOKE e− , ions ≥10 eV e−, ions ≥ 0.3MeV/u Cobut et al.. (2004)
STBRGEN e− , ions ≥10 eV e−, ions ≥ 0.3MeV/u Chatterjee and Holley (1993)
TRION e− , ions ≥10 eV e−, ions ≥ 0.3MeV/u Lappa et al.. (1993)
TRACEL e− , ions ≥10 eV e−, ions ≥ 0.3MeV/u Tomita et al.. (1997)
Table 2.1: Table of MC codes used in biophysical modelling, adapted from Nikjoo et
al.[133].
A few models for radiation based simulation will be looked at in further detail in Sec.
2.9.7. The models looked at in more detail are models which are still either in active
development or used clinically.
2.9.4 Chromosomal Aberration Models
Whilst there are no models that currently predict MN formation as a result of IR, models
of other chromosomal aberrations exist. DiPierdomenico et al. [134] and Li [135] use
chromosomal aberrations to predict carcinogenesis, whilst Sachs et al. [136] predicts the
formation of the aberrations themselves.
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DiPierdomenico et al. [134] uses umbrella terms for defining groups of chromosomal
aberrations. They are defined as either clonal of non-clonal chromosomal aberrations
(CCA or NCAA). The kinetic model presented focusses on the formation of NCCAs,
CCAs and the relationship between the two. The model topology is reproduced in Fig.
2.12
Figure 2.12: Model Topology from the work of DiPierdomenico et al. [134].
A system of differential equations is established to describe the populations of CCAs
and NCCAs across several stages of cancer, although these stages seem to bear no
resemblance to stages as defined by the WHO. The model, as of the 2006 paper, predicts
experimental results to a reasonable degree, but does not cope with later stages of
evolution.
Li [135] aims to predict carcinogenesis based on chromosome aberrations. He compares
the use of decision tree models to Bayesian network structures using principle component
analysis to predict an order of events relevant to tumour progression. Li highlights a
drawback of tree based models being that interaction between pathways as there is only
a direct link to the parent state. This is also true in the model proposed in this work.
However, the simplicity of the MiNiMUS model makes this less important as the major
conflicting point would be pathway of DSB repair and it is assumed that a single DSB
will only be repaired by one pathway at one time. If it were possible that a DSB could
be repaired by NHEJ and if that failed, HR, then the issue would not be with the tree
itself, but the ‘external’, to the tree, assumption that a DSB only has one opportunity
to undergo repair.
Whilst Li states that Bayesian networks offer a richer hypothesis, such as cause and
effect events where the cause is attributed to multiple parent events, he also states that
the main drawback to a Bayesian type analysis is the number exponential number of
parameters, which would be difficult to validate.
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The approach of Sachs et al. [136] is the most similar to the work presented here.
They present a model of aberration formation, based on graph theory, where the initial
consideration is DSBs and the model predicts different types of aberrations, combined
with experimental work using variations of FISH. As far as can be determined, the model
would not be able to predict MN formation. The Sachs model relies on the DSB ends to
be rejoined in some configuration and ‘incompleteness’ is not handled in the same way.
As MN, arising from IR, are fragments of DNA that have not been repaired, they would
fall into the ‘incomplete’ category.
2.9.5 Phenomenological Models
2.9.5.1 General
This section gives brief details of some of the phenomenological models used in radiobi-
ology. These are often used in track structure models, see Sec. 2.9.7, and so have been
described here.
2.9.5.2 Target Models
The single-target single-hit model, ([12], Sec. 4.6), assumes that just a single radiation
interaction in a specific place (target) is enough to inactivate the cell. The resulting
equation for survival is given in Eqn. 2.2.
p(Survival) = exp(−D/D0) (2.2)
The model is based on Poisson statistics and so the probability of survival is the prob-
ability of a cell receiving 0 hits. D0 is defined as the dose to cause an average of 1 hit
per cell.
This model produces a straight line on a log linear survival curve plot. Whilst this
may be appropriate for high LET radiation ([35] Fig. 3.3), but is not appropriate for
treatments such as X-rays as dose response curves for X-rays have a pronounced shoulder
type curvature at low doses, see photon dose response in Fig. 2.1.
An extension of this is the multi-target, single-hit model. The probability of a specific
target being inactivated can be described as 1 − p(survival) as described above. As
the name suggests, with a multi-target model, if a cell has more than one target, the
equation should be modified to account for this, see Eqn. 2.3.
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p(all n targets inactivated) = (1− exp(−D/D0))n (2.3)
The probability of survival is 1− p(all targets inactivated). This gives a similar form to
the survival curve, a straight line, but with a pronounced shoulder. This resembles em-
pirical observation more closely, but not perfectly as the gradient as the dose approaches
zero is also zero. This suggests that radiation has no effect at low doses which is not
supported by experimental evidence and, in fact, some cells lines show an enhanced cell
killing effect at low doses [137].
2.9.5.3 The Linear Quadratic (LQ) Model
The LQ model, while not a track structure model, is the de facto model used in many
laboratories and some clinical settings. It is an empirical model, although attempts have
been made to attach radiobiological relevance to its form ([12], Sec. 4.8). The linear
quadratic can be written as per Eqn. 2.4.
p(survival) = exp(−αD − βD2) (2.4)
Often survival curves are described by the ratio of alpha to beta. Joiner et al. ([12],
Sec. 4.10) state that a simplistic view could be that the alpha term represents single
track events and the quadratic component might arise from two track events. This
has not been proved and to a certain degree does not need to be proved as the model
has been shown to work empirically. However, a model based on first principles would
be more desirable. The drawback to the LQ model is that at low and high doses the
model sometimes breaks down. The model does not predict low-dose hypersensitivity.
At higher doses the output of the model causes the gradient to continue bending, but
this is not supported by experimental evidence which tends to exhibit a linear gradient
at higher doses ([35], Ch. 3). Low dose hypersensitivity is typically seen at doses below
1 Gy.
2.9.6 Other Phenomenological Models
Other phenomenological models exist for measuring cell survival, such as the Repairable
Conditionally Repairable (RCR) model, a modification of the LQ model, by Persson
[138] or the Lethal-Potentially Lethal (LPL) model by Curtis [139]. However, as stated
in Sec. 2.9.1 the focus in this part of the literature review is track structure models as
most phenomenological models predict cell death rather than strand breaks. The models
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presented above are for background knowledge as some track structure models use the
LQ model for certain calculations.
2.9.7 Track Structure Models
2.9.7.1 PARTRAC
PARTRAC started 25 years ago [140] and is still in active development at the Helmholtz
Zentrum Mu¨nchen.
The model is formed of a number of modules that interact with each other, each dealing
with a specific aspect of radiobiological modelling, for example, modules pertain to DNA
damage and separate modules dealing with the DNA target model exist. Fig. 2.13 is
extracted from Friedland et al. [141] showing the interaction of modules in PARTRAC.
Figure 2.13: PARTRAC Module Interactions Reproduced From [141].
2.9.7.2 PARTRAC Track Structure Calculation
As with other track structure models, PARTRAC follows the radiation source and sub-
sequent secondary particles from entry into the medium until they stop or exit the
medium, predicting energy deposition and interaction with the target model. PAR-
TRAC can predict the behaviour of photons, electrons, protons and other ions. It does
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this by assuming the medium is liquid water, which is a fairly common assumption
[133]. Each type of radiation source is modelled differently, but the only relevant types
for integration with MiNiMUS would be ions and photons. Photons are modelled using
data from the Evaluated Data Photon Library (EDPL97), which has interaction data
for photons with elements from atomic number 1 to 100.
PARTRAC uses the plane-wave Born approximation (PWBA) and the Bethe approxi-
mation for both light and heavy ions. The inverse mean free path (IMFP) for an ion is
calculated as the same as the IMFP for a photon with the same velocity multiplied by
the square of the effective charge (Z2eff ). Z
2
eff is calculated using the Barkas formula
[141].
Rather than the approaches taken in LEM and other models, where the effect of sec-
ondary electrons is based on radii from the main track, PARTRAC calculates the for-
mation of free radicals and their diffusion through the assumed water media on a time
basis. This is much more of a molecular dynamics type approach and while rigorous, it
could lead to long computation times. Friedland et al. [142] acknowledge this and have
made the time steps adjustable so a good compromise can be found.
2.9.7.3 PARTRAC DNA Target Model
In 2006, Friedland et al. [143] described the DNA target model in detail. A model of 6
billion base pairs (bp) of DNA is constructed. The smallest unit is a representation of a
nucleosome with 30 of these nucleosomes connected to form a chromatin fibre of 50 nm
totalling just over 6000 base pairs. These chromatin fibres are then stacked in 3s to form
a chromatin fibre stick which form the basis for the rest of the target model. A spherical
domain of roughly the size of a nucleus is divided into 46 chromosome territories, filled
with loops of 72 kbp made from chromatin fibre sticks totalling 0.5 Mbp. This has been
revised by the authors a number of times, but the basic idea of building a longer element
from small building blocks has remained.
In the 2011 review article [141], the DNA target model was described again. The target
model now depends on what is being investigated. A study looking at chromosome
fragmentation, which is a perfect match for MiNiMUS given how micronuclei are formed,
stated that the virtual nucleus size had increased to 15 µm in diameter and 5 µm in
height and was divided into 46 domains. However, this means that the model can
probably not predict aneuploidy as it is assumed that these 46 domains are fixed and
represent one chromosome each.
Each chromosome is made from the basic 50 nm elements connected to make a single
loop for each chromosome. The total genomic length is 6.6 Gbp. However, the DNA
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target model does vary greatly depending how PARTRAC is set up for a particular
investigation.
The DNA target model has the track structure superimposed on it to calculate the
damage. It is noted that the track structure calculations are based on a liquid water
target and the presence of chromatin will alter these results. Similar to the LEM, there
is a conversion of SSBs to DSBs depending on number of base pairs between them. In
the case of PARTRAC, this distance is only 10 bp. In addition to this 1% of the SSBs
induced will be converted to DSBs. The LEM uses a 25 base pair limit for converting
SSBs to DSBs. Friedland [141] gives details of the sensitivity analysis of both the base
pair threshold and the conversion:
“. . . increasing the distance between two SSBs for being scored as a DSB from 2 to 10
bp enhanced the DSB yield almost by a factor of 3; varying the rate of SSB to DSB
conversion from 0 to 3% increased the DSB yields by 50-100%.”
The PARTRAC model has shown data to support the assumption that the proximity
of SSBs causing additional DSBs to be much lower than assumed in other work such
as the LEM, 10 as opposed to 25 in the LEM [141, 144]. Although the data presented
by Friedland et al. (PARTRAC) is reportedly backed by empirical evidence, Elsa¨sser et
al. also claim to have used experimental data to support their assumption of 25 bp, so
there are further questions to be asked regarding the true conversion rate or whether
experimental design played a role in the outcomes being different.
It is beyond the scope of this literature review and project to look at this conversion in
depth, given that the MiNiMUS model does not currently consider SSBs, but it should
be noted as it may become relevant if PARTRAC is ever implemented to work as a
driver for the MiNiMUS code.
PARTRAC also appears to have a unique aspect to its model for damage induction.
Most other models have a set number of DSBs and SSBs per Gy whereas PARTRAC
includes damage according to a correlation of LET to DSB yield per Gy and Gbp. This
gives flexibility to the damage induction features of the model to adapt to changes in
the DNA content of cells as they progress through the cell cycle.
PARTRAC also includes modules for Non Homologous End Joining (NHEJ) repair.
NHEJ is an important pathway for DSB repair ([12], Sec. 2.7). For the purposes of
integrating PARTRAC and MiNiMUS, the PARTRAC repair modules would have to
be turned off or configured carefully so as not to interfere with the similar parts of the
MiNiMUS model.
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As with many models, PARTRAC is very complex. Friedland gives information on
the PARTRAC sensitivity analysis and states that whilst some of the parameters are
empirically derived, some are derived by a trial and error fitting process until the output
of the model matches experimentally observed results. He also states that PARTRAC
has been set up for use on one cell line and that adapting the model to use in other
models in his own words; “needs careful consideration” [141].
The biological impact in PARTRAC is measured by the number of SSBs, DSBs and
complex DSBs. Friedland [141] also states that cell inactivation has been studied with
PARTRAC along with observed LET dependence, but the biology of cell inactivation or
death in PARTRAC is not currently covered in the PARTRAC literature.
2.9.7.4 The Local Effect Model (LEM)
The Local Effect Model (LEM) was developed at GSI Helmholtz Zentrum fu¨r Schwerio-
nenforschung (GSI) [145] and is used in treatment planning at the HIT facility [146]. The
LEM has gone through several revisions and is currently in the 4th version. Siemens have
a separate implementation of the LEM, which is in use in their proprietary treatment
planning software [147].
The 3 main constituents of the LEM are: a photon survival curve, the radial dose profile
and a target geometry.
The LEM uses a track structure model, however underlying that is a photon dose re-
sponse curve and so is not based on a first principles approach. To take account of ion
species, LEM uses the Relative Biological Effectiveness (RBE). RBE is defined in ([12],
Glossary) as:
“Ratio of dose of a reference radiation quality and dose of a test radiation that produces
equal effect”.
RBE values are dependent on several factors such as particle species, Linear Energy
Transfer (LET), tissue properties, dose, oxygen concentration etc. [147].
The local dose deposition is calculated using a track structure model, taking into account
secondary electron emission arising from the radiation track. For every radiation track,
the average radial energy deposition is calculated using an approximate radius-based
inverse power law. The equation for a local dose (dloc) in a subvolume (∆V) of the cell
nucleus Vnucleus and a local biological effect (∆EIon(dloc)) is derived from the photon
dose response curve using the LQ parameters (α and β) where the subscript denotes
they come from a photon dose response curve.
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∆E(dloc) = −lnSγ(dloc) ∆V
Vnucleus
= (αγdloc + βγd
2
loc)
∆V
Vnucleus
(2.5)
The LEM is primarily concerned with DSBs, but if single strand breaks (SSBs) occur
within a certain number of base pairs of each other, the assumption in Scholz’s 2006
[144] paper is 25, they are considered to be a DSB. DSBs are ‘induced’ across the DNA
using a Monte Carlo simulation method, although the exact method is not given.
Similarly, if more than one DSB is found in a subvolume, then it is termed a clustered
DSB. The complexity of a single ion traversal is defined as being the ratio of the number
of clustered DSBs to the total number of DSBs. This complexity then affects the overall
effectiveness of the dose. The more clustered DSBs there are, the greater the overall
effectiveness of the dose and so the number of surviving cells is assumed to be less.
The complexity parameter will be affected by the size of the subvolume. For instance,
if the subvolumes were sufficiently large such that most subvolumes contained clustered
DSBs then the effectiveness of the radiation would be greatly exaggerated. The total
target volume is considered to be 500 µm3 which is roughly the size of a cell nucleus
[148]. The size of the subvolumes was found by fitting to experimental data for the
parameter IDSB which is defined as the length of the cuboidal element of a subvolume.
The fitted value was 540 nm for each subvolume, giving 3200 subvolumes in total for
a nucleus volume of 500 µm3. PARTRAC uses a similar method, but reports their
cylindrical nucleus to be 15 µm diameter by 5 µm giving a nucleus volume of just under
900 µm3 [141].
However despite the reliance on photon dose curves, the LEM is one of the few biophys-
ical models in clinical use for ion therapy [145].
2.9.7.5 Microdosimetric Kinetic Model (MKM)
This is a Japanese model by Kase et al. [149] similar to the LEM by Elsa¨sser et al. [144].
The MKM uses a photon dose response curve, similar to the LEM, to estimate the local
dose effect and then uses values of RBE to work out survival when using ion sources.
As with the LEM, the target nucleus is divided up and the local effect is calculated in
each subvolume. The cell survival probability is calculated using the summation of all
the local effects.
Although both MKM and LEM use photon survival curves, they are not calculated in
the same way. LEM uses a modified LQ model with a threshold dose as detailed in
Eqn. 2.5 and MKM uses the standard LQ model. MKMs main advantage over LEM is
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that the overestimation of RBE of lighter ions seen in some versions of LEM [150] is not
present in MKM.
One of the main differences between MKM and LEM is the track structure model that
dictates the local doses experienced by the subvolumes. Kase et al. [149] compared
an implementation of the LEM track structure model with the Kiefer-Chatterjee model,
itself, reportedly, a mix of a model from Kiefer and Straaten and Chatterjee and Schaefer,
as reported by Kase et al.. The particulars of the mixed model are covered by Kase et
al.[149]. The drawback to the Kiefer-Chatterjee track model is that it does not take into
account free radicals formed during radiation interactions, which are known to contribute
to the overall effect of the track ([35], Ch. 1) and so the Kiefer-Chatterjee track model
was unable to predict experimental data when using LEM-like principles. However Kase
states that this is not important in the MKM. The MKM model results presented show
good agreement with experimental results in terms of dose averaged LET estimation
[149].
2.9.7.6 Wang Model
Wang [151] reviews the LQ model and the LEM. Some of the shortcomings of the models
are highlighted, although there is no mention of which version of the LEM was analysed.
In addition to this, he gives a detailed description of a Monte Carlo-based radiobiological
model. The suggested flow diagram is reproduced in Fig. 2.14. Not stated in the
overview is the intention that all the clinical data collected should be put into a network
structure, based on systems biology methodology to understand the interaction between
both inter- and intra-cellular pathways that deal with repair of DNA damage.
This also highlights what is perceived to be the limiting factor in the model: Wang states
that details should be given about the oxygenation state of the tumour, cell types of the
surrounding cells, genetic make-up of the patient etc. Validating all of these parameters
will be particularly difficult as they will be challenging to determine in vitro, and in vivo
data may not be applicable.
To date, Wang [151] has had no follow up paper but, it has been cited by the 2011
PARTRAC paper [147]. Unfortunately it was a passing reference to the work, rather
than an in depth discussion on the ideas raised in [151]. Wang’s model is also cited
by El Naqa et al. [152] who provide a review of common techniques for modelling of
radiotherapy outcomes. In general, El Naqa et al. [152] agree with the idea that a
multi-scale model in both spatial and time domains could prove to be fruitful, but as
the main focus of the El Naqa et al. work was a review of Monte Carlo methods for
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Figure 2.14: The Wang Model [151].
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track structure and energy deposition models it was also more of a passing reference to
the work of Wang [151].
2.10 Summary
In this review, a number of key findings that direct both the experimental and mod-
elling methods have been stated. The aim of this project is to create a tool to assess
the effectiveness of radiation via micronucleus formation on a rapid timescale. Flow
cytometry offers rapid experimental quantification of MN frequency in cell cohorts by
using a double DNA staining technique. The method is proved to work in PBLs but has
yet to be done in human cell lines. Although the dose response for adherent cell lines
is not as well characterised, there still appears to be a generally positive dose response.
Failing this, the dose response in PBLs is predictable enough to allow modelling efforts
to continue and still be an effective, rapid assessment tool for assessing the sensitivity
of tissue to radiation response.
Track structure models could provide insight into the level of damage induced by IR. A
model like the LEM will predict damage inflicted, but is based on ion radiation tracks.
PARTRAC would be a better solution because the final model output is number of DSBs
which would suit the purposes of MiNiMUS input parameters. At this point, it would
not be viable to try to implement a track structure model to calculate damage induction,
but in the future it may be a sensible addition to the model. In the following chapter
a novel model is proposed to predict the formation of micronuclei, supported by a flow
cytometry based experimental programme.
Chapter 3
Methodology
3.1 Introduction
This chapter gives details of the methods identified in the previous chapter that best
fit the aim of providing rapid assessment of radiation induced micronuclei. This is
mostly by using the In Vitro Microflow R© flow cytometric analysis and the validation of
this process for use in mammalian attachment cell lines and, more importantly, human
cancerous cell lines. The details of the MiNiMUS model are given and the methods for
validating the tree structure code, the Monte Carlo methods and sensitivity analysis.
3.2 Tissue Culture and Protocols
3.2.1 Cell Line Particulars
3.2.1.1 LN18 and V79 Culture
LN18 is a well characterised, human glioblastoma cell line, widely used in the radiobi-
ology community. Similarly, V79 is a Chinese hamster lung cell line that is commonly
used in the radiobiology community. LN18 cells were cultured with Eagle’s minimal es-
sential medium (EMEM) with Earle’s balanced salt solution and without L-glutamine,
supplemented with 10% fetal bovine serum (FBS), 1% MEM Eagle non-essential amino
acids (NEAA), 1 mM sodium pyruvate (Invitrogen, UK), 1500 mg/L sodium bicarbon-
ate (Invitrogen, UK), 1% penicillin/streptomycin and 4mM L-glutamine. All medium
and constituents are from Lonza, UK, unless otherwise stated. This medium was used
for all flow cytometry experiments in this work. Subculture of cells was achieved by a
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1:4 split of a confluent monolayer in the case of LN18 or a 70% confluent monolayer in
the case of V79.
For the microscopy work, see Sec. 3.3.2, a different culture medium was used. LN18 was
cultured in Dulbecco’s modified Eagle’s medium (DMEM), supplemented to contain
5% FBS, 4 mM L-glutamine, 1 mM sodium pyruvate, 1500 mg/L sodium bicarbon-
ate, 4500 mg/L glucose and 1% penicillin/streptomycin. The V79s also used DMEM
media (Lonza, UK), supplemented to contain 5% FBS, 2 mM L-glutamine and 1% peni-
cillin/streptomycin.
3.2.1.2 M059J and M059K Culture
M059(J/K) is another human glioblastoma cell line, purchased from the American Type
Cell Culture bank. The J variant is exactly the same as the ‘normal’ K variant, except
it is lacking DNA-PKcs, meaning that it cannot perform NHEJ repair. This makes
the cell line very difficult to culture, but does give a model system to show the di-
rect affect of NHEJ repair. M059J and K were cultured using a 1:1 mix of DMEM and
Ham’s F12 medium (Invitrogen, UK), adjusted to contain 10% fetal bovine serum (FBS),
0.05 mM MEM Eagle non-essential amino acids (NEAA), 0.5 mM sodium pyruvate (In-
vitrogen, UK), 1200 mg/L sodium bicarbonate (Invitrogen, UK), 1% penicillin/strepto-
mycin, 15 mM HEPES and 2.5 mM L-glutamine. All medium and constituents are from
Lonza, UK, unless otherwise stated. Subculture of cells was achieved by a 1:6 split of
confluent monolayers.
3.2.2 Passaging of Cells
Adherent cells were grown in cell culture angled neck flasks (Nunclon ∆ 25 cm3 or
75 cm3, Fisher Scientific UK) in an incubator held at 37 ◦C and an atmosphere of 5%
CO2. To passage the cells the culture medium was aspirated off and then the monolayer
washed with sterile phosphate buffered saline (PBS). After the removal of the PBS,
enough 0.25% trypsin/versene (EDTA) solution to cover the flask surface was added to
the flask and left to incubate at 37 ◦C for 5 minutes. The flask were then agitated to
aid cell detachment and 4 ml of medium added in order to stop the digestion of the
cell membranes by the trypsin. This was then put in a centrifuge tube (Corning 15
ml, Fisher Scientific UK) and spun down for 5 minutes at 1500 RPM. The supernatant
medium was drained, leaving just the cell ‘pellet’. The pellet was then resuspended
and reseeded in new culture flasks dependent on experimental requirement or at a level
appropriate for continuing subculture as defined above. Fresh medium was then added
in order to cover the flask surface to a depth of a few mls, typically 5 ml in a T25 flask.
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The passaged cells were then kept incubated with the caps left slightly open, if there
was no vent in the cap, with the passage number written on the flask if required.
3.2.3 Cryopreservation of Cells
Cells were trypsinised and spun down as per Sec. 3.2.2. They were then resuspended in
culture medium supplemented with an extra 10% FBS and 10% DMSO (dimethyl sul-
foxide) at a concentration of approximately 2x105 cells/ml and pipetted into cryotubes.
Cryotubes are then placed in a cell freezing container (Nunclon, Fisher Scientific UK).
The outer container is filled with isopropyl alcohol. The insert is shaped to hold cry-
otubes. The container was placed into the -80 ◦C freezer. The alcohol ensures that the
cooling rate remains at -1 ◦C per minute as recommended by Freshney [153]. Alterna-
tively, the vial was placed in a liquid nitrogen storage vessel. The choice between these
freezing methods was based on the available space in the nitrogen storage and current
stock of the cell line being preserved as cell viability can be lower with cells stored in a
-80 ◦C environment compared to those stored in liquid nitrogen.
To reanimate the cells, the cryotube was placed in a water bath until the contents melt.
The contents of the tube were placed in a centrifuge tube with fresh medium and spun
down for 5 minutes at 1500 RPM. This removes the excess DMSO which can be toxic
to cells. Cells were then resuspended in fresh medium and plated as per the normal
passaging routine, as detailed in Sec. 3.2.2.
3.2.4 Irradiation and Clonogenic Survival Assay
For clonogenic survival testing, exponentially growing cell lines were trypsinised and
replated in 6 well plates, (Nunclon ∆, Fisher Scientific UK), at least 5 hours before
irradiation. This was to ensure sufficient time to attach and flatten, but not regain the
ability to divide before the time of irradiation. The number of cells plated was dependent
on the dose the plate was to receive, as shown in Tab. 3.1.
After irradiation the cells were incubated for 14 days in medium. The medium was then
aspirated off and each well washed with PBS. After aspiration of the PBS, each well
was covered in a crystal violet solution (5% crystal violet in PBS) for 2 minutes. Other
methods, such as those proposed as Freshney [153] suggest fixing the cells first, however
the LN18 cell line proved to be hardy enough that this step is not necessary. One final
gentle rinse with PBS ensured that the crystal violet did not stain the bottom edge of
the wells making scoring in those regions difficult. The plates were then left to air dry
before counting, which typically took a couple of hours. The well plates were scored by
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Dose (Gy) Cells Seeded
0 120
0.5 130
1 150
2 200
3 250
4 350
5 600
Table 3.1: Seeding Numbers for Clonogenic Survival of the LN18 Cell Line.
marking each colony counted with a fine-tip permanent marker on the under side of the
plate, to ensure no colonies are double counted or not counted at all. The results in each
experiment is the average of the counts for the 6 wells seeded per dose.
Counting of the control cells gave the basis for calculating plating efficiency (PE). Plating
efficiency is defined ([35], Ch. 3) in Eqn. 3.1. This PE is then used to calculate the
survival fraction (SF) at a dose point as per Eqn. 3.2.
PE =
Colonies Counted
Cells Seeded
(3.1)
SF =
Colonies Counted
Cells Seeded ∗ PE (3.2)
Plating efficiency is an important factor in minimising systematic errors in experimental
results. It takes into account sub-optimal growth conditions, sensitivities to normal
cell handling activities like trypsinisation and other factors that are independent of the
experimental programme. An abnormally low plating efficiency can indicate results that
may need to be treated with caution.
3.2.5 Cell Counting
Counting of live cells can be done in a number of ways, for instance using a haemocy-
tometer or a Coulter counter. Cell counting is critical for some protocols that require
a known number of cells to be seeded, such as the clonogenic method in Sec. 3.2.4.
Coulter counters use the Coulter principle to estimate a number of cells in a sample.
Briefly, the principle states that a sample can be passed through an aperture that has 2
electrodes either side of it. By measuring the change in impedance between the plates
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as a cell passes through. This impedance profile is then compiled into a particle size
distribution histogram [154].
The method of choice for this project was to use a haemocytometer, which is a form
of microscope slide with a precision set of grids inscribed upon it. By placing a glass
coverslip over the sample area, fluid can be pipetted onto the cytometer, which is drawn
up by capillary action. By counting cells on the appropriate grid there the cell concen-
tration was calculated. The haemocytometer was used because although it may seem
that a Coulter counter is a more precise measure of cell concentration, the maintenance
and use of a Coulter counter takes makes it a less desirable option as any debris caused
by lack of use or maintenance may be passed through the aperture and incorrectly be
designated a cell. Another more immediate benefit of using a haemocytometer is the
ability to identify cells with compromised membranes by the use of stains such as trypan
blue.
Counting by a haemocytometer was achieved by taking 20 µl of cell suspension solution
and adding it to 20 µl of trypan blue solution and mixing. The use of trypan blue to
quantify both the overall cell concentration, as it gives a good contrast between cells
and the blue staining of the medium, and also quantify approximate concentrations of
dying cells as they stain blue. Cells were counted on the four 1x1 mm square quadrants
and an average count taken. The cell count was then doubled to take account of the
mixing with the trypan blue. The cell concentration is then calculated by multiplying
the cell count by 104 to give a concentration with units of cells per millilitre.
3.2.6 Growth Curve
Cells were seeded at 1x104 cells per well in 24 well plates with at least 1 ml of culture
medium in each well. Once per day, 3 of the wells were trypsinised and counted according
the protocol in Sec. 3.2.5. The doubling time (tD) was calculated by plotting the time
point versus log2 of the cell count. The doubling time is then the inverse of the gradient
of the linear portion of the graph.
3.2.6.1 Logistic Growth Curve
An alternative way of analysing growth curve data is by the logistic method, which is
summarised in Eqn. 3.3 where Cn is the cell number. Logistic growth can be used when
there is a limiting factor imposed on the population. In the case of cell growth the
medium is not changed and so nutrient depletion can be considered a limiting factor.
Alternatively if the cell seeding is high enough, confluence of the monolayer within the
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well could be considered a limiting factor. The constants k and Cnmax are determined
by a minimisation of the χ2 error, as defined in Eqn. 3.4, with the constraint that Cnmax
could not be less than the largest experimental value.
dCn
dt
= kCn(Cn max − Cn) (3.3)
χ2 =
N∑
i=1
(Cn ex,i − Cn model,i)
σ2ex,i
(3.4)
3.2.7 Irradiation of Cells with X-Rays
Cells were irradiated at the Royal Surrey County Hospital (RSCH) using the Gulmay
machine set to generate 250 kVp X-Rays in a 20x20 cm field. Cells were irradiated in
either multi well plates or Petri dishes with the seeding is dependent on the particulars of
the experiment. All cells were seeded at least 5 hours before the irradiation such that the
cells adhered to the surface and the plate surface was kept covered in culture medium.
The cells are kept incubated at 37 ◦C until they are transported to the hospital, where
they are carried in a polystyrene box to reduce exposure to large temperature gradients
and UV exposure from the sun.
The applicator was placed 1 inch above the ‘solid water’ phantom which leaves enough
room such that a treatment dish can be inserted between them. The dosimetry is
calculated by the hospital medical physicists to take into account the applicator used,
filter used and distance from the sample. As the Gulmay machine is a clinical device,
quality assurance is already in place such that there is good confidence in the ability to
deliver a precise dose. The machine is checked on a daily basis where it has to deliver
a 1 Gy dose with an accuracy of ±2%. More stringent QC processes are undertaken
on a bi-weekly basis. A surrogate unit is used to calculate the dose in Gy, called the
monitor unit (MU). This is so that aspects that alter dosimetry, such as applicator size,
can be accounted for mathematically. The RSCH staff then enter a number of MU
to be delivered by the machine, which equate to the dose required for that particular
experimental configuration. The doses used in the experimental work are also in the
same order of magnitude as the fractionated dose delivered to patients and so no further
investigation of the possible errors in dosimetry were explored.
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3.2.8 Induction of Micronuclei with Mitomycin-C
Mitomycin-C (MMC) is a well known chemotheraputic drug and potent clastogen, often
used as a control drug for comparing results against new chemicals being tested as
potential genotoxins [66]. It is supplied in powder form and dissolved in MilliQ water
at a concentration of 0.5 mg/ml and kept frozen.
In this work, MMC is aliquoted to known concentrations in pre-prepared culture medium,
typically a dilution series with a maximum concentration of 0.3125 µg/ml. Cells were
been pre-plated into 24 well plates and given enough time to flatten and attach to the
plate surface. Medium was then aspirated off and replaced with the drug laced medium.
The cells were then typically incubated for 24 hours before the cells are then prepared
for flow cytometry using the In Vitro Microflow R© method, as described below in Sec.
3.3.3.
3.2.9 Temozolomide treatment
One experiment presented uses the alkylating agent temozolomide. The drug was pre-
pared in culture medium to a concentration of 25 µM from aliquots of 1 mg/ml and
a known molecular mass of 194.151 g/mol. Cells were treated for 4 hours with drug-
laced medium prior to irradiation and then it was replaced with fresh, drug-free, culture
medium soon after irradiation. Subsequent treatment of the cells was as per the normal
experimental protocol.
3.3 MN Detection Experiments
3.3.1 General
In the previous chapters, it has been shown that flow cytometry can be used to gain high
fidelity multi-parametric data from biological matter. This section will address how this
data was acquired and why it was considered a suitable method for MN detection.
Modern flow cytometers often have multiple laser sources such that a number of differ-
ent stains can be used without the emission spectra overlapping. The power behind the
technique comes with the analysis of these recorded events which can provide rapid si-
multaneous assessment of multiple parameters. In the case of MN detection in this work,
the fluorescence measured comes from two DNA stains, ethidium monoazide (EMA) and
SYTOX Green.
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3.3.2 Microscopy Experiments
To evaluate the accuracy of the flow cytometry results several experiments were car-
ried out where the number of MN were scored manually using microscopy techniques.
Experiments were carried out with both LN18s and V79s.
Cells were prepared and seeded onto Petri dishes at a density of approximately 5x104
cells per dish approximately 5 hours prior to irradiation. Dishes were irradiated as per
Sec. 3.2.7 at doses of 1/2, 1, 2 and 3 Gy with a control sample taken for sham irradiation.
One hour post-irradiation, the media was changed to media containing cytochalasin-b
(cyt-b), a drug that blocks cytokinesis in cells, to a concentration of 4.5 µg/ml.
The cells were then incubated for 1.5 doubling times, equating to approximately 27 hours
for LN18 and 19 hours for V79. After this time, the medium was aspirated off and then
the cell dish washed with cold PBS and cells fixed in an ice cold 1:1 solution of methanol
and acetone for 5 minutes to fix the cells. This was washed off with cold PBS and cells
stained with DAPI for 15 minutes in the dark at a concentration of 1 µl per 10 ml of
PBS. This was then aspirated off and then 10 µl of SloFade solution (Invitrogen, UK)
was added to each well and a cover slip placed over the sample, removing any excess
liquid and sealed in preparation for microscopy.
Scoring was carried out by eye using a fluorescence microscope (Nikon Eclipse Ci-S).
Only cells that had been blocked from dividing were scored and only MN arising from
these blocked cells were scored in order to follow guidelines from the OECD [66] and
Fenech [43].
3.3.3 In Vitro Microflow R© kit
3.3.4 General
For the flow cytometric analysis a commercial kit from Litron Laboratories [155] was
used (In Vitro Microflow R© (Micronucleus)). The basic protocol involves the use of two
nucleic acid stains, commonly used for labelling dead cells. The scoring criteria for MN
can be found in Sec. 4.6.1.
3.3.4.1 Staining Protocol
The dyes used in the kit are ethidium monoazide (EMA) and SYTOX Green. As they
are nucleic acid stains their binding to DNA is based on intercalation with the DNA
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bases [156, 157], the details of DNA intercalation has been characterised by Richards
and Rogers [156].
The full protocol is given by Bryce et al. [96] for suspension cultures. A full protocol for
attachment cultures, including the cytometric gating procedure, is supplied with the In
Vitro Microflow R© kit and is available on the Litron Laboratories website [93]. Briefly,
cells were grown in 24 well plates up to 80% confluence before treatment. The staining
procedure is time dependent and started at 1.5 to 2 doubling times from treatment.
This equated to approximately 27 hours post-treatment when using the LN18 cell line.
Several working solutions have to be made up in order to do the analysis. A blocking
buffer solution is made using a supplied concentrated buffer, water and FBS (2%). Dye A
solution is made by adding dye A (EMA) to cold buffer solution to a final concentration
of 1%. This is kept in the dark and on ice. In the kit, the lysis solutions are delivered
as ‘incomplete’. The appropriate amounts of SYTOX Green (0.4%) and RNAse (0.5%)
have to be added to each solution to create the ‘complete’ solutions. These are then
kept at room temperature and in the dark.
The cells are first incubated on ice for 20 minutes, then the culture medium is aspirated
off and the first dye solution is added. This is photoactivated for 30 minutes by placing
the plates on ice with a visible light source placed approximately 15 cm above the plate.
The dye will stain cells with already compromised membranes, most importantly necrotic
and apoptotic bodies. The dye solution is aspirated off and the plates are washed with
ice cold buffer solution. This removes any remaining EMA.
Two lysis solutions are used in the kit. They have been previously described by Bryce
et al. [96] as a preparation of deionised water with the constituents detailed in Table
3.2.
Lysis solution 1 is added to each well and incubated in the dark at 37 ◦C for an hour.
For adherent cell lines, this step also lifts the cells from the plate surface. Counting
beads are added to the second lysis solution and this is then added to the wells and
incubated for 30 minutes at room temperature. At this point, the samples are ready for
cytometric analysis and can be kept at room temperature for 24 hours or refrigerated
for up to 72 hours.
3.3.4.2 Cytometric Analysis
The solutions are transferred to FACS tubes. The FACS machine used is a BD FACS
Canto (BD Biosciences, UK) running FACSDiva 5 software. The samples were run at
either low or medium flow rate. The number of events scored varied, but if possible
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Lysis Solution Constituents
1 0.584 mg NaCl/ml H2O
1 mg sodium citrate/ml H2O
0.3 µl IGEPAL∗/ ml H2O
0.5 mg RNase A/ml H2O
0.4 µM SYTOX Green H2O
2 85.6 mg sucrose/ml H2O
15 mg citric acid/ml H2O
0.4 µM SYTOX Green/ml H2O
∗ IGEPAL is a detergent used to break down the cell membrane
Table 3.2: Constituents of Lysis Solutions.
at least 20-50 thousand events were scored per sample. The photomultiplier voltages
were set to reproduce the characteristic plot given in the kit protocol for forward scatter
versus side scatter. This can be seen in Fig. 3.1.
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Figure 3.1: Plot of Forward and Side Scattered Light for Gating in the In Vitro
Microflow R© method. Reproduced from [93].
Micronuclei were scored based on a few criteria given in Sec. 4.6. While the In Vitro
Microflow R© kit provides template for FACSDiva, BD’s cytometry software, it was not
compatible with the version of the software available with the University equipment.
The In Vitro Microflow R© protocol provides examples within its appendix of the plots
available on the template. A new flowsheet was created such that the data could be
acquired with the help of staff from the BioImaging and Flow Cytometry (BIAFC) core
facility. Data analysis was primarily done by exporting the raw data, FSC, files and
then analysing them using Flowing Software 2 [158].
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3.4 Modelling
3.4.1 Introduction
The following section covers all of the modelling aspects to this work. It is further split
into 3 sections. First is the model itself, including the assumptions made to form the
model. The second section is the numerical methods used to solve the model. The third
is a shorter section that covers the computational methods, particularly methods used
which are not considered a standard technique or are specific to this project.
3.4.2 The MiNiMUS Model
The objective for the model is to predict the numbers of MN formed from a dose of
IR. The doses being considered are in the therapeutic range of a single fraction, which
is normally 2 Gy. The model will be expected to predict formation from 1 to 3 Gy.
The model should be capable of incorporating the roles of DSB repair pathways. The
following assumptions are made in order to form this model:
3.4.2.1 Modelling Assumptions
In order to model the formation of MN using the decision tree, several assumptions have
to be made. Principle among these is that there is no concept of cell death. Depending
on the frame of reference this could be considered overly simplistic. It is known that
MN are prone to enter apoptosis [114], however this does not change the fact that they
existed as micronuclei in the first place. The link between MN, apoptosis and death is
becoming better characterised, but as this model is being validated experimentally it is
more appropriate to measure the number of MN. Further developments could introduce
counts of apoptotic cells as the In Vitro Microflow R© method does account for these,
but it was not appropriate in this first phase of modelling.
The model input is a number of DSBs and the output is a number of MN per 1000 cells.
There is no dependence on knowledge of when the damage was inflicted with regards
to the cell phase. DSBs are attributed to a cell phase using a uniform random number
generator based on the percentage of the total cell cycle time that phase constitutes.
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3.4.2.2 Biological Assumptions
The cell cycle phase time is considered to be significantly longer than the time taken to
repair by DSB repair pathways. Antonelli et al. [121] show that the maximum number
of γH2AX foci appear at 30 minutes post-irradiation and plateaus at approximately
12 hours with a γ-irradiated human fibroblast cell line, AG01522. These findings are
corroborated by Barnard et al. [103], who used PFGE to measure number of DSBs over
a time period.
It is also assumed that all cells are actively progressing around their cell cycle when
irradiation takes place. This would be the case for in vitro tumour tissue [159] or cell
lines with a mutation to the P53 gene.
The only repair mechanisms considered for DSB repair are NHEJ and HR. The proba-
bility that one of these will be selected over another is based on where they are active
in the cell cycle, hence HR is only available in late S and G2/M phases [127].
3.4.2.3 DSB Induction Assumptions
As discussed in Sec. 2.8, the quantification of DSBs with IR exposure is linear. In a
previous version of MiNiMUS a linear quadratic dose response for DSBs was used. Due
to this, the code still uses a linear quadratic equation to calculate DSB induction, given
in Eqn. 3.5.
n(DSB) = (aD + bD2) (3.5)
This equation gives a linear dose response by setting b = 0. In order to produce the
required 40 DSBs per cell, the parameters used with Eqn. 3.5 are a = 40 and b = 0.
Currently, these values are used for both photons and ions.
3.4.2.4 Cellular probability
It is assumed that any action within a cell, such as choosing one repair pathway over
another, can be described by a probability distribution function (PDF). In this work
the PDF being used it the Beta distribution. The Beta distribution only requires one
independent variable, the mean, to construct. The variance is also required, however
this has a maximum value for which the distribution is valid.
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The Beta distribution can be defined as in Eqn. 3.6, [160], where the mean and the
variance are defined in Eqn. 3.7 and Eqn. 3.8 respectively. In most literature, the
variables m and n are noted as α and β respectively. The reason for noting them as m
and n is to avoid confusion between the linear quadratic parameters of α and β used
elsewhere in MiNiMUS.
p(x) =
(1− x)n−1xm−1
B(m,n)
(3.6)
x¯ =
m
m+ n
(3.7)
It can be shown that in a Beta distribution with high values of m and n that the
distribution appears to become Gaussian, still within the limits of 0 and 1. This is
backed up by the skewness and kurtosis being close to 0 and 3 respectively. The kurtosis
increases as the mean is pushed towards the edges of the distribution range, however
this is not seen as an issue that requires any amendments to the modelling approach.
In real terms a high value of m and n translates to keeping the variance small. For this
reason the variances used to construct the PDFs in MiNiMUS are 20% of the maximum
variance, defined in Eqn. 3.8, with the maximum possible variance for a given value of
x calculated using Eqn. 3.9.
σ2 =
mn
(m+ n)2(m+ n+ 1)
(3.8)
σ2max = Min(mv1,mv2) (3.9)
mv1 =
x2(1− x)
1 + x
mv2 =
x(1− x)2
2− x
3.4.3 Numerical Methods
In order to solve the model proposed in the previous sections a binary decision tree was
created. The number of DSBs per cell is estimated according to Eqn. 3.5. Each of these
DSBs is then ‘sent’ through the tree and the outcome recorded. This is repeated for all
DSBs in that cell. The model utilises both Monte Carlo integration and simulation to
take into account the inherent unpredictability of cellular systems. The integration takes
the form of averaging the frequency over multiple simulated cells, usually 2-4 thousand.
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The results are displayed as a total number of MN per 1000 cells. This is so that the
output of the model is congruous with data reporting etiquette in literature. This Monte
Carlo simulation is covered in more detail in Sec. 3.4.5.
3.4.4 Binary Decision Tree
In order to model the formation of MN from DSBs arising from IR a binary decision tree
was created. This method makes it possible to incorporate the roles of HR and NHEJ.
The tree can be represented diagrammatically as shown in Fig. 3.2.
Figure 3.2: The MiNiMUS Decision Tree v1.1.
The tree is run for every DSB arising from treatment individually. The MiNiMUS tree
starts with a decision that double strand breaks either attempt to be repaired or not
repaired at all. It is known that dependent on position in the cell cycle certain repair
mechanisms have a greater probability of attempting to repair damaged DNA [128].
To account for this, each cell being simulated is assigned a position in the cell cycle
and the standard probabilities of each decision point are altered. Each DSB assigned
to that cell then uses the probabilities pertinent to that phase of the cell cycle. When
a new cell is simulated, the cell phase is redrawn and probabilities altered to match
that cell phase. Although this effectively quadruples the number of free variables it is
considered necessary, as it is known that mechanism of repair and hence the probability
of a specific pathway being chosen alters around the cell cycle, as described in Sec. 2.5.4.
Chapter 3. Methodology 62
An alternative to this strategy could be to have separate trees for each of the cell cycle
phases.
There are many repair pathways that a cell can utilise for differing types of DNA damage,
but the two major pathways for DSB repair are Non Homologous End Joining (NHEJ)
or Homologous Recombination (HR) [161] and hence are the only two considered in the
MiNiMUS model.
Regardless of repair pathway, the trees below the pathway are identical. Repairs are
either successful or not. Unsuccessful repairs have a further stage to decide whether
they form micronuclei.
The probabilities are assigned at runtime at known as the ‘standard’ probabilities. These
have been fitted to values from literature and have been further discussed in Sec. 4.11.4.
3.4.5 Monte Carlo Methods
Monte Carlo is an umbrella term for many statistical methods. The Oxford English
Dictionary (online) defines Monte Carlo as:
“Designating or involving any of various methods of estimating the solution to numerical
problems by the random (or pseudo-random) sampling of numbers with some chosen
frequency distribution” [162].
The program performs Monte Carlo simulation in order to model inherent cellular un-
predictability. For each cell that is modelled the probabilities are redrawn from a proba-
bility density function, which remains for all DSBs in that particular cell. These redrawn
probabilities are known as the ‘Monte Carlo’ probabilities. The density function used
for the MiNiMUS program is the Beta distribution. This decision was made as the nat-
ural range of a Beta distribution is between 0 and 1. Choosing most other distributions
would mean curtailing the distribution to fit between limits of probability.
3.4.6 Calculation of the Beta Function
Eqn. 3.6 gives the denominator of the Beta distribution as the Beta function, B(m,n).
This can be calculated using the Gamma function. The Gamma function can be calcu-
lated in a number of ways. Eqn. 3.10 gives the formation of the Gamma function as used
by the Fortan compiler being used in this work. The calculation of the Beta function is
given in Eqn. 3.11, which is valid for X > 0 and −n− 1 < X < −n, n is an integer > 0.
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There is a systematic error produced at this point as the values of m and n are not inte-
gers. It is assumed, although this is not confirmed in the compiler documentation, that
the values are rounded to the nearest whole integer before performing the integration.
Γ(X) =

∫∞
0 t
x−1exp(−t)dt∫∞
0 t
x−1(exp(−t)−∑nk=0 (−t)kk! )dt (3.10)
B(m,n) =
Γ(m) + Γ(n)
Γ(m+ n)
(3.11)
An issue occurs with large values of m and n as Γ(m + n) becomes too large, to the
point that floating point errors could occur. A better approach was found by using Eqn
3.12 so that the numbers remain calculable . This approach has also been suggested by
Press et al. [163]. The outcome of the Fortran implementation of ln(Γ(m)) is processor-
dependent and hence another source of error, although it is expected that any error
would not be very large.
B(m,n) = exp(ln(Γ(m+ n))− ln(Γ(m))− ln(Γ(n))) (3.12)
3.4.7 Generation of Random Numbers
The Monte Carlo simulation in the numerical solution to the model requires that ran-
dom numbers be generated that conform to the PDF of interest, which in this case, is
the Beta distribution. There is one pseudo-random number generator available in the
Fortran programming language. It produces random numbers conforming to a uniform
distribution between 0 and 1.
Press et al. [163] give a number of methods for producing random numbers, including
both uniform and non-uniform random numbers. One method given, is to use the inverse
function for the PDF that numbers need to be generated from. Whilst it is possible to
generate an inverse to the Beta distribution, there is not an intrinsic function available
in the Fortran standard.
Other methods use some kind of an accept/reject algorithm. In general these algorithms
work by selecting two random numbers, (U1 and U2). U1 is scaled between zero and the
median value of the probability distribution function being considered, in this case a Beta
distribution, and U2 is scaled in the range of x which in the case of a Beta distribution
is between zero and one. The function is evaluated at p(U2) and if U1 < p(U2), U2 is
selected as the probability for that particular decision in the next cell’s tree runs.
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However, as the Beta function can have a large kurtosis at the extremes of the range,
meaning that the sampling efficiency would be low if it remained unbounded. Several
ways of placing limits were tried including superimposing a Normal distribution over the
Beta, superimposing a triangle at the median point and restricting U2 between areas of
the x axis where p(x) 6= 0.
It was decided that the least computationally expensive method is to scale the U2 value
between areas where p(x) 6= 0. This is because the analysis to find the points at which
p(x) 6= 0 needs to be done once per construction of the PDF, as the PDF will vary
depending on model parameters, whereas superimposing another PDF or geometric
construction still requires assessment of every value of U2 before it is considered for the
accept/reject algorithm. In addition to this, finding PDFs or geometric constructions
that fit around the Beta distribution, particularly at the extremes of the range is difficult.
Results in efficiency increase using the scaling method is given in Fig. 4.19.
3.4.8 Sensitivity Analysis
The sensitivity analysis was carried out by taking the 17 tree variables and altering
their probabilities by a nominal 10%. In all runs of the sensitivity analysis, the random
number generator was run with a fixed seed, so that the generator produces the same
‘random’ numbers each run of the analysis, in the same order. This produces fixed
results for each scenario.
The simulation was run to establish a base case and then, in turn, each of the variables
was run twice, once to record the positive deviation and once for the negative deviation.
Only one variable is altered per run. The analysis is done using a 3 Gy simulation.
Whilst it is not critical that the simulation is done using a 3 Gy simulation, care must
be taken to ensure that a large number of MN are predicted in the base case. With
lower numbers of DSBs simulated there is less scope for deviation in the number of
DSBs predicted when the probabilities are altered. A 3 Gy simulation was chosen as it
sits at the top end of the range MiNiMUS is expected to predict and would therefore
give the largest latitude to show the extent of the tree sensitivity.
One key point to note is that although the input disturbance was set to be 10%, most of
the probabilities lie at the extremes of the range 0 to 1 and so it is not possible to alter
the probabilities without violating the limits of probability. In order to standardise the
results such that they could be compared, the numbers of micronuclei are divided by
the actual change in percentage for that variable, rather than the nominal change.
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3.4.9 Automated Fitting of Node Probabilities
In its current state, the MiNiMUS decision tree has a total of 17 probabilities. These
are made up of 4 phase dependant variables per phase and one phase independent
variable. In order to fit all of these variables using optimisation techniques, a total of 18
experimental data points would be needed. Given the dose range at which micronuclei
occur and the experimental constraints, it would be difficult to get enough data to fit
all of the variables concurrently.
The optimisation is done using a generic optimisation framework, originally written
in 2010, currently containing three optimisation methods; grid search, random search
and Nelder-Mead’s folding polygon methods. The random search and Nelder-Mead’s
methods are based on code from Press et al. [163].
The optimiser takes experimental data and asks the user to select the node probabilities
to fit. The optimiser will select a value to use for the probabilities chosen and then run
the simulation based on the doses of the experimental data given. It then reports the
number of micronuclei for that dose range. A sum of squares of errors (φ) is calculated
based on the numbers of MN predicted in the model (MNi model) and actual numbers
from experimental data (MNi exp), see Eqn. 3.13. This is then modified based on any
constraints that have been breached. At present, the only constraints used are the limits
of probability, zero and one. If the optimiser has suggested probability values outside of
this range, the objective function is heavily penalised, based on how far above or below
the respective limits have been breached.
φ =
n doses∑
i=1
(MNi exp −MNi model)2 (3.13)
3.4.10 Coding Methods
3.4.10.1 Computing Tools
The numerical solution to the proposed model was implemented in a program written in
Fortran using the Intel R© Fortran Composer XE 2013 compiler (www.intel.com). Other
key software used includes SAIG’s Ed4Windows (www.getsoft.com) and Microsoft Visual
Studio 2012 Ultimate (www.microsoft.com).
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3.4.11 Coding The Decision Tree
The decision tree is a coded as a linked list using pointer elements of a custom user
defined type called ‘node’. It contains logical variables to specify if the node is the end
of the tree and also whether the node is a MN. One other data element is a vector of
type real which is also a pointer. This stores the data relating to the probability of
that node. The rest of the type ‘node’ are pointers, of type ‘node’ themselves, relating
to the linked list structure. They are ‘parent’, ‘child’ and ‘sibling’. The tree code
itself is based largely on example code by Metcalf, Reid and Cohen [164] with some
modifications such as routines to amend nodes once the tree is built. These amending
subroutines are how the probabilities can be altered ‘on the fly’. The most important
part of the node structure is a vector variable of type real called ‘y’. This data element
stores the probabilities used to walk the tree. The first element is always the ‘standard’
probability and the second is the Monte Carlo probability, discussed further in Sec.
3.4.5. Depending on whether the program is run in Normal or Monte Carlo mode, the
appropriate probability is used.
The tree is hard coded into the program as it was thought that the ability to modify
the tree on the fly would not be needed. The tree is built at runtime and the data
structures stored until the program is shut down. The tree is walked using a pointer
of type ‘node’, called ‘current’ and the Fortran intrinsic number generator set with a
random seed based on the time. Current is set to the top of the tree and a random
number is drawn. If the probability being used in the next node is greater than that of
the random number current is set to point at it’s child if it is less than the probability
drawn it is set to child and then immediately to sibling. With the binary structure of
the tree, this gives the effect of choosing the other branch.
3.5 Summary
In this chapter the In Vitro Microflow R©method has been presented and an experimental
method detailed. Protocols for control experiments, where cells are stained with DAPI
and scored using microscopy techniques are also presented.
The basics of the modelling approach are set out with details about both the abstract
model, numerical methods and coding methods where appropriate. In the next chapter
the In Vitro Microflow R© experimental results will be used to fit the model parameters
to ensure that the model can predict the dose response of attachment cell lines, such as
LN18 and V79.
Chapter 4
Results
4.1 Introduction
This chapter shows the results of using the In Vitro Microflow R© cytometric method on
LN18 and V79 cell lines and the analysis needed to obtain micronuclei (MN) frequencies
from the cytometry data. More importantly, this is the point at which the experimental
work starts to support the modelling work such that there can be confidence in the
model proposed in the previous chapter.
The modelling work is also presented and some of the analysis undertaken in order to
validate that the model was performing as expected including validation of the Monte
Carlo techniques described in the previous chapter.
4.2 Culture of M059J and M059K
M059J/K cells are glioblastoma cells, but have significantly different morphology to
LN18. They are more dendritic compared to the LN18 cells. An example of M059J cells
can be seen in Fig. 4.1 and LN18 in Fig. 4.2. Despite using optimum growth media,
M059J/K grew extremely slowly compared to LN18 and had poor plating efficiency
making subculture difficult. This adds further weight to the argument that assays based
on clonogenic survival are not suitable for assessing radiation sensitivity in a short time
frame. Only one other member of the research group has used the M059J cell line, who
also expressed concerns that the cell line was difficult to culture. Unfortunately, due to
the slow growing nature and poor subculture performance the work with M059J/K was
taken no further.
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Figure 4.1: An Example of an M059J Glioblastoma Cell Showing its Dendritic Mor-
phology.
Figure 4.2: A Monolayer of LN18 Glioblastoma Cells.
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4.3 LN18 Growth Curve
LN18 cells were grown in 24 well plates and then counted at appropriate points. Fig.
4.3 shows the the average of 3 counts per dish and then the average of the 3 dishes to
make an average count for that time point. The doubling time (tD) was calculated to
be 18.9 hours, 12.3 6 tD 6 40.6 at 90 % confidence. For the purposes of calculating tD
the linear portion of the graph and hence period of exponential growth is considered to
be 0 to 94 hours.
This gave values of k = 1.68E−4 Cells−1h−1 and Cnmax = 367.33, which was the largest
value Cnmax could have taken. Taking Log2 of the values representing exponential growth
and determining tD gives tD = 18.04 hours with R
2 = 0.946, which is slightly better
than the raw data. The logistic curve is given graphically in Fig. 4.4
Both the χ2 and confidence intervals can be improved by not considering the first point
in the linear portion of the graph. However, it is clear that it should be part of the
analysis.
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Figure 4.3: Growth Curve of LN18 Cells. Raw Data with 90 % Confidence Interval
Shown.
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Figure 4.4: Logistic Growth Curve Model Fitted to LN18 Experimental Data. Error
Bars are 1SD Based on Dish Counts.
4.4 Clonogenic Survival of LN18 Cells
Cells were prepared and irradiated as described in Sec. 3.2.4. The survival curve can
be found in Fig. 4.5. The black and blue data are single experiments and each data
point is the average of 6 counts. The red data is by Barazzuol [119], produced in the
same laboratory and using the same irradiation protocols and facilities. Whilst the data
broadly agrees with each other, it should be noted that there are a limited dose points
in each experiment.
Given the small numbers of cells being seeded at each dose point, mistakes made with
the dilution lead to no cells being seeded in all 6 wells of a dose point. This highlights
further issues, beyond the length of time needed for the cells to grow colonies, with using
the clonogenic survival assay for estimation of treatment effectiveness on patient biopsy.
4.5 Brief Description of Experiments
The following table, Tab. 4.1, gives details of the damaging agents, cell line and dose
ranges for all experiments using the In Vitro Microflow R© protocol. For each experiment,
each dose point plotted on the following graphs is an average of at least 2 samples from
the same experiment at that dose. For graphs showing average data for a cell line, such
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Figure 4.5: Clonogenic Survival of the LN18 Cell Line after Irradiation with 250 kVp
X-Rays. Data Points are averages of 6 counts in single experiments. Error bars and
lines represent 1SD from raw counts. Red line is constructed from the α and β values
from Barazzuol [119].
as Fig. 4.10, the averages have been calculated as an average of all samples in all relevant
experiments at the specific dose.
Experiment Damaging Agent Dose Cell Line
Exp. 1 IR 0,1,2,3 Gy LN18
Exp. 2 IR 0, 1/2, 1,2,3 Gy LN18
Exp. 3 IR 0, 1/2, 1,2,3 Gy LN18
Exp. 4 IR+TMZ IR + 25µM TMZ 0, 1/2, 1,2,3 Gy LN18
Exp. 4 IR IR 0, 1/2, 1,2,3 Gy LN18
Exp. 5 IR 0, 1/2, 1,2,3 Gy LN18
Exp. 6 MMC 0 , 0.039 , 0.075 , 0.156 , 0.3125 µg/ml LN18
Exp. 7 IR 0, 1/2, 1,2,3 Gy V79
Exp. 8 MMC 0 , 0.039 , 0.075 , 0.156 , 0.3125 µg/ml V79
Exp. 10. MMC 0 , 0.039 , 0.075 , 0.156 , 0.3125 µg/ml V79
Exp. 11. MMC 0 , 0.039 , 0.075 , 0.156 , 0.3125 µg/ml V79
Table 4.1: Brief Description of Experiment Parameters.
Experiment 1 was the first experiment that used the In Vitro Microflow R© kit. The cells
showed very high MN frequencies. This is because not enough cells had survived either
the plating, irradiation or staining. The evidence became obvious when the cytometer
could only detect a very small number of events per second. The results of which should
be disregarded, but it included in this table for completeness.
Chapter 4. Results 72
Experiment 8 produced no dose response. The frequency barely changed over the dose
range, so it is expected that the serial dilution of the drug was incorrect. Experiment 9
was part of another study and so is not presented here. There is limited data available
in Experiment 10 due to an issue during the staining process, which is discussed in Sec.
4.6.4.
4.6 Cytometric Analysis
4.6.1 In Vitro Microflow R© MN Scoring Criteria
As discussed in Ch. 3, the In Vitro Microflow R© protocol states 5 scoring criteria for
MN [93].
1. Relative survival should be greater than or equal to 50 %. See Sec. 4.6.4 for more
details.
2. MN events must exhibit 1/100th to 1/10th the SYTOX Green fluorescent intensity
of a 2n nuclei.
3. MN events must fall within a Forward Light Scatter Vs. SYTOX Green region
4. MN events must fall within a Side Light Scatter Vs. SYTOX Green region
5. MN events must be EMA-negative...this helps to further exclude apoptotic and
necrotic chromatin from analysis. Even so, caution should be exercised when
interpreting MN data for test article concentrations that are associated with high
percentages of EMA-positive events. Under these circumstances, the MN scoring
region may be contaminated by apoptotic bodies.
It should be noted that ‘relative survival’ is an internal measure of survival and is not
linked to clonogenic survival. Further details on the calculation and use of relative
survival in the In Vitro Microflow R© protocol can be found in Sec. 4.6.4.
4.6.2 Changes to the Staining Procedure
Whilst a protocol was provided for the treatment of attachment cell lines, some minor
alterations needed to be made to the procedure when working with LN18 and V79 cells.
It is expected that the similar alterations may need to be made when working with other
cell lines.
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The protocol does not rely on a specific number of cells being seeded, merely that there
are enough cells to reach an acceptable level of cells counted, typically 10 - 20 thousand.
The protocol suggests that cells should be at more than 80 % confluence when stained.
The protocol also states that cells should not be agitated after the first lysis step at
avoid damage, however, LN18 cells attach to the well surface with considerable force,
even without the use of attachment aids, such as fibronectin. This attachment force
meant that some extra gentle pipetting was necessary when transferring to FACS tubes
in order to ensure that cells had detached from the well surface. In addition to this,
samples were pipetted before being loaded into the FACS machine for analysis to ensure
a well mixed suspension.
One other minor alteration was the use of a visible light lamp, rather than a fluorescent
lamp as recommended, for the photoactivation of dye A. The amount of fluorescence
shown in the analysis would indicate that a visible light is more than suitable in the case
of LN18 and V79.
4.6.3 Treatment of Cytometric Data
In order to comply with the scoring criteria in Sec. 4.6.1 and due to lack of compatibility
with the template provided by Litron, a suitable alternative was built in FACSDiva to
acquire the data. The data was then exported to FCS files and imported into a flowsheet
in Flowing Software 2, a package for interpreting and analysing flow cytometry data. On
the whole, the dot plots are copies of those within the In Vitro Microflow R© protocol,
with one exception. Plot A in the In Vitro Microflow R© protocol is a plot of forward
scatter vs. side scatter. In the In Vitro Microflow R© protocol, Plot A is used to determine
all events and exclude noise, which is defined as anything falling 2 decades below the
main cluster of cells. As can be seen in Fig. 4.6, the plot used in this work still excludes
this data 2 decades from the main cluster of cells, labelling the region as ‘noise’. In
addition to this, the cluster of fluorescent beads is marked with an appropriate region
called ‘beads’ and the main bulk of events are marked as a region called ‘cells’. The
subjectivity of gate placement is discussed in Sec. 5.10.
The colours on the flow cytometry plots show that the event has been classified by its
inclusion into a certain region, such as the yellow points in Fig. 4.6, which are classified
as ‘healthy’ cells. It should be noted that the region that the event has been assigned
to does not necessarily have to be assigned to a region visible on that plot. This is
because cytometry analysis is often done using a number of plots that represent the
same data in a number of ways. This leads to plots such as Fig. 4.6, where a number of
different colours appear in the same region. All of the events in the larger region have
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been defined as cells, but have further been categorised based on other characteristics
and hence appear in multiple colours on the plot.
Characterising the events at this point gives a convenient starting point for the analysis
of nuclei to bead ratios.
Figure 4.6: Example of a flow cytometry dot plot: FSC-A (Forward Scatter pulse
Area, which is analogous to event size) Vs. SSC-A. (Side Scatter pulse Area, which is
analogous to event granularity).
From this point, dot plots tend to have at least one axis representing fluorescence of either
EMA or SYTOX. However, these are labelled as PerCP Cy 5.5 and FITC respectively.
These labels are appended to the detector as FITC is a common fluorochrome with a
characteristic excitation and emission wavelengths, with the same being true for PerCP
Cy5.5. Although the stains being used are not FITC or PerCP Cy 5.5, the BD system
uses this nomenclature for its detectors. Other cytometers may call these detectors FL3
and FL1 for Per CP Cy5.5 and FITC respectively. The H, W or A suffix on an axis label
represents whether the points are displayed as the height of the voltage pulse, width or
integrated area of the pulse during acquisition. This can make a difference in some cases,
such as doublet discrimination, where cells stuck together may cause a larger pulse on
a width scale compared to single cells.
Once the region of all cells has been defined, the next dot plot takes all cells and defines
them as EMA positive by a region that runs tangential to the main cluster of live cells.
Whilst this seems counter intuitive to have the cells of interest not in a region this is
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handled by defining a meta-region known as ‘not EMA positive’ which encompasses all
events on that plot not within the EMA positive region. An example can be seen in Fig.
4.7.
Figure 4.7: Example of a flow cytometry dot plot: FITC-H (SYTOX Green fluores-
cence) Vs. PerCP-Cy5.5-H(EMA Fluorescence).
Once the ‘healthy’ cells have been identified, the final step is define which of these would
be micronuclei. These would be physically smaller than a standard sized nucleus and
as such the intensity of any staining would be less. So on a plot of forward scatter vs.
SYTOX fluorescence there is a large cluster of cells of a larger size and intensity. Cells
falling immediately to the south west of this main cluster may be hyperdiploid. This
is more associated with aneugenic actions of drugs. Since this is of no importance for
micronucleated cells the ‘healthy’ region is enlarged to accommodate this hyperdiploid
region. Micronuclei form an elongated region south west of the healthy cells so that
their size is still roughly in proportion to their fluorescence. This can be seen in Fig.
4.8.
The MN frequency is then defined as the number of events in the MN region divided by
the number of events labelled as cells multiplied by 1000 to give a number of micronuclei
per 1000 cells. This makes the data comparable to data from microscopy experiments,
which is often expressed as MN per 1000 cells. It is important to note that cells are not
cytokinesis blocked in this protocol, as when the cells are lysed the two nuclei would
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Figure 4.8: Example of a flow cytometry dot plot: FSC-H (Forward Scatter pulse
Height) Vs. FITC-H (SYTOX Green Fluorescence).
present as 2 separate events, however the cells must have undergone a cell division for
the MN to be present. The percentage of EMA positive cells is defined as the number of
events in the EMA positive region divided by the number events in the cells region then
multiplied by 1000. The nuclei to bead ratio is defined as the number of cells divided
by the number of events in the ‘beads’ region. This is where the use of flow cytometry
can be questioned. The placing of these gates can drastically change the outcome of the
analysis. This is discussed further in Sec. 5.10.
4.6.4 Relative Survival
Relative survival (% RS) is an internal measure of data quality used in the In Vitro
Microflow R© kit. Fluorescent counting beads are added to the second lysis solution
during the staining process, this is then used to calculate a nuclei to bead ratio (NBR)
during the analysis. This is defined in Eqn. 4.1, from [93]. It should be noted that %
RS does not have any direct link with clonogenic survival.
All of the criteria stated in Sec. 4.6.1 were taken into account when scoring MN. However
it should be noted that in an earlier publication Bryce et al. [1] stated that relative
survival had to be above 40 %.
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%RS =
Ratio of Sample NBR to Control NBR ∗ 100
Control NBR
(4.1)
The nuclei to bead ratio is defined as the ratio of the number of cell events to counting
beads in a sample. The relative survival is then the ratio of the NBR of a sample to the
NBR of the control sample. Using this approach has both positives and negatives. A low
NBR shows that either the harvesting procedure was not effective or that the number
of counting beads is disproportionately high. This is somewhat negated by using % RS
as a measure of data quality.
Tabs. 4.2 and 4.3 show the relative survivals for all samples in this work. At least
2 samples per experiment were negative controls. The negative control nuclei to bead
ratios used to calculate the relative survival was based on the average nuclei to bead
ratios of the negative controls. There were 3 exceptions to this, Experiments 7, 8 and
11. In these cases, one of the nuclei to bead ratios in the control samples were outliers
to the remaining data. They have been highlighted pink in Tabs. 4.4 and 4.5.
As discussed earlier in this section, there is a discrepancy in the relative survival require-
ments, with one publication stating 40 % is acceptable and the In Vitro Microflow R©
protocol stating 50 %. Data which fall under 40 % are highlighted in pink and data
falling under 50 % highlighted in yellow in Tabs. 4.2 and 4.3.
Only one data point falls under the 40 % limit and 6 data points lie between 40 and
50 %. Three of these are in Experiment 10. It was clear during the cytometric analysis
that there was an issue in the preparation of the sample before the cytometry took
place. In approximately half the samples there were no cells. After discussion with
Litrona it was decided that the first lysis solution did not detach the cells. This was
not a problem in earlier experiments with LN18 cells or two previous experiments with
V79. The resolution was to be more vigorous after the 1 hour incubation by pipetting
each well to aid detachment with visual inspection using a microscope with as little
illumination as possible to avoid photo-bleaching the DNA stains.
When looking at the other points that fall below the 50 % relative survival they do not
pose a problem to the averaging of the data as the other data points in that dose lie
closely, within 1.5 % MN frequency, to the disputed data points.
Relative Survival should not be taken as a literal number in the case of very high values.
A very high value of % RS shows that in the sample there were more nuclei harvested
than in the control. In the specific case in experiment 2, a 3 Gy sample has a % RS
value of 3984.78. This is a combination of two factors leading to a very large figures.
aPersonal Correspondence with Steven Bryce
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The NBR of the control sample is less than 1, while the NBR of the sample is 27.44.
This leads to a very large figure for % RS, which in this case could have been down to an
uneven distribution of counting beads across the samples or a very effective cell harvest.
In samples that have a low value, it is an indicator that the cell harvest for the sample
was not effective.
As stated in Sec. 4.5, Experiment 1 will not be considered due to it’s outlying data. It is
interesting to note that despite this data being obviously outlying, the relative survival
data appears to indicate the results are valid. This is an obvious downfall of analysing
data as a relative survival. There is no perspective on the quality of the dataset as a
whole, so defining data quality by relative survival alone should be avoided. The number
of events scored was, in most cases, 10 000 with an average of 51 % of each sample being
beads (σ2 = 0.013). Other than the first experiment and the caveats stated above
concerning Experiment 10, all other data sets are considered valid representations of
that cell line’s response to either IR, IR + temozolomide or mitomycin-C (MMC) as
appropriate.
4.7 Manual Scoring using Microscopy
The general method for scoring micronuclei using microscopy techniques is given in Sec.
3.3.2. The samples were analysed using a 10x objective on a Nikon Ci-S microscope,
excited by a mercury vapour lamp and appropriate filters to show DAPI excitation at
461 nm. Cells were scored if they appeared to be bi-nucleated only. Cells appearing to
be multi-nucleated were not scored. The question could be raised as to what constitutes
a micronucleated cell as it could be described as a multi-nucleated cell. In order to be
scored as a micronucleus, the micronucleus itself must be present in close proximity to
a bi-nucleated cell, but must also be a small fraction of the size of its parent nuclei. An
example is given in Fig. 4.9. Table 4.6 shows the average number of MN at each dose
for both LN18 and V79. The results for each cell line are the average of 3 experiments
where each experiment contained at least 2 samples per dose point.
The number of cells scored varied greatly. The average number of cells scored in an
experiment varied from 275 cells to 587 cells with a large variance of cells scored between
samples also. Whilst it would appear that there is little overlap in the results of the
flow cytometry and the microscopy scored experiments, it should be noted that due to
the comparatively low number of cells scored in the microscopy experiments the results
are very sensitive to minor changes in the raw MN counts. Any omissions or accidental
inclusions of MN will have a large effect in the frequency, number of micronuclei divided
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CA B
Figure 4.9: Examples of Cell Scoring by Microscopy: A) A Bi-nucleated Cell. B) A
Multi-nucleated Cell. C) A Micronucleated Cell.
Cell Line
LN18 V79
Dose (Gy) MN per 1000 Cells S.D. MN per 1000 cells S.D.
0 20.31 3.05 12.29 16.01
0.5 30.02 2.14 12.98 18.30
1 40.19 4.94 17.52 17.49
2 54.94 4.67 26.81 26.27
3 73.40 9.26 30.84 69.54
Table 4.6: MN Counts in LN18 and V79 Cells after Irradiation. Counted by Mi-
croscopy.
by total number of cells counted, which is then multiplied by 1000 to get the number of
MN per 1000 cells.
Figure 4.10 shows the results given in Tab. 4.6. It can be seen that the LN18 cell line
yields a slightly higher dose response than that of V79. However, neither of these dose
responses are of the same magnitude as the PBL samples shown in Fig. 4.21. The
differences between the dose response of PBL samples and anchorage dependent cell
lines are discussed in Sec. 5.5.3
In order to compare the microscopy scored results with the results from the In Vitro
Microflow R© experiments the data has been shown graphically in Fig. 4.12 and Fig.
4.13. It can be seen that although the MN frequencies appear to be low when compared
to the In Vitro Microflow R© data, they still sit within the range of results from other
experiments.
Comparisons of these results with the appropriate cell lines and the mathematical model
are given in the following sections.
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Figure 4.10: Dose Response of V79 and LN18 with IR, Counted by Microscopy. Error
bars Represent the Weighted SD of 3 Experiments per Cell Line.
4.8 Dose Response of LN18 Cells
4.8.1 Results of LN18 MN Frequencies using Flow Cytometry
Figure 4.11 shows the MN response as measured by Flow Cytometry. It appears that
temozolomide (TMZ) increases the MN count slightly. This is possibly because TMZ,
as an alkylating agent, would cause damage that would be repaired by Base Excision
Repair (BER) which can lead to further strand breakage. This is discussed further in
Sec. 5.6. However this result is slightly surprising as TMZ is known to be particularly
effective in cell lines with an MGMT-methylated status, hence it’s use as a concomitant
and adjuvant drug for radiotherapy, but LN18 is MGMT-unmethylated [119].
It would appear that there is no dose response in the LN18 cell line over the 0-3 Gy dose
range. On the whole, the data has large intra-experimental variance, which leads to the
error bars overlapping between experiments, even if the averaged data points do not. As
this method is still relatively new to anchorage dependent cell lines it is expected that
once the technique is honed the variance shown in in Fig. 4.11 will reduce. However, it
should be noted that due to the nature of flow cytometry a degree of variance should be
expected.
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Figure 4.11: MN Frequencies of the LN18 Cell Line with IR by Flow Cytometry.
Error bars Represent the SD of the Samples in that Experiment. The ‘Flow Average’
is the Average of Exp’s 2, 3, 4IR and 5 with Error bars representing the SD of those
Experiments.
A more useful way of analysing the flow data is to compare the average of the flow
results against the average result from the microscopy scored experiments. Figure 4.12
shows the average data for both microscopy and flow experiments. It can be seen that
the data overlaps if the error bars are considered. The obvious exception is the control
sample, where the flow cytometry gave a consistently high reading. The reason for this
is unknown, but could be due to the gate placement. The subjectivity of gate placement
is discussed further in Sec. 5.10.
Overall, the dose response of micronuclei with IR in LN18 is much less than PBL ex-
amples in literature. This is not ideal from a biodosimetry point of view, as a bigger
dose effect would make it easier to estimate the dose, assuming that the errors across
the dose range were small.
In 3 of the 5 In Vitro Microflow R© experiments, the number of MN per 1000 cells is
higher at 0.5 Gy than at 1 Gy. This is also true when the data is averaged, which
shows a significant increase in dose response at 0.5 Gy when compared to 1 Gy, but this
should be treated with caution. The 0.5 Gy result in Exp. 2 is skewing the averaged
result. However, this is partially taken into account with the large error bars associated
with the dose point in question. The averaged flow cytometry results, with associated
error bars, suggest that there is some degree of low dose hypersensitivity, although this
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Figure 4.12: MN Frequencies of the LN18 Cell Line with IR by Flow Cytometry and
Microscopy. The ‘Flow Average’ is the Average of Exp’s 2, 3, 4IR and 5 with Error
bars Representing the SD of those Experiments. The Microscopy Average’s Error bars
Represent the Weighted SD of the Three Microscopy Experiments.
has not previously been reported in the LN18 cell line. However, this is not supported
by the microscopy results, Fig. 4.10. The microscopy results also suggest that there
is no low dose hypersensitivity in V79 cells, despite evidence in other literature to the
contrary, [165]. It is clear that more investigation will need to be done to confirm or
refute the low dose hypersensitivity seen in the flow cytometry experiments. Evidence
for the existence of low dose hypersensitive effects can be found in the work of S lonina et
al. [166]. They show low dose hypersensitivity, using MN as a measure of chromosomal
damage, in anchorage dependent cell lines. The cell lines in question were patient derived
keratinocytes and fibroblasts.
4.9 Dose Response of V79 Cells
Several experiments were conducted in order to replicate the results from a paper by
Bryce et al. [99]. Experiments 7, 8, 10 and 11 were all carried out with the V79 cell
line. The cells in Experiment 7 were exposed to IR and in the other experiments cells
were exposed to MMC with a maximum dose of 0.3125 µg/ml and 4 dose points in a
serial dilution.
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The work by Bryce et al. [99] does not show a dose response curve, instead it gives
an x fold increase in MN over the control for the ‘top passing concentration’. The top
passing concentration is interpreted as the dose in which the cells had a relative survival
of over 50 %. In the case of the experiments presented, the top passing concentration
was 0.3125 µg/ml with the two samples averaging a RS of 54.59 % and both samples
being over the 50 % threshold. At this dose there was a 10.53 fold increase in MN over
the control sample, based on averages of 2 control and 2 treated samples.
In the work of Bryce et al. [99], data for V79s treated using MMC was from Abbot
Laboratories. Abbott reported a 44.9 fold increase in MN, with a top passing MMC
concentration of 0.75 µg/ml. Whilst this seems a lot higher than the 10.53 presented
in this work, it should be noted that the top passing concentration in Abbott’s data is
double the strength of the top passing concentration for the work presented in this work.
Differences in relative survival and top passing concentration can be down to a number
of factors: tissue culture methods, serum content of cell media, drug solvent, how long
the drug has been dissolved in its solvent, or whether the cells are exponentially dividing.
To this end it is not surprising that there would be minor variations in results. Given its
fit within the other data provided in Bryce et al. [99] the result of a 10.53 fold increase
of MN in V79 cells seems reasonable. LN18 cells exposed to MMC, with a top passing
concentration of 0.156 µg/ml, gave a 5.91 fold increase in MN over control samples.
One further experiment was conducted with IR and V79 cells. In this case, the % RS
was well over the 50 % limit imposed by Litron at the top dose of 3 Gy. The MN increase
in this instance was 3.06 fold. A similar % RS with MMC gave a 4.98 fold increase in
MN. Although there is some variation of MN fold increase in the V79 data, they are all
still considered to be a valid results. This further adds to the body of evidence that the
In Vitro Microflow R© kit was being used correctly.
Comparing experiments scored using microscopy and Exp. 7, irradiated and counted
using flow cytometry, yielded similar results with the LN18 cell line. The results are
shown in Fig. 4.13.
Three experiments were conducted with the clastogen mitomycin C (MMC). Experi-
ments 8 and 11 using the V79 cell line and experiment 6 with LN18. The V79 results
are shown in Fig. 4.14. The shape of the dose response is very similar to the experiments
conducted with IR.
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Figure 4.13: Irradiated V79s Dose Response. Counted using Flow Cytometry and
Microscopy. Error bars for Flow Cytometry are the SD of Samples from 1 Experiment.
Microscopy Error bars are Weighted SD of 3 Experiments.
0 . 0 0 0 . 0 5 0 . 1 0 0 . 1 5 0 . 2 0 0 . 2 5 0 . 3 0 0 . 3 50
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
MN
 pe
r 10
00 
cell
s
D o s e  ( µg / m l )
 E x p  8  -  V 7 9 E x p  1 1  -  V 7 9
Figure 4.14: Dose Response of V79 to Mitomycin C. Error bars Represent the SD of
the Samples in that Experiment.
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4.10 Correlation of EMA Positive results with MN Fre-
quency
As discussed earlier, Decordier has shown that micronucleated cells are undergo apop-
tosis preferentially to non-micronucleated cells. [114]. A review by Kirsch-Volders et
al. [70] in 2011 confirmed this with reference to other groups work on the subject. The
assumption is that each ‘event’ is a single nuclei that has turned apoptotic. It is known
that nuclei fragment during apoptosis ([12], Tab. 3.1), so it is possible that this frag-
mentation could cause multiple events per nuclei during flow cytometry. However, there
could be an element of cause and effect, where fragments that are stained with EMA
were thought to be have arisen because of apoptosis are actually MN that have then
died via the apoptosis pathway.
Unfortunately this has not been explored in literature up to this point. To analyse this,
dot plots of the fluorescence intensities of EMA (X axis) and forward scattered light
(Y axis) for all LN18 flow cytometry experiments were plotted. For the 3 main sub-
populations, healthy nuclei, micronuclei and EMA positive nuclei, the mean intensities
were recorded. The data was then exported from flowing software intro excel for further
analysis. As flow cytometry data is commonly displayed on a log scale, the log of the
raw data for mean Y values and mean X values was used to create Figs. 4.15 and 4.16
respectively.
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Figure 4.15: Variation in Forward Scatter Signals by Population in LN18 Experi-
ments. Error bars Represent the Inter-experiment SD.
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Figure 4.16: Variation in EMA Fluorescence Intensities by Population in LN18 Ex-
periments. Error bars Represent the Inter-experiment SD.
Figure 4.15 shows that across the dose range, the physical size of the populations is as
expected, the healthy nuclei being the largest, followed by the EMA+ population and
the micronucleated population being the smallest. This confirms that the hypothesis
that one EMA positive event is likely to represent a single cell, rather than fragmenting
and causing multiple events per cell. The difference in size between EMA+ labelled
cells and healthy cells is thought to be because of nuclear condensation during the early
stages of apoptosis.
It is assumed that cells stained positively with EMA are apoptotic events. At this point,
the difference in experimental methods between PBLs and attached cell lines will give
different result. In the attached cell line protocol the monolayer is washed a number of
times with a buffer solution. This potentially leads to cell debris being removed in the
process, so the population stained with EMA were still capable of attaching to the well’s
surface, but their cell membranes were compromised to the point that the EMA could
be taken into the cell and bind to the DNA.
Similarly, it can be seen in Fig. 4.16 that MN events have a consistently lower EMA
fluorescence intensity than events already labelled as apoptotic. This goes to further
suggest that they are most likely micronucleated cells that, at the time of staining with
dye A, had intact cell membranes. It could be argued that fluorescence intensity would
be based on size of the event being stained. However, for events that are, on average,
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6 fold difference in size of the EMA events, there is a 10 fold difference in fluorescence
intensity which would indicate that there should not be a concern that the fluorescence
intensity scales with physical size of the stained event.
4.11 Modelling
4.11.1 Validation of the Decision Tree Code
Validation of this one element of the MiNiMUS code can be achieved using commercial
decision tree software. Decision trees can be used in many areas of research, such as
business, legal, pharmaceutical and engineering. This flexibility comes from commercial
software just providing a framework for users to form their own models. This can also
be the primary downfall of such packages as they become confusing to use.
Decision tree software also comes bundled with tools to perform a myriad of analysis
around the tree model the user has built. Whilst these tools would be useful to use
with MiNiMUS it is impractical, as the probabilities change with every run through
the tree due to the Monte Carlo sampling. An embedded implementation using a com-
mercial package would become a lot more difficult than having a standalone Fortran
implementation.
However this does not stop validation of the Fortran implemented tree against a com-
mercial package as dummy probabilities can be used. The Fortran implementation of the
MiNiMUS tree has been compared against the same tree created in the commercial de-
cision tree software package called TreeAge [167]. This representation of the MiNiMUS
decision tree from TreeAge can be found in Fig. 4.17.
Figure 4.17: MiNiMUS Decision Tree, Represented in TreeAge [167].
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The Fortran implementation of the MiNiMUS tree was initialised with all probabilities
set to 0.5 and each node numbered. The test program runs through the tree 2000 times
and at each ‘End of Tree’ encounter the node number noted. This was carried out 10
times and averages taken. The intrinsic random number generator, which is in fact
pseudo-random, was given a fixed seed such that it would always produce the same
string of ‘random’ numbers for the validation case making runs comparable. In the case
of the tree in Fig. 4.17 the probability can be calculated analytically as none of the
probabilities change as they would in the Monte Carlo simulations. These probabilities
were compared to the average of all runs for each end of tree node. The results of the
analysis can be found in Tab. 4.7.
Node Name Mean Variance p(x) Model p(x) Analytical % Difference
No Repair MN 500.3 291.344 0.25015 0.25 0.06
No Repair No MN 504.9 232.767 0.25245 0.25 0.98
NHEJ MN 120.1 44.1 0.06005 0.062 -3.15
NHEJ No MN 125.7 76.233 0.06285 0.062 1.37
HR MN 122.8 71.733 0.0614 0.062 -0.97
HR No MN 125.9 155.433 0.06295 0.062 1.53
NHEJ Success 256.7 243.567 0.12835 0.125 2.68
HR Success 243.6 152.933 0.1218 0.125 -2.56
Average -0.01
Table 4.7: Validation of Tree Code.
As can be seen from the average percentage difference, the Fortran implementation,
p(x) Model, predicts the analytical probabilities to a satisfactory level so no further
alterations were made to the Fortran tree code.
4.11.2 Validation of Monte Carlo Sampling Routines
As discussed previously, the Monte Carlo elements of the model rely on drawing new
probabilities that form part of a specified probability distribution function. An accep-
t/reject style method was implemented to select the new probability. To verify this the
Monte Carlo sampling routine was run 1000 times and the value of U2, one of the two
random numbers drawn, was either declared as a ‘win’ if the value was thought to lie
within the PDF and a ‘loss’ if it did not. The data was put into a graph which can be
seen in Fig. 4.18. Although it would appear that some of the points along the PDF line
are wrongly classified, this is an artefact of the plotting package rather than an incorrect
designation.
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Figure 4.18: Monte Carlo Sampling Verification Results.
However, when the PDF being used has a small range in the x axis the sampling efficiency
was very low, see Fig. 4.19. To counter this effect the scaling of the U2 is varied. The
PDF is evaluated at points along the x axis using an interval halving routine, starting
at the mean point of the PDF, such that the lower and upper boundaries at set to a
point where the function evaluation is essentially zero. This means that the sampling
efficiency greatly improves, particularly at the extremes of the x axis range, where the
efficiency rises by an average of 30 %. Fig. 4.19 shows the increase in sampling efficiency
over the PDF range. Probabilities in MiNiMUS tend to lie at the extremes of the Beta
function’s range in the x axis. This means that the PDF’s means tend to lie at the
extremes of the range, making the sampling efficiencies poor. Fig. 4.19 shows the effect
of scaling U2 between the whole range and the restricted range as described above.
This increase in sampling efficiency greatly speeds up computation time for the model,
meaning that total run time is in the order of seconds.
4.11.3 Modelling Adherent Cell Lines
Whilst the experimental data shown previously suggests that both LN18 and V79 are
limited in their sensitivity to dose in terms of their numbers of micronuclei, the question
still remained as to whether the dose response can be modelled. The model was fitted
against the microscopy data as there was less experimental variation in the results.
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Figure 4.19: Increase in Sampling Efficiency Through Scaling of the Variables in the
Accept/Reject Algorithm.
Whilst literature suggests that the PBL dose response is non linear, this is not the case
for attached cell cultures. Both V79 and LN8 exhibit a linear dose response.
4.11.3.1 Cell Phase Durations
As LN18 are treated as asynchronous, actively cycling, cells. Due to this, cell cycle
phase fractions and total cycle time are required for the model. For LN18, a total cell
cycle time of 18.9 hours was determined by growth curve, see Sec. 4.3. Hui et al. [168]
give phase fractions for the LN18 cell line. Their experiment involved transfecting LN18
cells, but the negative control data is suitable to use. The resulting cell phase times can
be found in Tab. 4.8. A rounding error is likely to have caused the total to be 100.01 %
so G1 phase was reduced by 0.01 % from the original data as this would have the least
impact on the model.
Tab. 4.8 shows the dominant phase to be G1 for LN18 cells with a phase duration that
is 55% of the total doubling time, which is the same for asynchronous V79s. The main
difference between the two cell lines is the doubling time (TD), which is much shorter
in V79s (12.5h) than in LN18s (18.9h). The details of the phase durations is given in
4.9. The individual phase lengths were calculated by multiplying the phase fractions,
calculated by flow cytometry, with the total TD, which was calculated using a growth
curve.
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Cell Phase Phase Fraction (%) Phase Duration (h)
G1 55.93 10.56
S 36.82 6.96
G2 3.625 0.69
M 3.625 0.69
Total 100 18.9
Table 4.8: LN18 Cell Cycle Phase Durations. Phase Fraction Data from [168].
Cell Phase Phase Fraction (%) Phase Duration (h)
G1 55 6.88
S 25 3.12
G2 10 1.25
M 10 1.25
Total 100 12.5
Table 4.9: V79 Cell Cycle Phase Durations. Data from [165].
V79 cells were included in the analysis due to their cell phase fractions being similar to
LN18s. The results of the analysis are presented in the following sections.
4.11.3.2 Fitted Probabilities in Adherent Cell Lines
Table 4.10 shows the fitted probabilities that gave rise to the fitting shown in Fig. 4.20.
The model is fitted to the average results, given in Sec. 4.8 and 4.9.
Given the issue of the number of free variables with using automated fitting, highlighted
in Sec. 3.4.9 and discussed in Sec. 5.5.1, the values were fitted using the MN probability
variable. The same approach is used for modelling PBL samples.
The analysis was conducted using a cohort of 1000 asynchronous cells, using dose points
of 1, 2 and 3 Gy. The fitted MN probability was then used to construct a dose response
curve, Fig. 4.20, given the natural variance expected when using a Monte Carlo based
model, the simulation was run 5 times. The error bars represent the standard deviation
of the 5 runs.
It can be seen that the fitted value lies in between the experimental results for both V79
and LN18, whilst being within the experimental errors of both experiments.
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Variable G1 Phase S Phase G2 Phase M Phase
Any Repair 0.980 0.980 0.980 0.980
Repair Type 0.010 0.750 0.500 0.500
HR Success 0.990 0.990 0.990 0.990
NHEJ Success 0.975 0.975 0.975 0.975
MN Probability 0.015 0.015 0.015 0.015
Table 4.10: Model First Fit Probabilities for Attachment Cell Lines.
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Figure 4.20: Model Fit to Experimental Results for Attached Cell Lines. Error bars
represent one standard deviation from either experimental data or model prediction.
4.11.4 Modelling PBL Dose Response
The model is designed to predict numbers of micronuclei arising from doses of ionising
radiation. It has been shown that micronuclei arising from ionising radiation are almost
exclusively centromere negative [32], which is intuitive given the clastogenic nature of
radiation. As a proof of concept, data for PBL dose response to radiation was extracted
from literature, see Fig. 4.21 for references, to form experimental dose response curves
for micronuclei in the 0-3 Gy range.
The data of Vral et al. (2011) [29] and Wuttke et al. [78] is for PBLs including C+MN
and so the data is not so useful to tune the model, but is included for completeness
sake. Decordier et al. [30] do not state whether their data is for centromere negative or
positive and so it is assumed this analysis was not carried out and hence would be data
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including C+MN. As discussed previously, Sec. 2.3.1, IR is known to give rise to almost
exclusively C-MN and so the model should be fitted to data that are explicitly given as
C-MN.
PBLs show a good dose response curve to photon sources of radiation as shown in Fig.
4.21. More importantly, the dose response of PBLs is non linear, exhibiting a linear
quadratic type dose response. This is not the case for adherent cell lines, where the dose
response is linear.
The large deviation from the linear dose response exhibited by adherent cell lines could
be attributed to experimental method. In the data collated in this work, PBLs were
harvested from whole blood and then stimulated by PHA or similar before being irradi-
ated. However, at the point of irradiation it is most likely that the cells will all be in the
G0/G1 phases of their cell cycle. Leonard and Merz [169] show that chromosomal aber-
rations were more frequent when lymphocytes were irradiated shortly after stimulation
by PHA.
One explanation could be that the population of cells remains synchronised up to the
point of analysis. If the cell population is in the process of replicating DNA, there is a
higher chance of stalled replication forks causing additional DSBs, which could then form
additional MN. These additional MN would be indistinguishable from those caused by
IR. In asynchronous populations the mitotic index is more stable and so marked increases
in MN due to stalled replication forks is unlikely to be identified.
The model was fitted to the PBL data from literature in a similar fashion to the adherent
cell lines in Sec. 4.11.3. The results have also been plotted in Fig. 4.22. It can be seen
that the model fit to the published data at 3 Gy is very poor. This is the point at which
the data becomes significantly non-linear. The decision was taken to exclude the 3 Gy
data point from the fitting process, as it was known that the model cannot produce a
non linear effect to the same degree. The fitting was therefore conducted using dose
points of 0.5, 1 and 2 Gy.
When Fig. 4.22 was constructed, the model output for 3 Gy was included to show the
extend of the models inability to predict this non linear result.
Whilst this could be considered a significant drawback of the model, the goal was to
model the dose response in tumour tissue and so modelling PBL samples is less impor-
tant.
With the probabilities detailed in Tab. 4.11, the model was a number of times to produce
predictions of MN formation across the dose range of 0 to 3 Gy. This has been plotted
in Fig. 4.22 with data from Huber et al. and Vral et al. [31, 32] as they specifically
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Figure 4.21: Micronuclei Dose Response in PBL Samples from Literature. Data from
[29, 30, 31, 32, 78].
Variable G1 Phase S Phase G2 Phase M Phase
Any Repair 0.980 0.980 0.980 0.980
Repair Type 0.010 0.750 0.500 0.500
HR Success 0.990 0.990 0.990 0.990
NHEJ Success 0.975 0.975 0.975 0.975
MN Probability 0.050 0.050 0.050 0.050
Table 4.11: Model First Fit Probabilities for PBLs.
refer to C-MN. As discussed earlier, the model is unable to fit to data above 2 Gy due
to the non linear nature of the PBL dose response.
4.11.5 Sensitivity Analysis
The sensitivity analysis for the tree variables based on with the model set to predict
MN frequencies for LN18 samples, hence using the probabilities found in Tab. 4.10 and
the cell phase durations found in Tab. 4.8.
This has the potential to skew results because the phase durations influence the numbers
of DSBs potentially considered for each variable. Whilst it could be possible to equalise
the phase durations so that each phase has 25 % of the DSBs, this is not realistic.
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Figure 4.22: Model Fit to Literature PBL Dose Response. Data from [31, 32].
However, in general the results should be similar as the G1 phase is approximately 50
% of the overall duration and the S Phase covers most of the remaining duration.
The tornado diagram can be found in Fig. 4.23, which is ordered by the largest distur-
bance from the base case, taking into account the caveats in Sec. 3.4.8.
The most notable outcome of the sensitivity analysis is that nodes which receive more
DSBs during the simulation are the most sensitive. The most sensitive probability, ‘G1 -
NHEJ Success’, receives 99% of the DSBs in the base case for cells labelled as G1. The
LN18 cell cycle predominantly consists of G1 phase cells, so it is not surprising that this
is the most sensitive. This probability also directly precedes a decision on whether a
MN is formed.
Conversely, the ‘repair type’ probabilities are the least sensitive overall. These proba-
bilities do not precede a MN decision. The probabilities they come before in the tree,
found in Fig. 3.2, are the repair pathway success rates, which all have high probabilities
of repairing the DSB in the base case. If it were the case that the success percentages
was a lot lower on the nodes below this decision, it is expected that the ‘repair type’
nodes would have a greater impact on the sensitivity analysis.
As stated in Sec. 3.4.8, many of the probabilities in the base case are at the extremes
of the 0 to 1 probability range. This has meant that 12 of the 17 positive deviation
simulations were truncated as the deviation made the probability greater than one.
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Figure 4.23: MiNiMUS Tree Sensitivity Analysis Based on LN18 Phase Durations
and a 3 Gy Radiation Simulation.
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The last encouraging result in the sensitivity analysis is that the only variable that is
independent of cell phase, ‘MN Probability’, does not appear to be overly sensitive. This
variable appears at every MN formation decision and could easily have swayed the model
output, making it difficult to adapt to other tissue types as the assumption that MN are
formed from unrepaired DSBs should be independent of tissue type.
4.12 Key Findings
It is possible for flow cytometry to be used to gather data on attachment cell lines,
such as LN18 and V79, using the In Vitro Microflow R© method. However, the protocol
requires some modification based on cell line characteristics. There was a large variance
between the experimental data sets. Whilst it is hoped that this could be reduced with
more experience using the protocol, at this point the variance makes using the data set
for the MiNiMUS model challenging.
With the protocol challenges aside, the In Vitro Microflow R©kit achieves the main goal
of being able to detect MN in glioblastoma cells within a short time frame, as the process
can be completed within 2 to 3 days of irradiation.
Microscopy based experiments on LN18 and V79 produced linear dose responses over
a dose range of 0 to 3 Gy. Microscopy is also a valid technique to assess MN counts
within a few days of irradiation, but takes longer to complete than the flow cytometry
technique when analysis of the images is taken into account.
The MiNiMUS model has shown that it can predict the dose response of the attachment
cell lines, V79 and LN18. However, due to the non-linear nature of the PBL dose
response, it is not able to model the whole dose rage. Whilst this could be seen as a
limiting factor, the modelling of PBL samples was not a core requirement of the model.
In terms of a rapid assessment tool, these results are a mixed blessing. Whilst it has
been shown that cancerous tissue can be used with the In Vitro Microflow R© method,
the lack of a pronounced effect, similar to that of PBLs, makes the initial aim of using
biopsy tissue for the analysis more difficult.
Chapter 5
Discussion
5.1 Introduction
In this chapter the assumptions and aims are evaluated in the light of the experimental
and modelling activities. Some further thoughts on the next steps for the model are also
given.
5.2 Project Outcomes
The overall project goal was to create a model that can predict tissue sensitivity in cell
lines using micronucleus formation. This was to be achieved by experimentally measur-
ing micronucleus frequency after in vitro testing of patient tissue, either peripheral blood
lymphocytes or tumour tissue. Although it should be noted that if patient PBLs were
tested then the response would be for normal cells rather than tumour tissue. The model
is then responsible for estimating cell survival, based on the micronucleus frequency. In
this work the first half of the model has been constructed, such that micronucleus fre-
quency can be predicted. The link between micronucleus frequency and cell death is
yet to be implemented, primarily because the link between micronucleus frequency and
cell death is not characterised well enough. The relationship for the cell lines available
within the medical applications group is shown graphically for V79 and LN18 in Fig.
5.1 and 5.2 respectively.
In the previous chapter, the experimental and modelling outcomes were presented. The
dose response of micronuclei in the LN18 and V79 cell lines was measured using both
flow cytometry and fluorescence microscopy. The flow cytometry experiments showed
large amounts of variance between experiments. Whilst some of this could be down to
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Figure 5.1: Clonogenic Survival and Micronucleus Frequency of V79s. Clonogenic
data from [165].
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Figure 5.2: Clonogenic Survival and Micronucleus Frequency of V79s. Clonogenic
data from [119].
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learning a new experimental technique, it could also be because of the analysis being done
without the use of the supplied template, due to incompatibility with the University’s
equipment. It is expected that use of the supplied template could reduce this variance by
adopting the standardised placement of gates and highlighting where machine settings
may be altered to improve the quality of results.
The experiments where micronucleus frequency was determined by fluorescence mi-
croscopy showed much less variance than the flow cytometry work. The only drawbacks
with the using microscopy methods is that the sample analysis takes significantly longer
than flow cytometry. Also, the results will be dependent on who has analysed the sam-
ples, as they are with other immunostaining methods. Although this could be considered
analogous to gate placement in the flow cytometry protocol.
In its present state, the MiNiMUS model can predict the formation of micronuclei in
the LN18 and V79 cell lines over the dose range of 0 to 3 Gy. However, modelling of
PBL samples is not possible due to the non-linear nature of the PBL dose response. For
the proof of concept the model was required to predict MN counts from experimental
data, which has been completed. However, the challenge is now to implement the other
suggested features of the model, detailed in the first chapter.
Whilst it is disappointing that the dose response of LN18 was limited, it is encouraging
that the modelling approach can predict the formation with good accuracy, see Fig.
4.20, when fitted to experimental data provided. This forms a platform from which
further investigation into predicting cell death can be investigated. Methods for which
this may be achieved are discussed later in this chapter, Sec. 5.7. The model has been
designed based on several assumptions, which at this point need to be evaluated.
5.3 Assessment of Modelling Assumptions
5.3.1 Biological Assumptions
Whilst most of the biological assumptions made in Sec. 3.4.2.2 are basic assumptions and
require no more discussion at this point, the question of whether cells are cycling becomes
more pertinent given the more pronounced response of peripheral blood lymphocytes
(PBLs) over that of adherent cell lines. Naturally PBLs do not cycle on a regular basis
and require stimulation in some way, in the case of the literature used in this work
PHA was used. Any experimental data from PBLs should closely scrutinise the culture
methods to ensure comparable data. Further thoughts are given later in this chapter.
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5.3.2 Cell Death Assumption
The modelling assumptions made will need revising if the MiNiMUS model is to be
developed in the future. It is stated in Sec. 3.4.2.1 that there is no concept of cell death
in the MiNiMUS model.
This assumption’s validity is dependent on how the model is scrutinised. If the model
is required to present an accurate number of MN formed then this assumption is clearly
wrong as it has been stated a number of times that one fate of a MN is to enter apoptosis.
However, if the model is considered a black box then the assumption is valid as the output
of the model matches observed experimental results.
It was not clear from the outset that the numbers of apoptotic cells would cause this
issue as it was assumed that the time scales for cells to become apoptotic were larger
than the 1.5 to 2 doubling times. In hindsight the experimental evidence shows this is
clearly not the case, as EMA+ frequencies, which represent apoptotic cells, are present
in similar frequencies to the micronucleated response within the same time frame, data
not shown.
It would be possible to alter the model such that each decision is independently verifiable,
but this would mean altering the model to include cell death. In order to do this
another decision would have to be added onto DSBs that did become micronucleated;
the decision being whether the MN will then enter apoptosis or not. This could be
verified by repeating experiments that inhibit caspase 8 or caspase 9, both of which are
integral to apoptosis [170].
Decordier et al. [27] have shown that inhibiting caspase 8 and 9 leads to an increase
in micronucleated cells. Their protocol induced MN using drugs, rather than IR. The
caspase inhibitors were incubated with the drug for between 42 and 44 hours and no
dose was given. Whilst this would be longer than the incubation period used in this
work, other studies [171] have used much shorter incubation times, 20 minutes at a dose
of 1 µM, although this was with a PBL sample. As this model is still in the proof of
concept stage, either direction could be valid. However, as a tool to explore some of the
more intricate mechanisms of MN formation, having each decision point independently
verifiable would be more fruitful.
5.3.3 Background Micronuclei Levels
As it currently stands, MiNiMUS does not take into account background levels of MN.
This poses a challenge as MiNiMUS is designed to predict micronuclei formation from
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unrepaired DSBs arising from radiation. Whilst background levels of micronuclei could
well occur due to DSBs that do not arise from IR, quantifying this would not be possible.
The most effective way to take into account background levels of MN would be to
have the information provided from experimental measurements, as the variation from
person to person is unknown. With the control level known, MiNiMUS could then re-
fit the probabilities to give numbers of MN equal to the observed experimental value,
minus the background level. As the model can already predict the shape of the dose
response, subtracting a fixed value from each dose point should only require refitting
the probabilities. However, at the point at which this issue became apparent, it was
too late to make the necessary modifications. This should be seen as a priority for the
development of the model.
5.4 Use of the In Vitro Microflow R© Kit for Micronuclei
Detection
The key aim for this project is to model the dose response for micronuclei (MN) against
radiation dose for glioblastoma cell lines. The caveat to this is that the protocol has
to be completed within a short time frame, which means that alternative methods to
microscopy were desirable. The In Vitro Microflow R© cytometry method has been proved
to give good results in PBLs in literature, however it had not been carried out in human
or cancerous cell lines before.
In order to have confidence in the results gained from the In Vitro Microflow R© kit,
some experiments were carried out to try and reproduce results published by the kit
manufacturers. The In Vitro Microflow R© kit has been used on attachment cell lines,
particularly the V79 cell line [99]. Experiments were performed with both ionising
radiation (IR) and mitomycin-c (MMC) in independent experiments. The IR experiment
gave a good positive response curve with a 3 fold increase of MN at 3 Gy over the control
levels. This is slightly less than the increase published by Bryce et al. with MMC [99].
As the results of the experimental results in this work and those reported by Bryce et al.
[99] were similar, it was assumed that the kit was being used correctly, but as previously
discussed, the protocol may need minor revisions based on the characteristics of the cell
line being used. For instance, with LN18, extra pipetting was needed to detach cells
from the plate they were seeded on. Any implications of protocol changes should be
considered, such as the likelihood of lysing cells by extra pipetting. In this case it is
not thought that this extra pipetting had a large impact on the results, despite a large
inter-experiment variation in MN frequency.
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When the In Vitro Microflow R© protocol was tested with the LN18 glioblastoma cell line
there appeared to be little dose response compared to the PBL dose response. This was
confirmed with the microscopy based experiments, a comparison can be found in Fig.
4.12.
The manually scored cells exhibited approximately 20 to 70 MN per 1000 cells over the
0 to 3 Gy dose range. The flow cytometry agreed with the doses at 1 and 3 Gy, where
the averaged dose point being significantly higher, but with the error bars overlapping
the microscopy data point. At 2 Gy the microscopy result is slightly higher than the
cytometry result, outside the 1 SD errors on the respective data. Below 1 Gy there
was a significant difference between the flow cytometry results and the microscopy.
The variation in the cytometry results was significant, for which there is no current
explanation beyond those suggested in Sec. 5.2.
During the initial investigations into whether the In Vitro Microflow R© method would
work with brain tumour tissue, the key point was whether the cells were actively cycling.
Being cancerous, this is the case, but ultimately has lead to the downfall in terms of the
expected results. The apoptotic response in LN18 cells acts in a short time frame. Cells
were left approximately 27 hours post irradiation before they were stained, which is on
the lower end of the time frame suggested by the protocol. The EMA response shows
that within 27 hours the programmed death pathways are active.
5.5 Modelling of the Micronucleus Frequency
The MiNiMUS model is designed to predict the MN frequency and be used as a rapid
assessment tool, used in the treatment planning process, to indicate tissue sensitivity.
Whilst the work shown here has proved that such a method can predict the numbers
of MN in attachment cell lines, there are still a number of stages before this kind of
approach could be considered a useful addition over just having experimental results in
a clinical setting.
The most significant milestone will be incorporating the link between MN and cell death.
This model was built on the unstated assumption that the response of glioblastoma cells
would be similar to that of PBLs. Whilst it has been hypothesised that at least some
of the difference between PBL and attachment cell line dose response is because of the
effect of irradiating synchronised cells, as discussed in Sec. 4.11.4, the role of apoptosis
in attachment cell lines could also play a role.
There is significant evidence that MN enter apoptosis preferentially [70], but extensions
to the model will still need to be made in order for this to be taken into account. At
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this stage the principle of modelling MN formation has been proved, but in order for
this model to become more clinically useful the model really needs to predict cell death.
The dose response of glioblastoma tissue is disappointing, but if cell death can still be
predicted from this data then the model could still have a significant benefit to treatment
planning in a clinical setting.
In the further future of the model, it is hoped that once cell death can be predicted
based on counts of MN, that this could be used to test treatment planning options,
such as radiation type to see whether certain courses of action would have a benefit over
conventional photon treatment. Prediction of cell death and hence an output of survival
fraction, would make the results comparable with other data reported as cell survival
fraction.
As stated, this is a very long term goal, as the realities of bringing a model into clinical
use are not favourable, based on a range of factors, such as the difference in response to
in vitro vs. in vivo dose response, ethical and regulatory approval.
5.5.1 Automated Vs Manual Probability Fitting
Previous versions of MiNiMUS did not have the automated fitting routines enabled,
although they were coded. The reason for this is twofold.
Firstly, there is a limitation on the number of variables that can be fitted at any one
time, due to the practical number of experimental data points compared to the number
of variables that could be fitted. It is not practical to have the number of experimental
data points required to fit every variable that MiNiMUS uses. This was a serious design
floor that, unfortunately, is not possible to correct. The caveat to this would be if
individual experiments could be done to verify each probability individually, reducing
the number of free variables to the point at which a 4 to 5 dose point experiment could
fit the remaining variables. Whilst it is still a goal that MiNiMUS would operate in a
framework style mode, which would make this possible, that point is still a long term
goal.
Secondly, despite fitting routines where the objective function can have constraints im-
posed, they are not hard constraints.
The objective function calculates a new φ, the sum of squares of errors, and subsequently
modifies φ if the probability the optimiser has selected is beyond the limits of 0 and 1.
This reactive form of constraint leads to the optimiser spending large of runtime outside
the viable region as although the value of φ is very large, from one calculation to another,
it may not change significantly.
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One way to solve this issue is to use a grid search optimisation technique, where the upper
and lower bounds for a particular run can be given prior to the optimisation. Whilst the
brute force method of this kind of optimisation would normally take significantly longer
to run than more elegant methods, in this case, it is the more useful of the 3 available
methods in the GENOPT framework when fitting a single probability.
The other possibility is to have a fully manual fitting, where the probabilities are altered
by hand. This form of fitting is useful to get a close approximation to the experimental
data, using the same type of sum of squares of errors type calculation as the MiNiMUS
code, before using the model’s fitting routines refine the search.
There has to be a degree of forethought when attempting to fit to experimental data.
It has been shown that MiNiMUS produces close to a linear dose response and so if
experimental data gives a significant non-linear response, such as that with PBL samples,
then the fit will never be good. In this case, the fit to the more linear portions of the
dose response will get worse as the optimisation routines try to fit to the non-linear
experimental points.
With the model still in a proof of concept stage of development, both methods of fitting
should be considered useful, although it is expected that the end goal will see manual
fitting deprecated in favour of fully automated fitting.
5.5.2 Modelling Lymphocytes with MiNiMUS
It has been shown that MiNiMUS can model the dose response of peripheral blood
lymphocytes well. The original intention was to address an area of unmet clinical need
on assessing tumour response to radiation to elucidate underlying radiosensitivity. Given
that preliminary testing of the model used data published on PBLs, as this data was
readily available, it would be sensible to explore this relationship more.
It has been shown that the model presented can predict the dose response in both PBLs
and adherent cell lines. In terms of the way the model would be used in the future, the
differences between these tissue types becomes more important. Whilst biopsy samples
come from a static tumour, which might receive a uniform dose of radiotherapy, PBLs
circulate around the body and so from a sample it would not be possible within the
current model to estimate what fraction of that sample had been exposed to radiation.
If the model were to continue with lymphocytes being the primary experimental tar-
get an extra model would need to be put in place to characterise the flow of PBLs in
blood vessels, but also any lymphatic tissue within the area of interest. This opens up
opportunities to assess normal tissue complications by using MN as a biomarker. PBL
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systems in vivo could be considered a well mixed liquid phase system. Compartment
based models are useful because they can simulate flows of material, which lend them-
selves well to PBL systems. PBL systems are also treated as suspension cultures when
used in vitro, which means that it is possible to closely mimic their natural environment.
Clinically this is relevant as there have previously been studies into predicting normal
tissue complications based on lymphocyte response to treatment [172].
However, it should be noted that there are better end points to measure if PBLs are
being used as a biodosimeter, such as dicentrics for radiation exposure. This is primarily
because dicentric analysis of PBLs can take into both full and partial body exposure
[42].
5.5.3 Difference in Dose Response of PBLs and GBM
Several authors in the literature have shown a non-linear dose response curve for PBLs,
collated in Fig. 4.21. However, in GBM tissue the dose response is linear. This has
been shown both in the experimental work in this project, Fig. 4.11, and in work by
Shibamoto et al. [72] where the A6 astrocytoma cell line was used. However it should be
noted that this A6 cell line has not been found in further work. The American Type Cell
Culture Collection lists two cell lines as A6 and A-6, neither of which are astrocytoma
cell lines.
One explanation for this difference could be that in most PBL experiments found, the
cell were stimulated shortly before irradiation, meaning that they will have been syn-
chronised. The length of time before analysis varied, but it is possible that there was
still a large degree of synchronicity which lead to an increase in damage. This could be
explored further by ensuring that an asynchronous population exists before irradiation.
Huber et al. [32] left PBL samples 66 hours after irradiation before analysis, of which
the last 24 hours had cyt-b added to the medium to block cytokinesis. This raises the
question of whether this extended period of time will have impacts on the MN frequency,
given that some figures estimate the PBL cell cycle to be under 15 hours [173], although
the authors note that some cells reached the first mitosis 150 hours post-stimulation.
5.5.4 Quantification of Foci using Flow Cytometry
As stated previously, the use of flow cytometry in the field of radiobiology is becoming
more common. However, access to flow cytometry machines is not universal. In the
recent past there has been great success in using a fluorescence microscope as a virtual
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flow cytometer for DNA content histograms [165]. Could this be applied to cases where
fluorescence intensity makes foci too close to count? An example is given in Fig. 5.3.
Flow cytometry has been used to detect γH2AX foci in the past [111, 174], with Chappell
et al. also developing mathematical methods to describe the kinetics of phosphorylations
in fibroblast cells, including γH2AX phosphorylation. Valdiglesias et al. [175] shows a
meta analysis of studies using the H2AX response, a number of which use flow cytometry
for the analysis. Of the 68 studies investigated, 16 % used flow cytometry to score H2AX
foci and 4 % used both microscopy and flow cytometry.
Figure 5.3: Cells Treated with 10µM Camptothecin Exhibiting Large Fluorescence
Intensities. Green Foci are γH2AX Foci. Red Fluorescence Given by Propidium Iodide,
a DNA Stain. Picture Courtesy of Dr. C. Jeynes.
The proposed method would include elements of experimental work and a mathematical
model. The experimental component would involve processing samples using either a
flow cytometer or microscopy techniques that can identify fluorescence intensity from
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individual cells. These individual intensities can be aggregated into histogram form.
This, for a specific dose, should give a histogram similar to those shown at the top of
Fig. 5.4. The median intensities can be plotted against the dose, giving a plot similar
to that mocked up in the lower part of Fig. 5.4.
The power of flow cytometry is the statistical advantage over microscopy based tech-
niques, given the amount of data that can be processed in a short time frame. However,
microscopy based techniques should not be overlooked, given that access to facilities is
more common.
The main drawback of assessing DNA damage from fluorescence data is the inter-sample
staining intensity. This is a common operating issue when using flow cytometry, which
is overcome by altering photomultiplier voltages. Similar methods would have to be
considered if using microscopy based techniques. Part of the variation can be accounted
for using fluorescent standard slides and so any other variation in intensity must be
accounted for by the staining protocol.
The other challenge of this model is to quantify numbers of DSBs from samples. As
previously stated, foci counting becomes challenging at higher doses due to saturation
of the image. At higher doses it may become possible to predict the numbers of DSBs,
or other antibody stained end points, based on the correlation of the mean intensities.
Whilst there could be many methods to model this correlation using a known probability
density function, the Poisson distribution should be considered in the first instance, given
the discrete nature of the distribution.
Adding a further dimension to the model could be achieved by analysing samples over
time by fixing samples at set time points. It is commonly known that certain cellular
processes are dependent on time, such as γH2AX foci varying depending on time after
treatment. This could, with careful analysis be useful in determining the repair kinet-
ics at higher doses, which may differ from lower doses due to saturation of the repair
pathways.
Whilst this model has been designed to investigate numbers and dose response of DSBs,
the concept could easily be extended to other fluorochromes. This could be of particular
interest when looking at other proteins involved in DNA repair, rather than just the
γH2AX foci for DSB quantification.
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Figure 5.4: Potential Model for DSB Quantification. By Creating Histograms of Cel-
lular Fluorescence Intensity, it may be Possible to Visualise any Underlying Correlation
with Dose.
5.6 The Role of Base Excision Repair in DSB Induction
The base excision repair (BER) pathway is used much more regularly than DSB repair
pathways, owing to the numbers of base excisions being much higher than DSBs ([12],
Sec. 2.1). In BER the damaged base or bases are removed using glycosylase and then a
nick is made in the phosphate backbone, creating a single strand break, hence it being
drawn with the single strand break repair pathway in Fig. 5.5. At this point the repair
process is completed as either long or short patch depending on how many bases need
repairing.
If single strand breaks are in close proximity they can form a DSB [176]. As the dose
increases, there is a significant increase in numbers of base excisions and hence SSBs.
With this increase, the probability that a number of the intermediate SSBs, created
during the BER repair pathway, may be converted to DSBs. It is not thought, in the
case of photon irradiation, that extra DSBs created in this way will significantly increase
the numbers of MN in the clinically relevant dose range.
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Figure 5.5: Overview of Base Excision Repair and Single Strand Break Repair ([12],
Fig. 2.9).
It stands to reason that increasing the numbers of SSBs will improve the chances that
extra DSBs will be created. The theory that inhibiting SSB repair will lead to a clinically
observable improvement in treatment, has some backing in the radiobiology community.
There are many groups looking at poly(ADP-ribose) polymerase (PARP) inhibitors in
combination with radiotherapy. The PARP enzymes bind to the sites of processed SSBs
and recruit other enzymes such as XRCC1 [177], which itself is crucial in recruiting other
proteins in the chain, such as the ligase 3 which is responsible for the final ligation of
break in short patch repair ([12], Sec. 2.8).
Unfortunately, quantifying either base excisions or SSBs will present the same difficulties
as DSBs, it is thought that counting of foci would be impractical for the same reasons
it is considered impractical with DSBs. .
It should be noted that whist PARP is involved in the repair of SSBs, it also has down-
stream involvement in cell death pathways, such as apoptosis. Chiarugi and Moskowitz
[178] show that with an increase in PARP the cell’s adenosine triphosphate (ATP) and β-
nicotinamide adenine dinucleotide (NAD+) reserves are depleted, which, amongst other
effects, causes the release of mitochondrial apoptosis inducing factor. This shows that
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there is a double effect of PARP in terms of its clinical effect over and above inhibiting
SSB repair.
5.7 The Future of MiNiMUS
This project was started as a proof of principle exercise to see whether micronucleus
formation was suitable as a rapid measure of tissue sensitivity and whether the formation
of micronuclei could be predicted via a mathematical model. At the heart of the model
is a decision tree with fixed probabilities, although a Monte Carlo simulation alters these
to a degree as the program runs.
Whilst these probabilities predict the overall numbers of MN, it does not represent the
underlying biological processes. There is a potential that over or under compensation in
the estimation of one probability could be masking similar errors in other decisions in
the tree. As stated in 4.11.4, the model should currently be seen as a ‘black box’ type
model.
One way to solve these issues and validate each decision point independently is to replace
the arbitrary probabilities with mechanistic models of each decision point. MiNiMUS
and the tree structure would become a framework for a number of separate models all
run from within MiNiMUS, providing probability data relevant to a particular decision.
For instance, a model that predicts the availability of Rad51 with respect to time, and
give an overall probability that the mechanism for that particular DSB repair will be
NHEJ.
An alternative to mechanistic models for each decision point is to fit probabilities to
experimental data designed to look specifically at that decision. An example of this
would be using the M059J and M059K cell lines. M059J cells show a lack of DNA-
PKcs activity, which is integral to NHEJ repair, see Sec. 2.5.3 for details. Determining
the ability of M059K to repair damage caused by IR and comparing that the repair
deficient M059J cells should give a good indication of the probability required in the
NHEJ Success nodes in the decision tree, particularly if the experiments could be done
on synchronised cells,
The drawback of replacing arbitrary probabilities with mechanistic models is that the
overall model becomes more complex, which can lead to longer computation times and
difficulty in debugging if problems arise in the code. Currently, computation times are
in the orders of seconds per dose for 1000 cells and so this should not be of too great a
concern.
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5.8 Microscopy Based Techniques
As briefly discussed in Sec. 4.7, the microscopy based technique did not overlap com-
pletely with the flow cytometry based technique. This could be down to several factors,
which can broadly be classified as analysis based systematic error. The variance of the
flow cytometry based techniques is discussed in Sec. 5.10.
The dishes were scanned automatically using the microscope software. The software
took an image of the current field and then moved the stage, such there was no overlap
with the previous field. The software was set to scan 10 fields x 10 fields in a grid
pattern. These images were then scored by eye as no automated software was available
to do the task. This left a certain element of luck as to how many cells were captured
within the scanning area, despite cells being seeded across the whole Petri dish. It is
also possible that the fixing process destroyed some of the cells, although this cannot be
quantified.
As with flow cytometry, staining intensity plays a factor in whether micronuclei are read-
ily visible, but the largest factor to consider in this experiment is the data acquisition.
As the Petri dishes were scanned at 10x magnification, most micronuclei were visible.
However, it would not be surprising if the number of MN was underestimated due to
micronuclei being too small to be seen at this magnification.
Whilst it could be argued that images should be taken at a higher magnification, this
presents a number of other challenges. The time of acquisition and the number of images
per sample, in order to score the same number of cells that could be scored at lower
magnifications, would be greatly increased.
With a 10x magnification, analysis and acquisition time are already in excess of the
flow cytometry technique, which can be done within a couple of hours. In terms of the
technique being used as a rapid assessment tool, using higher magnification would be
unsustainable.
Whilst it has not been possible to practically assess automated image analysis systems
in this project, it should be further investigated as this could be a deciding factor as to
whether microscopy based techniques are viable, in terms of data acquisition speed, for
a rapid assessment tool.
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5.9 Summary
Overall the project has been a success. It has been shown that a modelling approach
using a decision tree structure can predict MN formation in anchorage dependent cell
lines. MiNiMUS is currently the only model dedicated to prediction MN formation
arising from IR, but models of other chromosome aberrations exist, a summary of which
can be found in Sec. 2.9.4. The experimental work has also shown that using fluorescent
DNA stains and flow cytometry to measure MN frequency in human cancerous cell lines
can be done using the In Vitro Microflow R© kit. This kit had not previously been used
in human or cancerous cell lines.
In this chapter some of the key assumptions the modelling work was based on have been
questioned. The only assumption that was found to not hold true is the question of cell
death. In the model, currently, there is no concept of cell death. A DSB will either form
an MN or not. From the experimental work it was clear that apoptosis plays a key roll
in the fate of MN when using the LN18 cell line.
In its current state, the model predicts formation of micronuclei and is fitted to observed
MN frequencies from the experimental work presented and PBL data from literature.
The arbitrary probabilities currently used within the model means that the model can
currently be considered a ‘black box’ model and as such, is fit for purpose. It is expected
that if further experiments take place, as recommended, with apoptosis inhibiting drugs
that the MN frequency will increase. This should allow cell death to be included within
the model by adding an additional node onto the tree to take into account MN that
then lead to apoptosis within the cell.
Other experiments should be planned that could aid the fitting process for the ‘black
box’ model. For instance, the glioblastoma cell lines M059J and K. These cell lines
are identical, except for the lack of DNA-PKcs in the J variant. This gives a direct
indication as the to role of DNA-PKcs in micronucleus formation, which could aid the
fitting of the NHEJ success variable.
Alternatively, these experiments could form the basis of experiments aimed at replacing
the arbitrary probabilities with mechanistic models aimed at predicting probabilities for
specifically that decision. This would move MiNiMUS into being a framework, encom-
passing other models to give a more rigorous method for modelling various aspects of
DNA repair and MN formation.
One key advantage of using flow cytometry is the ability to score thousands of cells
in minutes, rather than image based manual scoring that takes a significant amount of
time and is subjective, as one scorer may score things differently to another. However,
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flow cytometry is not free of subjectivity. It is highly dependent on where the gates
in the analysis software are placed. Although this is mitigated because the In Vitro
Microflow R© kit provides a software template. However, it was incompatible with the
version of FACSDiva available in this project and so an ab initio flow sheet was created
used for data acquisition and analysis.
5.10 Subjectivity in Flow Cytometry
Part of the concern with existing methods is the subjectivity in the clonogenic cell
survival assay. This subjectivity is a result of human measuring techniques because
when scored by eye it can be difficult to maintain the same level of discrimination on
what constitutes a colony across multiple samples or experiments. This is particularly
noticeable with cell lines that grow slowly, such as some GBM cell lines. A general
‘rule of thumb’ is often adopted when counting colonies: if a stained spot can be seen
with the naked eye, it is large enough to be a colony. This relies on the eyesight of
the scorer, which with natural variation in eyesight is likely to cause some differences
between counters.
Joiner ([12], Sec. 4.2) suggests a colony to be counted should contain at least 50 cells.
This threshold is difficult to measure in practice when scoring by eye. In addition to this
the plating efficiency is calculated by using the same counting method on the control
samples, introducing further errors into the calculation of survival fraction. Automated
systems are available, but access to these systems is not universal.
In this work, the effectiveness of radiation treatment is being investigated via micronu-
cleus formation because of the speed of data acquisition. MN can be detected by staining
and using microscopy and again, automated systems are available, but not widely so.
To remove the time constraints of manual scoring of cells, detection of MN using flow
cytometry was investigated. This is with a view to the experimental protocol being
completed in under a week.
Using a flow cytometer does not make the results free of subjectivity, the subjectivity is
better defined and shifted clearly into analysis rather than measurement. Assuming the
photomultiplier voltages are adjusted correctly, such that the first characteristic plot of
forward vs. side scattered light is correct, then data can be re-analysed using the FCS
data files.
The subjective element of flow cytometry is placing of gates when the data is analysed. If
the experiment is well designed and the desired outcome has been achieved, there should
be a number of separate populations that appear on the appropriate plot. However,
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where to place the boundaries of the gates when populations exist close together on a
particular plot is where it is possible to misrepresent data. An example of this can be
seen in Fig. 4.7, where the tail of the EMA negative population contains a large number
of cells. Fractional moving of the gate encompassing EMA positive events could lead to
a large difference in number of cells analysed for micronucleus characteristics.
The analysis in Sec. 4.10 showed that all samples marked as EMA positive were signifi-
cantly larger, in terms of forward scattered light, than those considered MN. This could
be used as an additional check to ensure correct placing of this particular gate.
Specific examples aside, it still remains a systematic error that should be taken into
account when using flow cytometry. Using the template provided with the In Vitro
Microflow R© kit is a reasonable way to reduce subjectivity between analysis in this
specific case, but the core issue applies to all cytometry experiments.
The question remains as to whether this subjectivity means the results are less useful
than other scoring methods? Automated scoring of micronucleated cells by light mi-
croscopy has achieved good agreement between automated and human scorers [30], but
in this study the automated system still required verification by eye. Concern was also
raised, in the Decordier study, about the ability of automated systems to recognise irreg-
ular shaped cells. Considering the dendritic nature of some glioblastoma cell lines, such
as LN18 and M059J/K, see Fig. 4.1, this would appear to be a significant drawback. It
could therefore be argued that flow cytometry methods offer the most rapid assessment
with the least concern over the accuracy of data gathering.
Chapter 6
Conclusions and Further Work
6.1 Conclusions
6.1.1 Development of a Rapid Assessment Tool
The MiNiMUS project aimed to develop a tool that could measure tissue sensitivity
to radiation within a short time frame. Whilst it is difficult to produce results from
clonogenic assays in under 2 weeks, the goal of this project was to make a tool that
produces results as quickly as possible.
Using flow cytometry, the experimental plan can be completed in under 3 days from IR
treatment, although this will depend on the doubling time of the cells. In order to see
MN formation the cells need to undergo at least 1 division. The In Vitro Microflow R©
protocol suggests that cells be prepared for flow cytometry 1.5 - 2 doubling times after
treatment. This means that if cells are particularly slow growing then the 3 day timetable
will inevitably slip. In the clinical case, this may need to be estimated as completing an
in vitro growth curve would diminish any time savings made by using flow cytometry.
The overall aim of predicting cell death has not yet been achieved, but the theory of how
to implement this and recommended experimental verification has been discussed within
this work, see Sec. 5.3.2. The prediction of cell death, based counts of micronuclei (MN),
could be used as a powerful tool aimed at aiding the creation of personalised treatment
plans for treating patients suffering with glioblastoma.
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6.1.2 Experimental
6.1.2.1 General
This project contained both an experimental and mathematical modelling component.
The experimental aim was to find a way of measuring sensitivity to IR within a short
time frame. In order to achieve this, the micronucleus assay was identified as a suitable
end point to measure sensitivity. Using fluorescent DNA stains and flow cytometry, long
analysis time and other concerns with image based scoring of micronuclei were overcome.
Using the In Vitro Microflow R© kit, by Litron Laboratories, the technique was extended
to work with human cancerous cell lines, previously the kit had only be used in PBL
samples and a limited number of animal anchorage dependent cell lines.
The kit was used in both the LN18 glioblastoma cell line and also in the V79 Chinese
hamster lung cell line. Experiments were done to repeat results detailed in literature
with V79 cells to ensure that the kit was being used correctly. Further experiments were
carried out with IR (0-3 Gy) and MMC (0-0.3125 µg/ml). Both LN18 and V79 showed
a linear dose response with IR. Similar characteristic results were achieved with MMC.
Finally, results from flow cytometry were compared with those from manually scored
samples stained with DAPI. There was a degree of overlap between the flow cytometry
results and the microscopy results, but the cytometry results varied too much for the
modelling work. The microscopy results have been compared to the cytometry results
in Fig. 4.12.
6.1.2.2 Use of the In Vitro Microflow R© Kit
The In Vitro Microflow R© kit provided the basis for experiments to determine MN
formation. However, there is little published data using this method with attachment cell
lines. A protocol for staining attachment cultures was provided by the kit manufacturer,
although some minor alterations needed to be made in order to get the technique to
work with LN18 and V79 cells. Pipetting of samples to ensure detachment from the well
surface was needed for both LN18 and V79 cells, against the advice of the protocol that
suggests avoiding vigorous agitation of the cell suspension.
Care should be taken when expanding this technique to other cell lines, in case the
strength of attachment is stronger than that of LN18.
The only other issue with the In Vitro Microflow R© kit was the incompatibility of the
supplied template with the version of FACSDiva available at the time of the experiment.
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Whilst this did not preclude the analysis of the data in this project, future work should
attempt use the template if possible.
6.1.3 Modelling
6.1.3.1 General
The aim of the model was to predict tissue sensitivity, supported by experimental work.
The following sections detail the modelling assumptions and numerical solution that
lead to the model in it’s current state.
6.1.3.2 Modelling Assumptions
Several assumptions were made in order to model the formation of MN. Firstly, there was
no concept of cell death. A DSB will either form a MN or not. Subsequent experimental
work has shown this to be unrealistic as it is suspected that the apoptotic cohort is
largely derived from the MN that have become apoptotic. However, at this point of the
project the goal of predicting experimentally observed results has been achieved, the
caveat being that these observed results may not reflect the true formation of MN due
to the apoptotic pathway.
Secondly, some biological assumptions have been made. Cells are actively cycling around
their cell cycle at all points between treatment and staining. DSBs can also be repaired
by either the NHEJ or HR pathway, which are independent of each other and active at
varying points in the cell cycle, as discussed in Sec. 2.5.4.
Thirdly, the number of DSBs induced by IR is linear with dose. Whilst this is widely
documented it highlights one of the key issue with the prediction of MN arising from
PBLs, which are non linear with dose. This does not affect the model goal of being able
to predict MN in tumourous tissue. However, if the model can be altered to take into
account this non linear affect, when simulating PBL samples, then this may be of use
in future.
Finally, it is assumed that any decision within a cell, such as whether a repair pathway
successfully repairs a DSB can be described by a probability distribution function and
in the case of the MiNiMUS model it is described using a Beta distribution, see Eqn.
3.6. In particular, a beta distribution which is described by a mean and variance, where
the variance is restricted to 20 % of the maximum variance for which the distribution
would be valid. This assumption forms the basis of the Monte Carlo simulation.
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6.1.3.3 Numerical Solution
The numerical solution to the model involved a decision tree, see Fig. 3.2, where all
that would arise within a cell as a result of IR would be walked through the tree. The
walk was achieved using a random number generator compared the the probability at
that decision point.
The probabilities were initially fitted to values from literature for PBL samples and then
experimental values for attachment cell lines. These fitted probabilities still used the
Monte Carlo simulation as described previously.
In order to reduce the impact of outlying data, a number of cells are simulated and then
the average MN frequency per 1000 cells is reported.
The model output has been plotted against the experimental data and can be found in
Fig. 4.20 and 4.22 for adherent cell lines and PBL respectively.
6.2 Recommendations for Future Work
6.2.1 Implementation of Cell Death within MiNiMUS
The current model is fitted to experimentally observed values. This obviously underes-
timates the true numbers of MN formed as the apoptotic signal is strong when using
LN18 cells. There is some suggestion that the MN dose response is the inverse of the
EMA+ signal, see Sec. 4.10.
In terms of the modelling approach, it should be simple to include cell death arising
from MN formation into the MiNiMUS model. A decision can be placed, subsequent to
a decision on whether a MN is formed. Experimentally, the number of ‘extra’ MN that
have been lost due to apoptosis can be quantified by inhibiting apoptosis using drugs,
such as caspase 8 or 9 inhibitors.
Whilst this would account for cells that have become apoptotic because of MN forma-
tion, it would not account for cells that would have entered apoptosis regardless of MN
formation. This could be a significant flaw, but further investigation would need to be
done to see the difference of prediction between the modified version of MiNiMUS and a
clonogenic assay. It would not be sensible to offer conjecture about this currently, given
that there is more work to do before the scale of the potential issue can be realised.
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6.2.2 Implementation of Ion Irradiation
Whilst ions have been implemented into the framework of MiNiMUS, they currently
mirror photon irradiation in terms of damage induction. It is known that ions cause
clustered damage, which will affect the numbers of MN. Whilst the relative biological
effectiveness (RBE) of protons is generally considered to be equal to that of photon
irradiation, the numbers of micronuclei tend to be higher, as shown by Prise et al. [179].
The resolution of complex break sites could be determined by spatial proximity of DSBs,
which lends more weight to the argument of incorporating a track based model to cal-
culate the damage induction for the decision tree.
6.2.3 Further Experiments to Aid Probability Fitting
6.2.3.1 Repair Deficient Cell Lines
Whilst experiments with LN18 give a general MN dose response, further experiments
using cells with specific deficiencies could be used to target specific decisions within the
tree. The obvious candidates for further study are the ‘success’ decisions. Whilst it
is possible to develop cell lines and knock out proteins that are responsible for various
cellular processes, it is sensible to use commercial cell lines where possible.
The M059J/K are designed to aid studies into DNA repair, due to the lack of DNA-
PKcs activity in the J variant, which is a key protein in the NHEJ repair pathway, see
Sec. 2.5.3. Experiments within this project were not continued due to the difficulty in
subculture of M059J/K cell lines, but a more direct measure of the probabilities used
within the MiNiMUS tree could move the model away from being a ‘black box’ type
model to something with more tractable foundations.
The question should be asked as to the impact of measuring asynchronous populations
and translating those results into a probability matrix containing discrete cell phase
probabilities. In the case of the work in this project, the S and G1 phases have been
of similar proportion of the cell cycle, with the G2 and M phases playing an almost
insignificant role in terms of percentage of the overall cell cycle.
Synchronisation of cells with other time sensitive protocols, such as the flow cytometry
techniques presented in this work, was not done in the first instance as it was unclear
whether the protocol would work and indeed whether synchronisation would be neces-
sary. In terms of the black box model, it is clear that it is not necessary to synchronise
the cells as the model can predict the experimental results. This is largely due to the
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aforementioned similarities in cell phase proportions durations of S and G1 phases in
LN18 and V78 cells.
If the model was to move into the proposed framework architecture with mechanistic
models this may need to re-addressed, whilst taking into account the differences in repair
capacities and DSBs found in different phases discussed in Sec. 2.8 and by Olive et al.
[123].
6.2.4 Replacing MiNiMUS Probabilities with Mechanistic Models
As discussed in Sec. 5.7, the long term goal is that MiNiMUS will host a number of
models concerning DNA damage and repair rather than arbitrary probabilities based on
fitting, which were suitable for this proof of principle project.
The MiNiMUS model will still make the same predictions, currently numbers of mi-
cronuclei, but as stated above the overall goal is to predict cell death. The method of
calculation will remain the same, except the probabilities that have, up to this point,
been based on a few biological principles and fitted by eye would be provided by other
models that have been designed to calculate the probability specifically.
Whilst it may be difficult to design experiments to directly measure the probability at
every decision point within the MiNiMUS tree as it stands, mechanistic models open up
the possibilities for abstract experiments that do no necessarily have any relationship to
micronucleus formation.
6.2.5 Estimation of Dose Response
Flow cytometry provides a large amount of data on a cell by cell basis. If the correct
fluorochrome is used then it can be used to answer questions about how cellular processes
alter with dose. For instance γH2AX for DSB induction or annexin V for apoptosis.
This fluorescence data could then be collected in the form of histograms that show the
cohort’s reaction to IR/drug based treatment at that specific dose. Further experiments
at multiple dose points could be used to give an idea of the dose response over the range
by looking at the median intensities of the histograms and aggregating them into a single
scatter plot. This has been mocked up in Fig. 5.4 and could provide an easy method to
answer the questions about dose response when foci become challenging to count.
Whilst this would prove important for the assumptions made in this work, it does not
quantify the numbers of γH2AX foci. However, the solution would be to develop an
image based technique where DSB counts at low enough doses can be cross-referenced
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with the intensity data measured on the flow cytometer. Using extrapolation it may be
possible to quantify the number of DSBs when the foci become too difficult to count.
Developing this idea further, this proposed model lends itself to being included in group
efforts to create a virtual flow cytometer, originally proposed by Barry [165], and extend
the technology into laboratories that do not have access to flow cytometry facilities,
where an fluorescence microscope could perform a similar job. The obvious drawback of
this approach is ensuring that intensities levels are kept consistent, but this is seen as
an operational issue, rather than a flaw that could negate the use of the model entirely.
The advantage of this is that flow cytometer’s are large pieces of equipment that require
specialist training to operate and represent a considerable capital investment. On the
other hand most laboratories will have access to fluorescence microscopy and hence could
represent a desirable alternative to either outsourcing experimental time or maintaining
a flow cytometer. The overall benefit, should the technology be successful, is that more
data should start to become available in literature from groups who previously relied on
foci counts for particular radiobiological markers.
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tation)
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rope, Geneva, CH, March 2012. (Conference Attendee)
- European Congress of Chemical Engineers 9, Den Haag, NL, April 2013. (Oral
Presentation)
- Mathematical Modelling of the DNA Damage Response, Surrey, UK, June 2013.
(Oral and Poster Presentation)
A.2 Manuscripts
- MiNiMUS: A model to predict the formation and numbers of micronuclei in cells.
(In preparation)
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Appendix B
MiNiMUS Source Code
B.1 General
Included in this work is a CD containing both the source code for the MiNiMUS model
and accompanying version of the group common library that is compatible with MiN-
iMUS. These are kept within the ‘SOURCES’ folder on the CD.
In addition to the source code, a compiled version of the programme that can be run
from the batch file called ‘64’ is also present in the folder labelled ‘MiNiMUS’. As the
batch file name suggests, this is built for 64-bit architecture, but 32-bit executables can
be built from the accompanying source files.
In order to run, the programme uses some other, smaller, compiled programmes and
files supplied as part of the Magsoft [180] suite of programmes as well as a range of
configuration and files created at runtime.
The MiNiMUS folder containing the compiled programme files will need to be copied to
a local machine and the batch file altered to take into account the new file location as
it is an absolute reference.
The ‘secret.cfg’ file will also need to be altered to take into account the location of the
default web browser and the location of the default configuration file as this is also stored
as an absolute path.
B.2 Altering Model Probabilities
Whilst it is not recommended to alter the probabilities, as they have been fitted to the
cell lines used within this work, they can be altered by changing the values in the main
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configuration file. They are labelled in the following format:
MINIMUS TREE <Cell Phase> <Node Name>
After altering probabilities the MiNiMUS programme will need to be restarted for these
changes to take effect.
B.3 Running the Programme
As stated previously, the main programme should be run using the supplied batch file to
ensure the correct version of the programme is used. Once the programme starts, ‘Main
Simulation’ should be selected and then ‘Fresh Experimental Input’ should be selected
in order to initialise variables used in the simulation. From this point a single dose point
can be calculated using the ‘Start Simulation’ options, with the Monte Carlo routines
either turned on or off. Alternatively a dose range can be simulated in one run of the
program by selecting the ‘Simulate Dose Range’ option.
Regardless of simulation type, the simulation will run and display the micronucleus
frequency at the end. Simulations can be run back to back, but to alter the dose
simulated, in the case of single dose simulations, ‘Fresh Experimental Input’ needs to be
run between simulations.
Once the appropriate data has been gathered, it is recommended to close the programme
using the ‘Post Process and Exit’ option on the main menu.
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